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 i 
ABSTRACT 
The human epidermis is a self-renewing stratified epithelial tissue that forms the outermost 
protective layer of the skin. The epidermis is comprised of a number of cell types, the most 
abundant of which are keratinocytes. Normal function of the epidermis requires that 
keratinocyte proliferation, differentiation, and apoptosis be precisely regulated and a failure to 
regulate these processes is a feature of many skin diseases. Although the precise mechanism by 
which epidermal homeostasis is regulated is still far from clear, much progress has been made in 
the characterisation of signaling pathways involved in normal epidermal function. A key group 
of signaling proteins that have been clearly implicated in epidermal function are the Rho family 
of small GTP-binding proteins. This thesis focuses on one member of the family, RhoE/Rnd3, 
and the analysis of the role it plays in the regulation of proliferation, differentiation, apoptosis 
and cell-cell adhesion in the epidermis.  
Use of RNA interference to specifically ‘knock-down’ expression of RhoE has led to the 
discovery of a novel role for RhoE in regulation of cell-cell adhesion and apoptosis. Loss of 
RhoE expression resulted in keratinocytes developing resistance to apoptosis mediated via either 
the intrinsic or extrinsic pathways. RhoE depletion was also associated with increased 
expression of desmosomal proteins and increased numbers of desmosomes. Resistance to 
apoptosis was shown to be a function of desmosome-mediated cell-cell adhesion and a 
component of demosomes – plakoglobin – was shown to play a key role in RhoE-mediated 
resistance to apoptosis.  
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CHAPTER 1 INTRODUCTION 
 
1.1 The epidermis 
1.1.1 Introduction to the epidermis 
Human skin is comprised of two layers: the dermis and the epidermis, which are separated by 
the basement membrane (Fuchs 2007) (Figure 1). The dermis is composed largely of vascular 
connective tissue and the basement membrane is made up of extracellular matrix (ECM) 
proteins and proteoglycans and is rich in growth factors secreted by keratinocytes and dermal 
fibroblasts (Marinkovich et al. 1993; Fuchs 2007). The upper most layer of the skin is the 
epidermis and although comprises only 25% of the total thickness of the skin it is vitally 
important for protecting the body from the environment (Leigh et al. 1994). The role of the 
epidermis is to act as a mechanical barrier protecting against infection from pathogens, noxious 
stimuli and UV irradiation. The epidermis also prevents dehydration and re-epithelialises during 
wound healing (Koster et al. 2007). In order to fulfil these roles the epidermis must continually 
replenish and maintain itself through proliferation, differentiation and apoptosis (Gniadecki 
1998; Fuchs 2007; Koster et al. 2007). 
 
The epidermis is a stratified epithelium made up predominantly of layers of specialised 
epithelial cells known as keratinocytes. Other cell types found in the epidermis include 
Langerhans cells, which have an immunological function, and melanocytes, which absorb UV 
irradiation (Leigh et al. 1994). The different layers of keratinocytes that make up the  
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Figure 1 Organisation of the epidermis. 
The epidermis is comprised of layers of keratinocytes, the basal layer houses keratinocytes with 
proliferative ability, stem cells and transit amplifying cells, which are anchored to the basement 
membrane. The suprabasal layers of the epidermis include: the spinous layer, the granular layer 
and the stratum corneum. These layers are comprised of differentiating keratinocytes, which are 
in different stages of the differentiation process. 
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epidermis include the basal layer, spinous layer, granular layer and the outermost stratum 
corneum (Koster et al. 2007) (Figure 1). Cells in the basal layer adhere to the underlying 
basement membrane and have the ability to undergo proliferation (Gniadecki 1998; Blanpain et 
al. 2004). The formation of the suprabasal layers results from the process of terminal 
differentiation (Koster et al. 2007). Keratinocytes that have initiated differentiation exit the cell 
cycle and migrate upwards with their morphology ever-changing until they become apart of the 
stratum corneum and are sloughed from the surface of the skin (Koster et al. 2007). Each of the 
suprabasal layers is composed of keratinocytes at specific points in the differentiation process 
and is based on gene expression, proliferation potential and adhesive properties (Fuchs 1990). 
 
Epidermal homeostasis is vital for epidermal function and abnormalities in proliferation, 
differentiation, adhesion or apoptosis are a feature of many skin diseases (Fuchs 2007). A 
balance between cell loss and cell proliferation must be maintained as reduced proliferation 
results in the epidermis becoming too thin. Conversely too much proliferation results in 
hyperproliferative disorders such as psoriasis and cancers (Fuchs 2007). Psoriasis is common 
skin disease and is characterised by inflammation and hyperproliferation in the epidermis 
resulting in scaly patches of skin (Bata-Csorgo et al. 1995; Ilkovitch 2010). Basal cell and 
squamous cell carcinomas are the most common types of skin cancer (Motley et al. 2002). Both 
basal and squamous cell carcinoma occurs in the epidermis usually through sun exposure and 
are most commonly treated by surgical excision. If left untreated, invasion and metastasis can 
occur (Rubin et al. 2005; Lansbury et al. 2010). A less common type of skin cancer is melanoma 
which arises through the transformation of melanocytes, in response to UV irradiation (Diepgen 
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et al. 2002). Melanomas are highly malignant and responsible for the majority of deaths 
associated with skin cancer (Diepgen et al. 2002). For normal epidermal function, maintaining 
the architecture of the epidermis is vital. Disruption of adhesion, through disturbed expression 
of adhesion components, can also lead to uncontrolled proliferation, resulting in severe 
pathologies such as cancer and psoriasis (Muller et al. 2008). Pemphigus vulgaris and 
pemphigus foliaceus are autoimmune diseases that cause skin blistering through the production 
of antibodies against the desmosomal components desmoglein 1 and 3, which results in 
acantholysis (loss of cell–cell adhesion) (Waschke 2008). Apoptosis is important for the 
regulation of epidermal homeostasis and provides protection against diseases such as 
autoimmune disorders, cancer and infection through the removal of affected cells (Kalden 2004; 
Rovere-Querini et al. 2005). 
 
1.1.2 Keratinocyte proliferation 
Cell proliferation in normal epidermis is confined to keratinocytes present in the basal layer with 
two types of keratinocytes undergoing division (Watt 1988; Gniadecki 1998; Blanpain et al. 
2004; Fuchs 2007). Stem cells have unlimited proliferative capability and transit amplifying 
cells undergo a finite number of rounds of division before committing to terminal differentiation 
(Potten 1981). Mechanisms that control the transition from stem cell to transit amplifying cell to 
differentiating cell are poorly understood. 
 
Keratinocyte proliferation is mainly regulated in G1 phase (Gniadecki 1998). Progression 
through G1 relies on the sequential activation of cyclin dependent kinases (CDK), which is 
  5 
regulated by growth factors and adhesion to the ECM (Assoian et al. 2001; Muller et al. 2008). 
The main CDKs involved in G1 phase are CDK4, CDK6 and CDK2 and they are activated on 
binding with cyclins (Klein et al. 2008). Cyclin D (D1, D2 and D3) binds to CDK4 and CDK6 
whereas cyclins E and A bind to CDK2 (Gniadecki 1998; Welsh 2004). In mid-G1 phase the D-
type cyclins are synthesised primarily in response to growth factor stimulation of the Ras-
dependent pathway involving the sequential activation of Raf, MEK then the sustained 
activation of extracellular signal-related protein (ERK) (Diehl 2002). Of the three D-type 
cyclins only cyclin D1 is frequently over-expressed in cancer (Diehl 2002). Over-expression of 
cyclin D1 in mice causes hyperplasia in basal keratinocytes confirming a key role for cyclin D1 
in the epidermis (Robles et al. 1996). Cyclin D1 binding to CDK4/6 is the rate-limiting step in 
progression through G1 phase (Klein et al. 2008). Adhesion to the ECM and growth factors 
present in the basement membrane induce cyclin D1 expression and promote proliferation 
(Assoian et al. 2008), whereas the repression of cyclin D1 expression is a hallmark of cell 
differentiation (Mejlvang et al. 2007) but cyclin D1 is not required in mouse keratinocytes 
(Robles et al. 1998).  
 
The major targets for the activated CDK-cyclin complexes are members of the retinoblastoma 
(Rb) family, which includes retinoblastoma protein (pRb), protein p170 and protein p130 
(Poznic 2009). In quiescent cells these proteins are hypophosphorylated and complex with the 
E2F transcription factor family of proteins, pRb and p170 complex with E2F1, E2F2 and E2F3, 
while E2F4 and E2F5 complex with p130 (Sardet et al. 1995; Berckmans et al. 2009; Poznic 
2009). Binding of the Rb family members to the E2F transcription factors leads to the 
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transcriptional repression of E2F target genes (Berckmans et al. 2009). During G1 the Rb 
proteins are initially phosphorylated by the activated CDK4/6-cyclin D complexes resulting in 
the release of the E2F transcription factors and then the subsequent induction of E2F target 
genes, which includes cyclin E and A (Poznic 2009). Cyclin E then complexes with CDK2, 
activating it while the CDK4/6-cyclin D complex further aids the activation of CDK2 by 
incorporating the CDK2 inhibitor p27Kip1 into the CDK4/6-cyclin D complex (Sherr 1993). 
There are two families of CDK inhibitors; the Cip/Kip family (p21Cip1, p27Kip1 and p57Kip2) which 
bind CDK4/6-cyclin D, and CDK2-cyclinE/A, and the INK4 family (p15INK4A, p16INK4B and 
p18INK4C) that bind to CDK4/6-cyclin D only (Abbas et al. 2009). Activation of CDK2-cyclin E 
leads to the hyperphosphorylation of the Rb family proteins resulting in the release of more E2F 
transcription factors and the transcription of genes required for the G1 to S phase transition 
(Poznic 2009).  
 
1.1.3 Terminal differentiation  
A keratinocyte undergoing terminal differentiation goes through a number of phenotypic 
changes that include withdrawal from the cell cycle, altered protein expression, changes in 
adhesion, migration up through the epidermis as well as changes in morphology. Terminal 
differentiating keratinocytes make up the stratified suprabasal layers of the epidermis and are 
key for maintaining the protective function of the epidermis (Fuchs 1990; Fuchs 2007). The 
precise trigger for a basal keratinocyte to undergo differentiation is unclear but the process itself 
has been well-documented (Fuchs 2007).  
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One of the earliest events of terminal differentiation is the irreversible withdrawal from cell 
cycle that occurs in a specific subset of basal cells known as the transit amplifying cells (Albers 
et al. 1987). As these cells exit the basal layer they enter the spinous layers (4 to 8 layers thick) 
these cells are now known as spinous cells (Figure 1). Spinous cells are post mitotic but still 
metabolically active (Fuchs 1990). Synthesis of glutamine and lysine rich envelope proteins 
occurs, such has involucrin, and are deposited at the inner surface of the plasma membrane 
(Rice et al. 1979). The spinous cells also switch production of keratins, with the down-
regulation of basal keratins, keratin 5 and 14, coupled with the up-regulation of keratin 1 and 10, 
which is a reliable indication of terminal differentiation (Fuchs et al. 1980; Fuchs 2007). Keratin 
1 and 10 form tonofilaments and connect to desmosomes, which provide cell-cell adhesion 
allowing spinous cells to form connected sheets and columns, producing a 3D lattice (Fuchs 
1990; Fuchs 2007). Membrane-coating granules are also made at this stage and will later fuse 
with the plasma membrane and release lipids into the intracellular spaces of the granular and 
stratum corneum cells (Swartzendruber et al. 1989). Once spinous cells reach the granular layers 
keratin and envelope protein synthesis is stopped and the synthesis of profilaggrin occurs. 
Profilaggrin is processed to produce filaggrin, which bundles the keratin tonofilaments into 
macrofibrillar cables (Fleckman et al. 1985; Fuchs 2007). The next stage involves 
permeabilisation of the cell resulting in an influx of calcium ions leading to the activation of 
transglutaminase, which catalyses the formation of E-(y-glutamyl) lysine bonds cross linking 
the envelope proteins producing a proteinaceous sack to hold the keratin macrofibrils (Rice et al. 
1979; Fuchs 2007). The final stage of terminal differentiation, known as cornification, is the 
release of lytic enzymes, which eradicate all metabolic activity through the destruction of the 
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nucleus, organelles and the lipid bilayer producing dead flattened stratum corneum cells 
(squames) that are comprised of cornified sacs containing keratin macrofibrils. These squames 
are sealed together by lipids producing the impermeable stratum corneum, which is continually 
replenished by basal keratinocytes executing a program of terminal differentiation (Fuchs 1990; 
Fuchs 2007). 
 
1.1.3.1 Markers of terminal differentiation 
Several molecular markers and morphological characteristics are commonly used to assess 
keratinocyte terminal differentiation. A switch in the production of keratin 5 and 14 to keratin 1 
and 10 (Fuchs et al. 1980; Fuchs 2007), along with the up-regulation of involucrin are 
commonly used markers for terminal differentiation (Watt 1983). Other molecular indicators 
include an up-regulation of periplakin, desmocollin 2 and transglutaminase (Rice et al. 1979; 
Legan et al. 1994; Nemes et al. 1999). The key morphological change associated with 
keratinocyte terminal differentiation is an increase in cell size with cells becoming larger and 
flatter (Watt 1983).  
 
1.1.4 Cell adhesion in the epidermis 
The architecture of the stratified epidermis is highly organised and requires both cell adhesion to 
the basement membrane and to neighbouring cells (Figure 1). The basement membrane is rich in 
extracellular matrix proteins as well as growth factors and keratinocytes in the basal layer 
adhere to these proteins through focal adhesions and hemidesmosomes (Braga 2002). Adhesion 
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to the basement membrane is important for these basal keratinocytes to maintain their 
proliferative ability as loss of adhesion to the ECM has been shown to induce differentiation 
(Green 1977; Muller et al. 2008). Cell-cell adhesion in the epidermis is important for 
maintaining epidermal architecture and mechanical strength as well as playing a role in signal 
transduction (Braga 2002). Tight junctions, adherens junctions and desmosomes are cell-cell 
adhesion complexes and like focal adhesions and hemidesmosomes they all link to the 
cytoskeletal network increasing the mechanical strength of the adhesion (Fuchs 2007; Waschke 
2008) (Figure 2). 
 
In addition to being required for structural integrity, adhesion complexes can serve as 
transducers of extracellular signals to control proliferation, differentiation and apoptosis (Muller 
et al. 2008). For example, integrin-mediated adhesion complexes, focal adhesions and 
hemidesmosomes transduce pro-proliferation signals (Muller et al. 2008). In contrast, cadherin-
mediated adhesion complexes, adhesion junctions and desmosomes transduce anti-proliferative 
signals (Muller et al. 2008). Proliferation in the epidermis requires adhesion to the basement 
membrane in normal keratiocytes (Green 1977; Muller et al. 2008). Signals can be transduced 
by the regulation of receptor tyrosine kinases (Perrais et al. 2007) and the activation of Rho 
family GTPases (Noren et al. 2001). 
 
1.1.4.1 Focal adhesions  
Focal adhesions form in basal keratinocytes and aid adhesion to the basement membrane. They  
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Figure 2 Cell adhesion in the epidermis. 
Basal keratinocytes adhere to the basement membrane via focal adhesions and hemidesmosomes 
while cell-cell adhesion occurs through tight junctions, adherens junctions and desmosomes. For 
mechanical strength focal adhesions, tight junctions and adherens junctions are connected to the 
actin cytoskeleton whereas hemidesmosomes and desmosomes are connected to the intermediate 
filament network.  
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are important for maintaining tissue integrity as well as having roles in cell spreading, motility 
and signaling (Borradori et al. 1999; Petit et al. 2000). The adhesion receptors in focal adhesion 
are integrins, which are heterodimeric transmembrane glycoprotein receptors involved in 
adhesion to ECM components (Petit et al. 2000). Integrins found in focal adhesions include: 
α2β1 integrins which binds to collagen I and α3β1 integrins which binds to laminin 5 (Muller et 
al. 2008). For increased stability focal adhesions are connected to the actin cytoskeleton, this 
interaction is mediated through multiple proteins such as focal adhesion kinase (FAK), tensin, 
vinculin, paxillin, talin, α-actinin and filamin, which made up the focal adhesion complex (Petit 
et al. 2000). 
 
1.1.4.2 Hemidesmosomes 
Hemidesmosomes are the key molecular structures that physically attach basal keratinocytes to 
the basement membrane and are essential for mechanical strength, spatial organisation and 
tissue architecture in the epidermis (Litjens et al. 2006). Hemidesmosomes are composed of the 
transmembrane proteins α6β4 integrins and the tetraspanin CD151, which connect to 
intermediate filaments via the plakin family members, plectin and BP230. Hemidesmosomes 
bind to collagen 17 and laminin 5 in the ECM (Borradori et al. 1999; Litjens et al. 2006).  
 
1.1.4.3 Tight junctions  
The role of tight junctions is to provide a barrier function that renders the epidermis 
impermeable to solutes and ions and to prevent apical and basolateral diffusion of membrane 
components (Braga 2002; Brandner et al. 2002). Tight junctions are composed of specific 
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transmembrane proteins, occludin and claudin, and plaque proteins, ZO-1 and symplekin. 
Occludin and the family of claudins play a role in cell adhesion while the plaque proteins are 
involved in linking the tight junction to the actin cytoskeleton (Brandner et al. 2002).  
 
1.1.4.4 Adherens junctions  
Adhesion junctions are required for mechanical strength by forming cell-cell adhesions and 
linking to the actin cytoskeleton. The main adhesion receptor in epidermal cells is E-cadherin, a 
member of the cadherin family, which forms adhesive cell–cell contacts through homotypic 
interactions. E-cadherin dimerises and clusters in a calcium-dependent manner, leading to 
recruitment of α - and β -catenin, members of the armadillo family, which mediate the 
association of E-cadherin with the actin cytoskeleton (Jamora et al. 2002; Niessen 2007). 
 
1.1.5 Desmosomes  
Desmosomes are intercellular junctions that provide mechanical strength to tissues such as the 
stratified epithelium and myocardium by adhering cells together and intracellularly linking to 
the intermediate filament network (Garrod et al. 2008). Termed “cellular rivets” due to their role 
in providing mechanical strength, they are also dynamic structures that are subject to 
transcriptional and post-transcriptional regulation and have roles in tissue morphogenesis, 
proliferation and differentiation (Yin et al. 2004; Muller et al. 2008). 
 
Desmosomes are highly organised, electron dense, disc-shaped structures that form on closely 
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opposing plasma membranes of neighboaring cells. They are less than 1µm in diameter and 
consist of two identical cytoplasmic plaques that are associated with the intermediate filament 
network separated by a central core region that spans the intercellular space between the 
opposing cells (Garrod et al. 2008). Desmosomes are comprised of proteins from at least three 
distinct gene families, cadherins, armadillo proteins, and plakins (Huber 2003). The 
desmosomal cadherins are further divided into desmocollins (Dsc1–3) and desmogleins (Dsg1–
4) and these two subfamilies mediate calcium-dependent cell–cell adhesion (Garrod et al. 2002). 
The armadillo proteins include plakophilins (PKP1-3) and plakoglobin/gamma-catenin (Diepgen 
et al.) and make up the desmosomal plaques, along with desmoplakin, linking cadherins to 
desmoplakin (Hatzfeld 1999). Desmoplakins I and II (DspI/II) are members of the plakin family 
and are integral to the desmosomal structure by linking the intermediate filaments to the to the 
rest of the desmosome (Yin et al. 2004).  
 
All desmosomes contain desmoplakin, plakoglobin and at least one isoform each of plakophilin 
and the desmosomal cadherins desmocollin and desmoglein. There are also a number of 
accessory proteins that are associated with desmosomes (Garrod et al. 2008). The desmocollin 
and desmoglein members of the transmembrane cadherin family cooperate to form the adhesive 
interface of the desmosome and unlike E-cadherin in adherens junctions, the desmosomal 
cadherins form both homophilic and heterophilic interactions (Garrod et al. 2002; Jamora et al. 
2002). The cytoplasmic tail of the desmosomal cadherins binds the armadillo proteins 
plakoglobin and plakophilin. They in turn bind to desmoplakin, which links the intermediate 
filament network to the desmosome (Schmidt et al. 2005) (Figure 3). Plakoglobin and β-catenin 
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are both members of the armadillo family and plakoglobin has been shown to substitute β-
catenin in adherens junctions (Bierkamp et al. 1999; Green et al. 2007). Desmosomes are 
stabilized laterally by interactions among the proteins present in the junction and by plakophilin 
(Hatzfeld 2007). The interactions between these proteins are not yet fully understood (Garrod et 
al. 2008). 
 
1.1.5.1 Regulation of desmosomes and adherens junctions 
The formation of both adherens junctions and desmosomes is calcium dependent (Chitaev et al. 
1997; Jamora et al. 2002). Calcium binding to the extracellular domain of the desmosomal 
cadherins induces conformational changes required to mediate the formation of desmosomes 
(Dusek et al. 2007). In the presence of calcium desmosomal cadherins become rigid, the change 
in conformation allows both homodimers and heterodimers to form in a cis interaction between 
cadherins on the same membrane. This is followed by a trans interaction with cadherin dimers 
on the opposing membrane of another cell, forming the adhesive interface (Steinberg et al. 
1999). In low calcium conditions these calcium dependent desmosomes and adherens junctions 
break up due to the cadherins losing their ability to form dimers leading to cell separation. 
Calcium-independent desmosomes have been identified and maintain structural integrity in low 
calcium conditions. These desmosomes are hyper-adhesive and are thought to form due to the 
highly organised structure of the desmosome trapping calcium ions (Garrod et al. 2008).   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Figure 3 Desmosome structure. 
Desmosomes contain desmoplakin, plakoglobin and at least one isoform each of plakophilin and 
the desmosomal cadherins desmocollin and desmoglein. Desmocollin and desmoglein form the 
adhesive interface between two neighboring cells while plakoglobin, plakophilin and 
desmoplakin form the intracellular plaque which links to the intermediate filament network. 
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1.1.5.2 Desmosomes and terminal differentiation 
Electron microscopy has revealed that desmosomes vary in appearance and size in different cell 
types and in distinct layers of the epidermis. Desmosomes in the basal layer of the epidermis 
appear small and less organised when compared to those in suprabasal layers. The number of 
desmosomes increases as keratinocytes move up through the suprabasal layers until the final 
stages of terminal differentiation where desmosomes break down (Skerrow et al. 1989; 
Chapman et al. 1990).  
 
Desmosomal cadherin expression is tightly regulated in a cell-type specific manner and also 
during terminal differentiation and stratification of the epidermis (Garrod et al. 2008). 
Desmocollin 2 and desmoglein 2 are ubiquitously expressed in all tissues containing 
desmosomes, including all epithelia, heart myocardium and in dendritic cells of lymph nodes 
(Nuber et al. 1995; Schafer et al. 1996). In the epidermis all seven of the desmosomal cadherins 
are expressed, with their expression changing depending on the cell position and differentiation 
state (Green et al. 2007). As well as desmosomal cadherins, plakophilins also are differentially 
expressed in the stratified epidermis (Garrod et al. 2008). Migration up through the epidermis is 
associated with an increase in desmocollin 1, desmoglein 1 and plakophilin 1 and a decrease in 
desmocollin 3, desmoglein 3 and plakophilin 2 (Dusek et al. 2007; Garrod et al. 2008). 
Plakoglobin and desmoplakin are expressed in the basal layer but their expression is up-
regulated in the suprabasal layers (Klein-Szanto 1977; Arnemann et al. 1993). Desmocollin 2 is 
weakly expressed in the basal layer and is up-regulated in the spinous layer. However in higher 
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suprabasal layers desmocollin 2 expression is down-regulated (Legan et al. 1994). Desmoglein 2 
is only expressed in basal cells whereas desmoglein 4 is only expressed in upper granular and 
stratum corneum layers (Bazzi et al. 2006; Garrod et al. 2008) (Figure 4). 
 
The differentiation-specific expression patterns of the desmosomal cadherins as well as 
overlapping expression means single desmosomes can contain more than one type of 
desmocollin and desmoglein (North et al. 1996; Garrod et al. 2008). This differential expression 
of desmosomal caderins is not fully understood but evidence is emerging for its importance in 
the maintenance of cell relationships during morphogenesis and the regulation of terminal 
differentiation and proliferation (Yin et al. 2004). Sorting of luminal and myoepithelial cells in 
3D mammary cultures is prevented when pairing of desmoglein 2 with desmocollin 2 or 
desmocollin 3 is prevented (Runswick et al. 2001). Misexpression of desmogelin 2, desmoglein 
3 or desmocollin 3 in the suprabasal layers of the epidermis results in increased cell proliferation 
and altered differentiation (Merritt et al. 2002; Hardman et al. 2005; Brennan et al. 2007). These 
data indicate the importance of desmosomal cadherin expression patterns for normal terminal 
differentiation and morphogenesis. 
 
1.2 Apoptosis 
1.2.1 Introduction to apoptosis 
Mammalian cells undergo several types of cell death, including necrosis, autophagy and 
apoptosis. Necrosis occurs when cells are damaged by acute cellular injury. Cells die due to 
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Figure 4 Differentiation-specific expression of desmosomal proteins in the epidermis. 
In the epidermis desmosomal protein expression is regulated in a differentiation-specific 
manner. This schematic represents the relative alterations in expression levels of desmosomal 
proteins in the different differentiation layers of the epidermis. Dsp, Desmoplakin I/II; PG, 
Plakoglobin; Dsc, Desmocollin; Dsg, Desmoglein; PKP, Plakophilin 
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vacuolation of the cytoplasm, swelling and lysis resulting in leakage of cell contents which can 
be harmful to surrounding cells and can cause inflammation (Kerr et al. 1972). Necrotic cells 
frequently exhibit changes in nuclear morphology but organised chromatin condensation, which 
is characteristic of apoptosis, is not observed (Edinger et al. 2004). Autophagy has been 
classified as a distinct form of non-apoptotic death that is separate from necrosis. During 
autophagy, double membrane vesicles encapsulate cellular organelles and cytoplasm. The 
autophagosomes fuse with lysosomes and the contents are degraded and recycled. Autophagy is 
a highly regulated process and provides a mechanism for the turnover of damaged organelles 
and long-lived proteins (Maiuri et al. 2007). Apoptosis is critical for normal epidermal 
homeostasis and is required for epithelial turn over (Ziegler et al. 1994) it also plays an 
important role during development (Kerr et al. 1972). The function of apoptosis is the removal 
of unnecessary, damaged and harmful cells and the process involves a sequence of cytoplasmic 
and nuclear changes that result in the death of single cells (Haake et al. 1993). Apoptosis 
culminates in the cleavage of DNA by endonucleases and the condensation and fragmentation of 
the nucleus. The plasma membrane undergoes blebbing and the cell breaks up into discrete, 
membrane bound fragments, with the cytoplasmic organelles and plasma membrane retaining 
their integrity. During apoptosis there is no leakage of the cell content so no inflammatory 
response is initiated and the dead cells are rapidly phagocytosed by neighbouring cells or by 
macrophages (Gandarillas et al. 1999). The duration of apoptosis from initial cell shrinkage 
through to removal of apoptotic bodies requires as little as 1-3 hrs in lymphocytes, but up to 48-
72 hrs in epidermal keratinocytes (Haake et al. 1993). 
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Apoptosis can be initiated via two major pathways, the intrinsic pathway, involving subcellular 
organelles, or the extrinsic/death receptor pathway, which involves the activation of death 
receptors in response to ligand binding (Servais et al. 2008). Typically both pathways converge 
to a final common pathway involving the activation of caspase cascade (Ghobrial et al. 2005). 
The caspase cascade involves initiator caspases (2, 8, 9, 10) becoming activated by aggregation 
and proteolytic cleavage induced by the intrinsic or extrinsic pathway. Once activated the 
initiator caspases activate executioner caspases (3, 6, 7), which are responsible for the cleavage 
of regulatory and structural molecules, culminating in the death of the cell (Slee et al. 2001; 
Ghobrial et al. 2005).  
 
1.2.2 The intrinsic apoptosis pathway 
The intrinsic pathway is most commonly centred around mitochondrial outer membrane 
permeabilisation (MOMP) and cytochrome c release, which is regulated by members of the Bcl-
2 family (Green et al. 2004) (Figure 5). Lysosomes and the endoplasmic reticulum can also be 
involved in the intrinsic apoptosis pathway (Servais et al. 2008). A diverse group of apoptosis 
promoting stimuli such as cytotoxic drugs, radiation, heat shock, survival factor deprivation and 
other cellular stresses can induce apoptosis via the intrinsic pathway. Although these stimuli 
may damage cells in very different ways, all of these pathways engage the intrinsic apoptosis 
pathway by triggering MOMP (Slee et al. 1999). 
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Figure 5 Intrinsic-apoptosis pathways. 
The intrinsic-apoptosis pathway converges around MOMP. A Stimuli inducing the intrinsic-
apoptosis pathways affect the anti- and pro-apoptoic members of the Bcl-2 family, which 
regulate the activation of Bax and Bak causing MOMP. B Ischemic injury can also cause 
MOMP by opening pores in the mitochondrial membrane. C Some stimuli induce DNA damage 
and the up-regulation of p53. p53 can interact with Bcl-2 family members inducing Bax 
activation. After MOMP is induced cell death can occur via two pathways: D Caspase-
dependent cell death involves cytochrome c inducing the formation of the apoptosome and 
caspase 9 activation resulting in the activation of the caspase cascade and cell death. E Caspase-
independent cell death occurs due to the release of AIF and endonuclease G from the 
mitochondria, which induces DNA fragmentation and cell death. 
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1.2.2.1 MOMP and the Bcl-2 family 
MOMP can be induced through different mechanisms. Reduced oxygen conditions such as those 
seen in ischemic injury can induce pores present in either the outer or inner mitochondrial 
membranes to open, changing the membrane potential and leading to swelling and disruption of 
the membrane (Green et al. 2004) (Figure 5B). However MOMP is most commonly mediated by 
Bcl-2 family proteins which consist of both anti-apoptotic Bcl-2 members that act as repressors 
of apoptosis by blocking the release of cytochrome c, and pro-apoptotic members that act as 
promoters (Green et al. 2004). Pro-apoptotic members of the Bcl-2 family include Bax, Bak, 
Bad, Bcl-Xs, Bid, Bik, Bim, Puma, Nova and Hrk, and anti-apoptotic members include Bcl-2, 
Bcl-XL, Bcl-W, Bfl-1 and Mcl-1 (Reed 1994). These proteins share one or more Bcl-2 
homology (BH) domains and control MOMP mostly at the mitochondrial outer membrane 
(Kuwana et al. 2003). The pro-apoptotic multi-domain proteins Bax and Bak (containing BH-1, 
-2, and -3 domains) mediate MOMP when activated by inserting into the outer mitochondrial 
membrane, forming pore-like structures (Korsmeyer et al. 2000; Basanez et al. 2002) (Figure 
5A). They can be activated by other Bcl-2 family members, the BH3-only proteins, Bad, Bim, 
Bid, Puma as well as non-Bcl-2 family proteins (Kuwana et al. 2003). Both Bid and Bim 
activate Bax directly (Kuwana et al. 2005). Following a death signal, pro-apoptotic Bcl-2 family 
members undergo posttranslational modifications that include dephosphorylation and cleavage 
resulting in their activation, oligomerisation and translocation to the mitochondria (Scorrano et 
al. 2003). Anti-apoptotic Bcl-2 family members, Bcl-2, Bcl-xL, Mcl-1, and others, sequester the 
BH3-only proteins and probably the activated Bax and Bak proteins, preventing MOMP from 
occurring (Kuwana et al. 2005). Other BH3-only proteins, for example Puma, Noxa, and Bad, 
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can antagonize the anti-apoptotic Bcl-2 family members sensitising cells for death (Letai et al. 
2002; Kuwana et al. 2005) (Figure 5A).  
 
Bax and Bak can be activated and inhibited by non-members of the Bcl-2 family. The tumour 
suppressor p53 promotes apoptosis by inducing expression of the BH3-only protein PUMA 
(Jeffers et al. 2003). p53 can also induce MOMP and apoptosis in the absence of transcription 
through direct activation of Bax (Chipuk et al. 2004) or Bak (Leu et al. 2004) or through binding 
to Bcl-2 and Bcl-xl, blocking their activity (Chipuk et al. 2004) (Figure 5C). Caspase activation 
can also result in the activation of Bax and Bak in the extrinsic-apoptosis pathway with caspase 
8 cleaving Bid which in turn activates Bax (Yamada et al. 1999; Korsmeyer et al. 2000). 
 
1.2.2.2 Events following MOMP 
On the permeabilisation of the outer mitochondrial membrane pro-apoptotic proteins are 
released into the cytoplasm. These include cytochrome c, apoptosis induced factor (AIF), 
second mitochondria derived activator of caspase (Smac)/direct inhibitor of apoptosis protein 
(IAP)-binding protein with low PI (DIABLO) and endonuclease G (Figure 5). Once in the 
cytoplasm these proteins can initiate the activation of the executioner caspases or can act as 
caspase-independent death effectors (Saelens et al. 2004).  
 
1.2.2.3 Caspase-dependent apoptosis 
When cytochrome c is released from the mitochondria it binds to the adapter protein apoptosis 
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inducing factor 1 (Apaf-1) inducing deoxyadenosine triphosphate binding, conformational 
change and oligomerisation of Apaf-1 resulting in the formation of the apoptosome (Li et al. 
1997; Adrain et al. 1999; Bao et al. 2005). The initiator caspase 9 is recruited to the apoptosome 
and activated by proteolytic cleavage (Acehan et al. 2002). Active caspase 9 initiates the caspase 
cascade by the simultaneous activation of the executioner caspases 3 and 7 (Slee et al. 2001). 
Caspase 3 plays an important role in propagating the caspase cascade in addition to its role as an 
executioner caspase by driving the activation of caspases 2 and 6 (Slee et al. 2001). Following 
caspase 2 and 6 activation the initiator caspases 8 and 10 are also activated (Slee et al. 1999). 
Caspase 3 appears to be the primary executioner caspase and is required for multiple proteolytic 
events leading to the death of the cell, while caspases 6 and 7 have either minor or highly 
specialised roles (Slee et al. 2001). Activated caspase 3 leads to the cleavage of nuclear lamin 
and the breakdown of DNA through DNAases resulting in condensation of chromatin, DNA 
fragmentation and finally the death of the cell (Servais et al. 2008) (Figure 5D). 
 
Caspases can also be controlled downstream of Bcl-2 family proteins. The inhibitor of apoptosis 
protein (IAP) appears to directly block caspase activity and/or activation. IAP activity can in 
turn be blocked by other regulatory proteins such as Smac/DIABLO that can bind too IAP and 
block its anti-apoptotic activity (Du et al. 2000; Verhagen et al. 2000) (Figure 5D).  
 
1.2.2.4 Caspase-independent apoptosis 
MOMP can commit the cell to caspase-independent death due to irreversible loss of 
mitochondrial function and mitochondrial release of caspase-independent death effectors such as 
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AIF (Susin et al. 1999) and endonuclease G (Li et al. 2001). AIF appears to exert its effects in a 
caspase-independent manner by translocating to the nucleus and triggering the chromatin 
collapse and digestion (Susin et al. 1999). Endonuclease G induces caspase-independent DNA 
fragmentation and cell death (Li et al. 2001) (Figure 5E). 
 
The targeted induction of apoptosis in recent years has been a focus for cancer therapy with 
many apoptosis-inducing and anti-apoptosis-inhibiting agents appearing in clinical and 
preclinical trials (Ghobrial et al. 2005; Green et al. 2005). Peptides and drugs that mimic the 
BH3-only proteins have promise as agents that can cause MOMP and apoptosis, or sensitize 
cells for death (Oltersdorf et al. 2005). Conventional chemotherapeutic drugs, such as cisplatin, 
etoposide and doxorubicin, induce MOMP in an indirect fashion by increasing pro-apoptotic 
signals for example by inducing p53 expression and by affecting Bcl family members (Fulda et 
al. 2006). 
 
1.2.2.5 Cisplatin 
The chemotheraputic drug cisplatin is commonly used to treat small lung cancer (Wang et al. 
2004) and gastric cancer (Wagner et al. 2006). Cisplatin is a DNA macrochelator and blocks 
DNA replication and gene transcription by inducing single and double-stranded DNA breaks 
(Ries et al. 1986; Siddik 2003). Cisplatin-induced DNA damage results in an up-regulation of 
p53, which induces the expression of p53-induced death domain (PIDD) protein and PUMA 
(Wei et al. 2007). PIDD promotes the activation of caspase 2, which causes the release of 
Apoptosis-Inducing Factor (AIF) from the mitochondria (Seth et al. 2005). AIF is a caspase-
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independent promotor of apoptosis (Daugas et al. 2000). PUMA antagonises Bcl-xl (Jiang et al. 
2006) allowing Bax to translocate from the cytoplasm to the mitochondria and alter the integrity 
of mitrochodrial membrane resulting in cytochrome c release (Ott et al. 2007). Once in the 
cytoplasm, cytochrome c interacts with Apaf1 forming the apoptosome, which promotes caspase 
9 activation. Active caspase 9 then initiates the activation of the executioner caspases, caspase 3 
and 7, inducing the caspase cascade. Caspase 3 and 7 activation results in the classic 
morphological signs of apoptosis, membrane blebbing, cell shrinkage and DNA fragmentation 
all resulting in cell death (Servais et al. 2008) (Figure 6). 
 
1.2.3 The extrinsic apoptosis pathway 
The extrinsic apoptosis pathway initiates apoptosis by the ligation of cell surface death 
receptors. On ligand binding the death receptor propagates apoptosis by activating the caspase 
cascade either by the activation of the execution caspase 3 or by inducing MOMP (Sprick et al. 
2004). Death receptors are members of the tumour necrosis factor (TNF) receptor family with 
over 20 members that are involved in a wide range of biological functions such as the regulation 
of apoptosis and survival, differentiation or immune regulation (Walczak et al. 2000; Ashkenazi 
2002). Members of the TNF receptor family are defined by a cytoplasmic death domain, which 
plays a crucial role in transmitting the death signal from the plasma membrane to the 
intracellular signaling pathways (Walczak et al. 2000). The best-characterised death receptors 
include CD95 (APO-1/Fas), TNF receptor and TNF-related apoptosis-inducing ligand (TRAIL) 
receptors. The corresponding death receptor ligands to the TNF receptor family members  
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Figure 6 Cisplatin-induced apoptosis. 
Cisplatin induces the intrinsic apoptosis pathway by inducing DNA damage leading to the up-
regulation of p53, which induces the expression of PUMA and PIDD. PUMA and p53 inhibit 
Bcl-xL and activate Bax, which translocates to the mitochondria inducing MOMP resulting in 
the activation of the caspase cascade and cell death. PIDD activates caspase 2, which leads to 
the release of AIF resulting in DNA fragmentation and cell death.  
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include CD95 ligand, TNF and TRAIL (Walczak et al. 2000). 
 
1.2.3.1 CD95 and TRAIL ligation and initiation of the caspase cascade  
Signaling through CD95 and TRAIL receptors occurs on ligand binding which is followed by 
receptor trimerisation. This leads to the clustering of the death domains on the receptors. 
Adaptor molecules, such as Fas-associated death domain (FADD), are recruited to the clustered 
death domains (Walczak et al. 2000). FADD recruits the initiator caspase, caspase 8, to the 
activated receptor to form the death inducing signaling complex (DISC) (Kischkel et al. 1995). 
Recruitment of caspase 8 to the DISC induces its activation through oligomerisation and auto-
cleavage. For the CD95 and TRAIL signaling pathway, cell type specific mechanisms have been 
identified (Scaffidi et al. 1998; Fulda et al. 2002). In type I cells, caspase 8 is activated at the 
DISC to a level sufficient to directly activate the downstream executioner caspase 3 (Scaffidi et 
al. 1998). In type II cells, the amount of active caspase 8 generated at the DISC is insufficient to 
activate caspase 3 and MOMP is required for full activation of caspases (Scaffidi et al. 1998; 
Fulda et al. 2002). This occurs by activated caspase 8 cleaving Bid, a pro-apoptotic member of 
the Bcl-2 family, activated Bid in turn activates Bax resulting in MOMP (Yamada et al. 1999) 
(Figure 7). Type I cells include lyphoblast and lyphoma cells (Scaffidi et al. 1998; Fulda et al. 
2002). Most epithelial cells including keratinocytes are type II cells and require MOMP for full 
initiation of the caspase cascade (Kim et al. 2004). 
The cytosolic protein Fas-associated death-domain-like IL-1β-converting enzyme-inhibitory 
protein (FLIP) interferes with the initiation of the caspase cascade by binding to the DISC, 
preventing caspase 8 activation (Scaffidi et al. 1999; Krueger et al. 2001) (Figure 7A). High 
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levels of FLIP expression have been found in many tumour cells and has been linked with 
resistance to CD95L or TRAIL-induced apoptosis (Fulda et al. 2002; Longley et al. 2006). 
 
1.2.3.2 NF-κB and apoptosis  
In contrast to CD95 and TRAIL, which leads to the recruitment of FADD and caspase 8 to the 
activated receptor, TNF receptor activation results in the recruitment of TNF receptor associated 
death domain (TRADD), receptor interacting protein 1 (RIP 1) and TNF receptor associated 
factor 2 (TRAF 2) (Figure 7B). This leads to the activation of the nuclear factor kappa B (NF-
κB) and anti-apoptotic signaling (Zhang et al. 2000; Harper et al. 2003). The NF-κB 
transcription factors are involved in the regulation of many biological processes, such as 
inflammation and apoptosis (Karin et al. 2002). In its inactive form, NF-κB is sequestered in the 
cytoplasm by the inhibitor of NF-κB (IκB) family proteins, which bind to NF-κB and mask its 
nuclear localization signal (Maldonado et al. 1997). Upon stimulation the IκB are 
phosphorylated by IκB kinases (IKK) targeting the IκB for degradation resulting in the nuclear 
localisation signal of NF-κB to be unmasked and NF-κB is translocated to the nucleus. Once in 
the nucleus, NF-κB binds to regulatory DNA elements affecting the gene expression of a 
multitude of genes (Maldonado et al. 1997). TNF receptor activated NF-κB induces the 
transcription of inhibitor of apoptosis proteins (IAP) (Karin et al. 2002) and other anti-apoptotic 
proteins (Wang et al. 1998; Diessenbacher et al. 2008). After the initial burst of anti-apoptotic 
signaling from NF-κB, the receptor associated signaling complex dissociates and reassembles in 
the cytoplasm with FADD and caspase 8, resulting in the activation of caspase 8 (Micheau et al. 
2003). However the initial burst of anti-apoptotic signaling from NF-κB usually protects the cell 
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Figure 7 Extrinsic apoptosis pathways. 
On ligand binding receptor trimerisation occurs leading to the clustering of the receptors death 
domains. A Ligation at the TRAIL receptor leads to the recruitment of the FADD forming the 
DISC resulting in the activation of caspase 8. In type I cells activated caspase 8 activates 
caspase 3 resulting in cells death, whereas in type II cells activated caspase 8 induces MOMP 
via Bid to activate the caspase cascade resulting in cell death. B Ligation at the TNF receptor 
leads to the recruitment of TRADD, RIP1, and TRAF2 resulting in the activation and 
translocation of NF-κB, which induces the expression of IAP inhibiting apoptosis. Dissociation 
of the TRADD, RIP1 and TRAF2 complex, from the receptor is followed by FADD binding and 
the activation of caspase 8. However the activation of caspase 8 is usually not sufficient to over 
come the initial anti-apoptotic signaling from NF-κB. 
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from caspase 8 activation, resulting in cell survival (Zhang et al. 2000). Inhibition of NF-κB 
activation is required to sensitise cells to TNF-induced apoptosis (Rothe et al. 1995). 
 
The activation of NF-κB has an important role in the regulation of the extrinsic apoptosis 
pathway, by having both anti- and pro-apoptotic functions, determining the outcome of specific 
apoptotic stimuli (Kuhnel et al. 2000). The anti- and pro-apoptotic functions of NF-κB are 
determined by the genes NF-κB is targeted to and the level of gene transcription. An example of 
an anti-apoptotic function is the activation of TRAF 2 and IAP (Wang et al. 1998), while a pro-
apoptotic function is the activation of p53 and caspases (Kuhnel et al. 2000). 
 
1.2.3.3 TRAIL and NF-κB 
NF-κB can be activated by numerous stimuli such as growth factors, cytokines, radiation, stress 
and pharmacological agents such as cisplatin and TRAIL (Walczak et al. 2000). TRAIL and 
TNF both activate NF-kB in human keratinocytes but only TRAIL efficiently induces apoptosis 
(Diessenbacher et al. 2008). When activation of NF-κB is inhibited TNF but not TRAIL-
induced apoptosis is dramatically enhanced (Karin et al. 2002; Diessenbacher et al. 2008). 
Interfering with TRAIL-induced NF-κB activation does not alter keratinocyte sensitivity to 
TRAIL-induced apoptosis, indicating that TRAIL-induced NF-κB activation is an apoptosis-
independent signal pathway in keratinocytes and is involved in IL-8 expression (Leverkus et al. 
2003). 
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1.2.3.4 TRAIL and cancer 
TRAIL receptors are constitutively expressed in a wide range of tissues. There are two agonistic 
TRAIL receptors, which contain the death domain, TRAIL-R1 and TRAIL-R2, enabling them to 
activate the apoptotic machinery upon ligand binding. There are also antagonistic TRAIL 
receptors (TRAIL-R3, R4 and R5), which bind TRAIL, but do not transmit a death signal 
(LeBlanc et al. 2003). Unlike TNF and CD95L, TRAIL exhibits selectivity for triggering 
apoptosis in tumour cells and not normal cells (Wiley et al. 1995). In addition, TRAIL exerts 
potent antitumour activity in vivo without exhibiting systemic toxicity unlike TNF and CD95L 
making TRAIL a potentially ideal cancer therapy (Walczak et al. 1999). TRAIL induces 
apoptosis in primary and transformed keratinocytes (Leverkus et al. 2000). 
 
1.2.4 Terminal differentiation as a form of cell death  
Terminal differentiation and apoptosis share some similarities but are considered distinct 
processes, both of which culminate in cell death (Gandarillas et al. 1999). Normal function of 
the epidermis requires keratinocytes to undergo terminal differentiation in order to produce the 
ultra-structure of the epidermis required for protection of underlying tissues. Terminal 
differentiation is an organised process of cell death with the final stage, known as cornification, 
producing the stratum corneum, which is made up of dead keratinocytes fused together forming 
an impermeable barrier (Fuchs 1990). By contrast, apoptosis also known as programmed cell 
death, is required for the removal of undesirable cells during both development and homeostasis 
of adult tissue (Edinger et al. 2004).  
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Whilst these two processes can be distinguished both morphologically and biochemically both 
terminal differentiation and apoptosis are metabolically active processes that induce dramatic 
cellular changes (Lippens et al. 2009). Initiation of terminal differentiation is associated with 
loss of adhesion to the basement membrane through the loss of integrins (Green 1977). This loss 
of adhesion in endothelial and epithelial cells can induce a form of apoptosis known as anoikis 
(Frisch et al. 1997). Adhesion to the ECM via intergrins prevents terminal differentiation in 
keratinocytes but also inhibits other cells from undergoing apoptosis (Green 1977; Adams et al. 
1989; Frisch et al. 1997). Apoptosis is a rapid process taking a few hours and occurring in single 
cells. Cells undergoing apoptosis break up, without leaking cellular contents, and are engulfed 
immediately after death by phagocytes, macrophages and surrounding cells (Lippens et al. 
2009). By contrast, terminal differentiation is a slow process occurring in individual cells in the 
suprabasal layers. The process takes up to two weeks and the dead cells are utilised for barrier 
function and are removed from the surface of the epidermis when they are shed (Gandarillas 
2000). Terminally differentiating cells also become larger and flatter, unlike apoptotic cells that 
shrink during the process (Gandarillas et al. 1999; Gandarillas 2000). In both cases cellular 
content is eliminated and proteolysis is the major cellular event (Gandarillas 2000; Lippens et al. 
2009). During apoptosis caspases 3, 6, 7, and 9 are responsible for proteolysis but the respective 
knockout mice show no skin abnormalities (Lippens et al. 2009). Caspase 14 is required for 
normal skin development and is activated during cornification. However, caspase 14 is non-
apoptotic indicating that the proteolytic events important for each process are different (Lippens 
et al. 2000). 
  34 
1.3 Rho GTPases 
1.3.1 Introduction 
Rho family GTPases are master regulators of many aspects of cellular behaviour including the 
regulation of the actin cytoskeleton, vesicular transport, gene expression, enzymatic activities, 
the cell cycle, cell morphogenesis, cell migration and apoptosis (Etienne-Manneville et al. 2002; 
Jaffe et al. 2005). Rho GTPases are a distinct family within the Ras superfamily of small 
GTPases with 22 mammalian genes encoding Rho GTPases identified (Jaffe et al. 2005). These 
small GTPases are 20-30 kDa and share 30-50% identity (Takai et al. 2001). Most Rho GTPases 
act as “molecular switches” cycling between two conformations; the ‘active state’ bound to GTP 
and the ‘inactive state’ bound to GDP (Etienne-Manneville et al. 2002; Jaffe et al. 2005) (Figure 
8). The ability to hydrolyse GTP is determined by five primary sequence motifs in the GTP-
binding domain, which is highly conserved among the members of the Ras superfamily (Bourne 
et al. 1991; Takai et al. 2001). 
 
The switch mechanism by which Rho GTPases function enables Rho GTPases to sort and 
amplify transmembrane signals for the regulation of complex cellular processes. Rho GTPase 
activity is regulated by ancillary proteins, which facilitate the exchange of GDP and the 
hydrolysis of GTP, thereby regulating the switch (Schmidt et al. 2002; Bustelo et al. 2007) 
(Figure 8). Guanine nucleotide exchange factors (GEF) stimulate the release of GDP allowing 
GTP to bind, thereby activating the GTPase (Rossman et al. 2005). Once in a GTP-bound state, 
Rho GTPases can activate downstream effectors. GTPase activating proteins (GAP) stimulate 
the intrinsic GTPase activity hydrolysing GTP to GDP inactivating the switch (Bernards 2003). 
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This form is the resting state and guanine nucleotide dissociation inhibitors (GDI) can bind to 
the Rho GTPase maintaining the association with GDP. GDIs block spontaneous activation of 
the Rho GTPases by covering their C–terminal geranylgeranyl moiety stabilising them as 
cytosolic Rho-GDI complexes (Olofsson 1999; Bustelo et al. 2007). Regulation of the Rho 
switch is complex with over 60 GEFs and 70 GAPs identified (Etienne-Manneville et al. 2002). 
Rho GTPases can also be regulated through posttranslational modifications such as  
phosphorylation, ubiquitination and isoprenylation (Lang et al. 1996; Wang et al. 2003; Bustelo 
et al. 2007). 
 
1.3.2 RhoA  
RhoA is a member of the Rho GTPase family and has been implicated in many different cellular 
processes, including cytoskeletal organisation, gene expression, proliferation, differentiation and 
apoptosis (Takai et al. 2001). Known downstream effectors of RhoA include: Rho kinases 
(ROCK I and ROCK II), citron, the mammalian diaphanous-related formins (mDia1, 2 and 3), 
protein kinase C-related proteins (PRKs) and protein kinase N1 (PKN) (Schwartz 2004). ROCK 
I and II were the first Rho effectors to be identified and were characterised for their roles in 
mediating the formation of RhoA-induced actin stress fibres and focal adhesions (Ishizaki et al. 
1996; Leung et al. 1996; Ishizaki et al. 1997; Riento et al. 2003). Citron is involved in 
cytokinesis and cell cycle progression (Madaule et al. 2000). The mammalian diaphanous-
related formins stimulate actin polymerisation and stabilise microtubules during cell migration 
(Schwartz 2004). Protein kinase N1 is involved in endosomal trafficking (Amano et al. 1996; 
Schwartz 2004). 
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Figure 8 The Rho GTPase cycle. 
Guanine nucleotide exchange factors (GEF) stimulate the release of GDP allowing GTP to bind. 
In a GTP-bound state Rho GTPases can activte downstream effectors. GTPase activating 
proteins (GAP) stimulate the intrinsic GTPase activity to hydrolyse GTP returning the Rho 
GTPase to an inactive state. Guanine nucleotide dissociation inhibitors (GDI) bind to the Rho 
GTPase maintaining the association with GDP.  
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1.3.3 Regulation of actin stress fibres by RhoA 
RhoA regulates actomyosin-based contractility through its downstream effectors ROCK I and 
ROCK II, which are required for the formation of stress fibres in fibroblasts, epithelial and 
endothelial cells (Riento et al. 2003). Actin stress fibres are contractile fibres that and are 
composed of actin filaments, α-actinin, myosin II, tropomyosin and myosin light chain kinase 
(MLCK). They run along the cell body and terminate at focal adhesions attaching the cell to the 
underlying substratum generating tension, enabling cell adhesion and cell spreading (Pellegrin et 
al. 2007).  
 
ROCK I and ROCK II are important for the formation of RhoA-induced actin stress fibres. 
Inhibition of ROCK activity results in the loss of actin stress fibres and focal adhesions whereas 
over-expression of ROCK induces actin stress fibre formation (Leung et al. 1996; Ishizaki et al. 
1997; Uehata et al. 1997). ROCK I/II are serine/threonine kinases that are associated with actin 
stress fibres and phosphorylate a number of proteins involved in actin stress fibre formation 
(Katoh et al. 2001; Pellegrin et al. 2007). Phosphorylation of the motor protein, myosin II, 
induces actomyosin-based contraction and increased actin stress fibre assembly. MLC II can be 
phosphorylated by the calcium-dependent MLCK or by ROCK I/II (Amano et al. 1996; Katoh et 
al. 2001; Pellegrin et al. 2007). Myosin light chain phosphatase (MLCP) dephosphorylates 
myosin II inhibiting contractility, ROCK prevents this by phosphorylating and inhibiting the 
phosphatase (Kimura et al. 1996). To increase actin stress fibre formation ROCK 
phosphorylates LIM kinase I and II, which are involved in the regulation of actin dynamics 
(Maekawa et al. 1999; Scott et al. 2007). Phosphorylated LIM kinase I and II in turn 
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phosphorylates and inhibits the actin depolymerising activity of cofilin resulting in increased 
actin stress fibre assembly (Scott et al. 2007). 
 
Actin stress fibres produced by the actions of calcium-dependent myosin light chain kinase are 
usually located to the periphery of the cell whereas RhoA-ROCK induced stress fibres are 
located in the cell body (Totsukawa et al. 2000). Over-expression of constitutively active ROCK 
induces thick actomyosin bundles with a stellate morphology that are distinct from actin stress 
fibres induced directly by Rho (Amano et al. 1996; Leung et al. 1996). RhoA and ROCK I/II 
regulate cell adhesion through the formation of these contractile actin stress fibres, which in turn 
induces the formation of focal adhesions (Petit et al. 2000).  
 
1.3.4 ROCK I 
The serine/threonine kinase p160ROCK/ROCKI was identified as a Rho substrate by T. Ishizaki 
et al. (1996) and was confirmed to be a downstream target of Rho but not Rac, and to mediate 
the formation of focal adhesions and stress fibres (Ishizaki et al. 1997). A homologue of 
ROCKI/p160ROCK/ROKB was isolated by Leung et al. (1996) and is known as ROKa/Rho-
kinase/ROCKII. ROCK I/II are serine/threonine kinases of 160kDa and consist of an amino-
terminal kinase domain followed by a coiled-coil region. At the carboxyl terminal there is a Rho 
binding domain and a pleckstrin homology (PH) domain with an internal cysteine-rich domain 
(Ishizaki et al. 1997; Riento et al. 2003). The carboxyl terminal region of ROCK I/II constitutes 
an autoinhibitory region reducing kinase activity (Amano et al. 1999). The amino acid 
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sequences of the two ROCK isoforms have 65% identity with the highest identity (92%) in the 
kinase domains (Nakagawa et al. 1996). 
 
1.3.5 Regulation of ROCK activity 
In its GTP-bound form, RhoA enhances the activity of ROCK I/II by binding to the Rho-
binding domain relieving the autoinhibition mediated by the carboxyl terminal region (Leung et 
al. 1995; Nakagawa et al. 1996; Fujisawa et al. 1998). The best-characterised activator of ROCK 
is RhoA, but other mechanisms for ROCK regulation have been identified. Lipids, such as 
arachidonic acid, can activate ROCK I/II (Feng et al. 1999). Protein oligomerisation might also 
regulate ROCK activity through amino terminal transphosphorylation (Riento et al. 2003). 
During apoptosis, caspase 3 cleaves the C-terminus of ROCK I resulting in a loss of 
autoinhibition with the active kinase responsible for membrane blebbing (Coleman et al. 2001; 
Sebbagh et al. 2001). Over-expression of the Rho family GTPases GEM, RhoE and Rad has 
been shown to inhibit ROCK function, with GEM and RhoE inhibiting ROCK I induced neurite 
retraction, while Rad inhibits ROCK II functions (Ward et al. 2002; Riento et al. 2003).  
 
1.3.6 Y-27632 
A number of pharmacological compounds which inhibit ROCK I/II kinase activity have been 
identified and used to investigate the function ROCK I/II (Darenfed et al. 2007). The most 
commonly used of these is a small molecule inhibitor called Y-27632 ((+)-(R)-trans-4-(1-
aminoethyl)-N-(4 pyridyl)-cyclohexanecarboxamide). Y-27632 was first discovered by 
Yoshitomi Pharmaceutical Industries and inhibits ROCK I/II by competing for the ATP binding 
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site (Ishizaki et al. 2000; Darenfed et al. 2007). The use of this compound was shown to inhibit 
smooth muscle contractility and normalise high blood pressure in rat models by inhibiting 
ROCK I/II (Ishizaki et al. 2000). Y-27632 is commonly used at a concentration of 10µM where 
it was thought to be a specific inhibitor of ROCK I/II (Davies et al. 2000). However, further 
analysis revealed that at this concentration protein kinase C-related protein kinase (PRK-2) is 
also inhibited by Y-27632 (Davies et al. 2000). PRK-2 is an effector of both Rho and Rac and is 
involved in the regulation of the actin cytoskeleton (Vincent et al. 1997). Therefore studies that 
rely solely on the use of Y-27632 should be treated with caution. 
 
1.3.7 ROCK substrates 
The kinase domains of ROCK I and ROCK II share 92% identity and many of the proteins 
described as ROCK substrates have only been categorised using one isoform. However, the two 
ROCK isoforms have been shown to interact with and phosphorylate different substrates to 
different degrees. For example, ROCK I binds to and strongly phosphorylates RhoE whereas 
ROCK II does not bind to RhoE and only weakly phosphorylates RhoE in vitro (Riento et al. 
2005). Studies using RNAi to specifically deplete either ROCK I or ROCK II have identified 
distinct substrates and distinct roles for each protein (Yoneda et al. 2005; Lock et al. 2009) 
 
Known ROCK substrates include: MLC II, MLCP, LIM kinase I and II, the ERM family 
proteins (ezrin, radixin, moesin), NHE-1 and several intermediate filament proteins, such as 
desmin, vimentin and glial fibrillary acidic protein, are also phosphorylated by ROCK I/II to 
regulate intermediate filament structure assembly (Schwartz 2004). MLCP, myosin II, LIM 
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kinase I and II are all essential for the formation of actin stress fibres (Pellegrin et al. 2007). The 
ERM proteins act as linkers between actin filaments and the plasma membrane (Fehon et al. 
2010). The Na/H+ antiporter NHE-1 promotes the reorganisation of actin filaments and focal 
adhesion assembly (Schwartz 2004). ROCK I/II can oligomerise and may regulate kinase 
activity through amino terminal transphosphorylation (Garg et al. 2008). 
 
1.3.8 Role of RhoA and ROCK I/II in keratinocyte terminal differentiation 
In the early stages of keratinocyte differentiation Rho signaling is activated and plays a role in 
the establishment of calcium-dependent cell–cell adhesion, which is important for 
differentiation (Braga et al. 1997). Rho activity also suppresses the expression of differentiation 
markers, such as keratins 1 and 10, through its effector citron kinase and for differentiation to 
occur citron kinase is selectively down-regulated (Grossi et al. 2005). Consistant with this the 
inhibition of endogenous Rho signaling induces the expression of differentiation markers 
(Grossi et al. 2005). 
 
The RhoA effectors, ROCK I and ROCK II have also been implicated in regulating the switch 
between proliferation and terminal differentiation in keratinocytes (McMullan et al. 2003; Lock 
et al. 2009). ROCK I/II activity increases during suspension induced terminal differentiation and 
inhibiting ROCK I/II activity with treatment with Y-27632 inhibites terminal differentiation and 
increases cell proliferation. Expression of a constitutively-active truncated ROCK II construct 
induces cell cycle arrest and increases the expression of differentiation markers such as 
involucrin, desmocollin 1 and 2, and desmoplakin (McMullan et al. 2003). Recent data using 
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siRNA to analyse ROCK I and ROCK II function has revealed opposing roles for ROCK I and 
ROCK II in keratinocyte differentiation. ROCK I-depleted cells have an increase in keratin 10 
and involucrin and a decrease in keratin 5 whereas ROCK II-depleted cells have the opposite 
profile with decreased keratin 10 and involucrin and increased keratin 5 protein levels. Taken 
together, these data suggest that loss of ROCK I expression promotes keratinocyte terminal 
differentiation and that loss of ROCK II expression has the opposite effect, inhibiting 
keratinocyte terminal differentiation (Lock et al. 2009). 
 
1.3.9 Role of RhoA and ROCK I/II in cell proliferation 
RhoA regulates G1-S phase transition with the inhibition of RhoA leading to G1 cell cycle 
arrest (Olson et al. 1995). RhoA inhibits the expression of the cyclin dependent kinase inhibitor, 
p21Cip1 and promotes the up-regulation of cyclin D1 (Olson et al. 1998; Welsh et al. 2001). 
RhoA has been proposed to have a dual role in regulating cyclin D1, blocking early G1 
expression of cyclin D1 and promoting sustained extracellular signal-regulated kinase (ERK) 
activation and mid-G1 expression of cyclin D1 (Welsh et al. 2001). The induction of type-D 
cyclins is the rate limiting step in the G1 to S phase transition and thus their regulation is 
thought to play a significant role in controlling cell cycle progression through G1 phase (Welsh 
et al. 2001). However inhibition of ROCK I/II activity with Y-27632 increases cell proliferation 
and expression of active ROCK II induces cell cycle arrest in keratinocytes (McMullan et al. 
2003). 
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Cytokinesis is the last stage of the cell cycle and it is driven by actomyosin contractility 
constricting the parent cell into two daughter cells. Cycling between active and inactive forms of 
Rho is required for cytokinesis to occur and the Rho effectors ROCK I/II and citron are also 
involved (Madaule et al. 2000). 
 
1.3.10 Role of RhoA and ROCK I in apoptosis 
During apoptosis one of the first morphological changes observed is membrane blebbing, which 
is regulated by myosin light chain phosphoryation and actomyosin contractility (Mills et al. 
1998). Once caspase 3 is activated it can in turn activate ROCK I (but not ROCK II) by cleaving 
the autoinhibitory C-terminus of ROCK I and induce membrane blebbing (Coleman et al. 2001; 
Sebbagh et al. 2001). In cells treated with an apoptotsis-inducing agent the over-expression of 
full-length ROCK I has no affect on apoptosis (Ongusaha et al. 2006). However, over-
expression of the 130kDa fragment of ROCK I produced by caspase 3 cleavage increases 
apoptosis by increasing caspase 3 activation (Chang et al. 2006; Ongusaha et al. 2006). 
Depletion of ROCK I using RNAi or treatment with the ROCK I/II inhibitor Y-27632 protects 
cells from camptothecin-induced apoptosis (Ongusaha et al. 2006). Increasing evidence suggests 
that ROCK I/II-mediated focal adhesion and integrin activation are involved in cell survival as 
ROCK I/II inhibition can initiate events committing the cell to undergo apoptosis (Shi et al. 
2007). As well as membrane blebbing ROCK I/II signaling is involved in the fragmentation of 
apoptotic cells (Shi et al. 2007). The role of ROCK I/II in the initial stages of apoptosis remains 
less clear with both pro-apoptotic and anti-apoptotic roles being identified (Ongusaha et al. 
2006; Shi et al. 2007). 
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1.4 RhoE 
1.4.1 Introduction 
The small GTPase RhoE (also known as Rnd3) has been implicated in the regulation of many 
cellular processes including the organisation of the actin cytoskeleton, proliferation, 
differentiation and apoptosis (Guasch et al. 1998; Riento et al. 2003; Villalonga et al. 2004; 
Bektic et al. 2005; Liebig et al. 2009). RhoE is a member of the Rnd family, which consists of 
Rnd1, Rnd2 and Rnd3/RhoE. Although RhoE is most closely related to the Rho subfamily 
(RhoA, RhoB and RhoC), novel structural and biochemical properties have been identified 
(Foster et al. 1996). RhoE lacks GTPase activity, is unaffected by GAPs and has a high affinity 
for GTP, resulting in a constitutively active form that is not regulated by the conventional 
GTPase cycle (Foster et al. 1996; Guasch et al. 1998; Nobes et al. 1998) (Figure 8). Instead it is 
thought that gene regulation, post-translational modification and localisation contribute to 
RhoE’s regulation (Riento et al. 2005). Up-regulation of RhoE expression has been 
demonstrated in response to a number of different stimuli. These include growth factor 
stimulation (Tanimura et al. 2002; Riento et al. 2003), B-Raf/MEK activation (Hansen et al. 
2000; Klein et al. 2008), p53 induction (Ongusaha et al. 2006), cytotoxic drug treatment 
(Villalonga et al. 2004; Shurin et al. 2008), and UVB irradiation (Murakami et al. 2001; Boswell 
et al. 2007). RhoE is a substrate for ROCK I, which phosphorylates RhoE on a number of 
residues, regulating RhoE activity by increasing protein stability and altering the localisation of 
RhoE (Riento et al. 2005; Ongusaha et al. 2006). Endogenous RhoE localises both to membrane 
and cytosolic components (Riento et al. 2003). ROCK I-phosphorylated RhoE is localised in the 
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cytosol suggesting RhoE membrane association is regulated by ROCK I and PKCα 
phosphorylation (Riento et al. 2005; Madigan et al. 2009). In addition prenylation plays a key 
role in localising RhoE to the membrane (Foster et al. 1996). Phosphorylation of RhoE has been 
shown to correlate with actin stress fibre disruption and inhibition of Ras-induced 
transformation suggesting phosporylation regulates RhoE activity (Riento et al. 2005).  
 
1.4.2 RhoE and ROCKI 
Unlike active RhoA, which induces actin stress fibres and focal adhesions, over-expression of 
RhoE inhibits the formation of actin stress fibres in a number of different cell types (Guasch et 
al. 1998; Nobes et al. 1998; Riento et al. 2003). In MDCK cells expressing active RhoA, over-
expression of RhoE restores actin stress fibre formation to wildtype suggesting RhoE can inhibit 
RhoA signaling (Guasch et al. 1998). RhoA induces actin stress fibres through the activation of 
ROCK I/II (Pellegrin et al. 2007). However, of the known RhoA effectors (ROCK I, mDia1, 
PRK1 and ROCK II) RhoE only interacts with ROCK I (Riento et al. 2003; Riento et al. 2005). 
A number of possible mechanisms have been suggested for the inhibition of actin stress fibre 
formation by RhoE. Firstly RhoE binds to and activates p190RhoGAP, which in turn catalyses 
the intrinsic GTPase activity of RhoA inhibiting actin stress fibre formation (Wennerberg et al. 
2003). A second mechanism for RhoE inhibiting actin stress fibres involves RhoE binding to 
ROCK I inhibiting ROCK I-dependent phosphorylation of MLCP (Riento et al. 2003). In 
addition, RhoE and Rnd1 bind to a protein of unknown function called Socius (Katoh et al. 
2002). RhoE appears to localise Socius to the membrane resulting in the loss of actin stress 
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fibres (Katoh et al. 2002).  
 
Interestingly the interaction between RhoE and ROCK I does not occur through the Rho-binding 
domain of ROCK I, but through RhoE binding to the N-terminal kinase domain of ROCK I 
(Riento et al. 2005) (Figure 9). However, although RhoE and RhoA bind to different regions of 
ROCK I they cannot bind simultaneously to ROCK I (Riento et al. 2003). RhoE specifically 
binds to ROCK I but not ROCK II even though the kinase domains share 92% identity. 
However, the two regions surrounding the kinase domain, 1-76aa and 338-420aa, which are also 
important for RhoE binding and ROCK I dimerisation, are not conserved in ROCK II (Riento et 
al. 2003; Riento et al. 2005; Garg et al. 2008). An interesting feature of the interaction between 
ROCK I and RhoE is that the region of RhoE which binds to ROCK I is independent of its 
switch/effector region and involves the opposite surface of RhoE (Komander et al. 2008). This 
type of binding is uncommon among GTPase complexes (Vetter et al. 2001; Komander et al. 
2008). Site-directed mutagenesis to disrupt the ROCK I:RhoE interaction resulted in a loss of 
RhoE phosphorylation but no increase in actin stress fibres (Komander et al. 2008). However, 
when mutations in the switch/effector region of RhoE were made no loss of actin stress fibres 
occur, even though the mutated RhoE was still able to bind ROCK I (Komander et al. 2008). 
These data suggest RhoE’s effect on actin stress fibre formation is not due to antagonising 
ROCK I (Riento et al. 2003) but by binding to other proteins via its effector region to prevent 
actin stress fibre formation (Komander et al. 2008). 
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Figure 9 The structure of ROCK I and ROCK II. 
Domains present in ROCK I and ROCK II include; an N-terminal kinase domain, a Rho-binding 
domain (RBD), and a pleckstrin homology (PH) domain with an internal cysteine-rich domain 
(CRD). Also indicated is the region predicted to form a coiled-coil structure, and the RhoE 
binding region of ROCK I (numbers indicate amino acids). 
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1.4.3 Role of RhoE in terminal differentiation of keratinocytes 
In a recent study endogenous RhoE expression was reported to be up-regulated during 
keratinocyte terminal differentiation induced by calcium addition, TPA treatment or E-cadherin 
clustering (Liebig et al. 2009). Over-expression of RhoE results in increased cell size and 
localisation of RhoE over-expressing keratinocytes to the stratified layers (Liebig et al. 2009). In 
RhoE-depleted keratinocytes both stratification and cell size was unaffected but a delay in the 
up-regulation of the differentiation markers involucrin, keratin 1 and transglutaminase was 
observed (Liebig et al. 2009). ROCK kinase activity during the induction of keratinocyte 
differentiation is required for the up-regulation of RhoE expression (Liebig et al. 2009) and this 
would be consistant with that of ROCK being required for keratinocyte terminal differentiation 
(McMullan et al. 2003). These results indicate RhoE expression increases the potential of 
keratinocytes to undergo stratification (Liebig et al. 2009). However, in vivo, over-expression of 
RhoE in the skin of transgenic mice had no effect on epidermal histology (Boswell et al. 2007). 
 
1.4.4 Role of RhoE in cell proliferation 
A number of studies have implicated RhoE in the regulation of cell proliferation. However, the 
data are contradictory. Over-expression of RhoE in fibroblasts and U87 glioblastoma cells 
induces a G1 phase cell cycle arrest due to a decrease in cyclin D1 levels (Villalonga et al. 2004; 
Poch et al. 2007). ERK activation, which is important for cyclin D1 expression, was inhibited in 
U87 glioblastoma cells but not fibroblasts over-expressing RhoE (Villalonga et al. 2004; Poch et 
al. 2007). Another study in which RhoE was over-expressed in prostate cancer cell lines, 
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showed a G2/M phase cell cycle arrest due to a decrease in cyclin B and cyclin-dependent 
kinase 2 protein levels (Bektic et al. 2005). These studies suggest that RhoE over-expression 
inhibits cell cycle progression, although the mode of action is different in each case. 
Keratinocytes depleted of RhoE showed increased proliferation and enhanced levels of ERK 
phosphorylation (Liebig et al. 2009). However, depletion of RhoE in melanoma cells has no 
effect on proliferation (Klein et al. 2009).  
 
Correlating with its ability to block cell proliferation, RhoE over-expression inhibits both Ras 
and Raf induced cell transformation (Villalonga et al. 2004). RhoE expression is induced by Raf 
activation (Hansen et al. 2000) and by mutant B-RAF expression (Klein et al. 2008). RhoE has 
also been implicated as a regulator of cross-talk between the B-RAF/MEK/ERK and 
Rho/ROCK/LIM kinase/cofilin pathways with RhoE expression correlating with the progression 
toward an invasive phenotype in melanoma cell lines (Klein et al. 2008). Consistent with this 
RhoE depletion decreased migration and invasive outgrowth (Klein et al. 2008). Collectively, 
these data highlight the importance of RhoE, a mutant B-RAF effector, to invasive melanoma 
behavior (Klein et al. 2009). 
 
1.4.5 Role of RhoE in apoptosis 
RhoE has been implicated in apoptosis by several studies. However, as with RhoE’s role in cell 
proliferation, no firm conclusions can be drawn from the data. One study in prostate cancer cell 
lines found that RhoE was under-expressed when compared to normal prostate cells (Bektic et 
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al. 2005). When RhoE was over-expressed in the prostate cancer cell lines apoptosis was 
induced (Bektic et al. 2005). In a separate study, RhoE was identified as an up-regulated gene in 
response to NF-κB2/p52 signaling in prostate cancer cell lines. NF-κB2/p52 signaling protects 
prostate cancer cells from androgen deprivation-induced apoptosis (Nadiminty et al. 2010). The 
discrepancies in RhoE expression in these two studies may be due to the stage of the prostate 
cancer cell lines used. The initial stages of prostate cancer are androgen-dependent and 
progression to a castration-resistant stage occurs after failure to treat with androgen-deprivation 
therapy. Cell lines used in the Nadiminty et al. paper were early stage prostate cancer cell lines 
where NF-κB2/p52 signaling is critical. In the Bektic et al. paper androgen-insensitive prostate 
cancer cells such as PC-3 and DU145 were used. In these cells RhoE over-expression induced 
cell cycle arrest and apoptosis (Bektic et al. 2005; Nadiminty et al. 2010).  
 
Another study demonstrated that the over-expression of RhoE in U87 glioblastoma cells and 
other tumour cell lines induced apoptosis (Poch et al. 2007). The over-expression of RhoE in the 
Bektic et al. (2005) and Poch et al. (2007) studies increased the basal/spontaneous rate of 
apoptosis (Bektic et al. 2005; Poch et al. 2007). However, apoptosis was not induced when 
RhoE was over-expressed in fibroblasts (Villalonga et al. 2004).  
 
Some studies have implicated RhoE in a protective role against apoptosis. In transgenic mice 
RhoE over-expression in the skin increased protection from UVB irradiation (Boswell et al. 
2007). In addition over-expression of RhoE in a gastric adenocarinoma cell line enhanced 
resistance to multiple antitumour drugs by suppressing the expression of Bax at a post-
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transcriptional level (Li et al. 2009).  
 
RhoE expression is induced by a number of apoptosis-inducing stimuli, including camptothectin 
(Ongusaha et al. 2006), cisplatin (Villalonga et al. 2004) and UVB irradiation (Murakami et al. 
2001; Boswell et al. 2007). RhoE is also a transcriptional target of the tumour suppressor protein 
p53, which promotes apoptosis, and induces RhoE transcription in response to DNA damage 
(Jeffers et al. 2003; Ongusaha et al. 2006). Two studies, which used siRNA to inhibit RhoE 
induction following apoptotic stimuli, increased the levels of apoptosis (Ongusaha et al. 2006; 
Boswell et al. 2007). Interestingly siRNA, whilst preventing the induction of RhoE, had no 
affect on basal expression of RhoE (Ongusaha et al. 2006; Boswell et al. 2007). Ongusaha et al. 
(2006) reported that RhoE inhibits ROCK I activity during genotoxic stress (Ongusaha et al. 
2006), however, Boswell et al. (2007) reported that RhoE induction was independent of p53 and 
ROCK I activity (Boswell et al. 2007). In a separate study depletion of RhoE in melanoma cells 
had no affect on apoptosis (Klein et al. 2009).  
 
1.5 Project aims 
Normal homeostasis of the epidermis requires a balance between proliferation and 
differentiation (Fuchs 2007). Apoptosis is also important for the removal of damaged or infected 
cells from the epidermis (Lippens et al. 2009). The RhoA effectors ROCK I and ROCK II have 
been implicated in being key regulators of the switch between proliferation to differentiation in 
keratinocytes, with distinct functions for each kinase (McMullan et al. 2003; Lock et al. 2009). 
  52 
ROCK I has also been implicated in having a role in apoptosis (Coleman et al. 2001). Here I 
investigated the function of the ROCK I binding protein RhoE (Riento et al. 2003), using 
keratinocyte cell lines in which RhoE expression was both stably and transiently depleted, using 
RNAi. These cell lines were used to investigate the role of RhoE in keratinocyte proliferation, 
differentiation and apoptosis.  
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 General laboratory reagents 
Y-27632 (Cat. No. Y0503) and cisplatin (cis-Diammineplatinum(II) dichloride) (Cat. No. 
P4394) was purchased from Sigma (Poole, UK). Recombinant human TRAIL (TNF-related 
apoptosis-inducing ligand) (Cat. No. 375-TEC) was purchased from R&D systems 
(Minneapolis, MN). All other chemicals were purchased from Sigma (Poole, UK) unless 
otherwise stated in text. 
 
2.1.2 Cell culture materials  
Cell culture reagents were purchased from Gibco (Paisley, UK) or Sigma (Poole, UK). 
 
2.1.3 Constructs 
Over expression vectors containing wild type (wt) mouse RhoE and empty vector (EV) control, 
pCMV5RhoEFlag and pCMV5EVFlag, were a gift from A. Ridley (King's College London) 
(Riento et al. 2003), pCAG-myc-p160 (WT) wild type ROCK I and pCAG-myc-KD kinase dead 
ROCK I were a gift from S. Narumirya (Kyoto university Japan) (Ishizaki et al. 1997). For 
creating a RhoE-depleted and control cell line shRNAmir human pGIPZRhoE (Cat. No. 
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RHS4430-98513300) and pGIPZNSC (non-silencing control) (Cat. No. RHS4346) were 
purchased from Open Biosystems. For the sequence of shRNAmir human pGIPZRhoE mapped 
to the human RhoE sequence See Appendix 1. 
See Table 1 
 
2.1.4 Oligos 
Two custom siRNA oligos against RhoE were purchased from Dharmacon, in transient RhoE 
depletions oligo A was predominantly used (oligo B was used for verification (stated in text)). 
For the sequences of RhoE oligos mapped to the human RhoE sequence See Appendix 1. On 
target siRNA oligos against ROCKI_6 (Cat. No. J-003536-06-0005), ROCKI_7 (Cat. No. J-
003536-07-0020), Plakglobin (Diepgen et al.) (Cat. No. J-011708-10), Desmoplakin (Dsp) (Cat. 
No. J-019800-07) and PRMT5 (Cat. No. J-015817-06) were purchased from Dhramacon. 
ROCKII_5 (Cat. No. SI02223746), ROCKII_6 (Cat. No. SI02223753) and non-silencing control 
(Ctrl) (Cat. No. SI03650325) were purchased from Quiagen.  
See Table 1  
 
2.1.5 Antibodies 
See Table 2 
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Table 1 Target sequences of shRNA constructs and siRNA oligos used in this study 
 
Oligo / Construct 
name 
Target sequence 
shRNAmir pGIPZRhoE  UCUGAUAAUCUGUUGGUUUAU 
RhoE_A UAGUAGAGCUCUCCAAUCA 
RhoE_B CAAACAGAUUGGAGCAGCU 
Ctrl AAUUCUCCGAACGUGUCACGU 
ROCKI_6 CUACAAGUGUUGCUAGUUU 
ROCKI_7 UAGCAAUCGUAGAUACUUA 
ROCKII_5 AAGCUACAUAUGGAGCUUAAA 
ROCKII_6 AUGCACUUGUAUAAAGCCAUA 
Dsp GGGAUGAGUUCACCAAACA 
PG AGACAUACACCUACGACUC 
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Table 2 Antibodies used in this study 
Antibody Antibody 
Name 
Supplier Cat. No. Species Dilution 
for WB 
Dilution 
for IF 
Actin Alexa-
594-
conjugated 
Phalloidin 
Molecular 
Probes 
A-12381 N/A N/A 1:400 
Bax - Cell 
Signaling 
Tec. 
2774 Rabbit 1:250 1:100 
BrdU - Boheringer 
Mannheim 
1170376 Mouse N/A 1:10 
Caspase 9 - Cell 
Signaling 
Tec. 
9502 Rabbit 1:1000 N/A 
Cyclin D1 DCS6 Cell 
Signaling 
Tec. 
2926 Mouse 1:1000 N/A 
Desmocollin 
1 
U100 Progen 65192 Mouse 1:500 N/A 
Desmocollin 
2 
- Progen 610120 Rabbit 1:500 1:100 
Desmocollin 
3 
U114 Progen 65193 Mouse 1:100 1:100 
Desmoglein 
1 and 3 
32-2B David 
Garrod 
- Mouse 1:25 N/A 
Desmoglein 
2 
33-3D David 
Garrod 
- Mouse 1:25 N/A 
Desmoglein 
2 
10G11 Progen 61059 Mouse 1:10 N/A 
Desmoglein 
3 
G194 Progen 651112 Mouse 1:10 N/A 
Desmoplakin 11-5F David 
Garrod 
- Mouse 1:25 1:50 
Desmoplakin H300 Santa Cruz sc-33555 Rabbit 1:500 N/A 
Ecadherin HECD1 Vania 
Braga 
- Mouse 1:500 1:100 
ERK  Santa Cruz sc-94 Rabbit 1:2000 N/A 
Phospho-
ERK 
pERK Santa Cruz sc-7383 Mouse 1:1000 N/A 
Involucrin SY-5 ICRF - Mouse 1:1000 N/A 
Keratin 1 KRT1 Abnova H000038 Mouse 1:1000 N/A 
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48-M01 
Keratin 5 EP1601Y Abcam ab52635 Rabbit 1:20,000 1:100 
Keratin 14 - Thermo-
scientific 
MS-115-
PO 
Mouse 1:500 N/A 
Pan-keratin - Invirogen 18-0059 Rabbit N/A 1:100 
Mitotracker CMXRos Molecular 
Probes 
M-7512 N/A N/A  
Myc-tag 9B11 Cell 
Signaling 
2276 Mouse 1:1000 1:100 
Plakoglobin VB3 Vania 
Braga 
- Rabbit 1:500 1:100 
Plakoglobin  BD  Trans. 
Labs. 
610253 Mouse 1:1000 - 
Periplakin AE11 Santa Cruz sc-80605 Mouse 1:100 N/A 
RhoE  Upstate 05-723 Mouse 1:500 1:100 
ROCKI H-85 Santa Cruz sc-5560 Rabbit 1:250 N/A 
ROCKII - BD  Trans. 
Labs. 
610623 Mouse 1:500 N/A 
α-Tubulin DM1A Sigma T6199 Mouse 1:10,000 1:100 
Hoechst 
33342 
- Invitrogen H21492 N/A N/A 1:400 
Anti-mouse 
FTIC 
- Jackson 
Labs 
115-095-
146 
Goat N/A 1:100 
Anti-mouse 
Texas Red 
- Jackson 
Labs 
115-075-
146 
Goat N/A 1:100 
Anti-rabbit 
FTIC 
- Jackson 
Labs 
111-095-
144 
Goat N/A 1:100 
Anti-rabbit 
Texas Red 
- Jackson 
Labs 
111-075-
144 
Goat N/A 1:100 
IRDye Anti-
mouse 
800cw 
- Odyssey 926-
32210 
Goat 1:15,000 N/A 
IRDye Anti-
mouse 
680cw 
- Odyssey 926-
32220 
Goat 1:15,000 N/A 
IRDye Anti-
rabbit 800cw 
- Odyssey 926-
32211 
Goat 1:15,000 N/A 
IRDye Anti-
rabbit 680cw 
- Odyssey 926-
32221 
Goat 1:15,000 N/A 
Anti-mouse 
HRP 
- Amersham 
Life Sci. 
NA931 Sheep 1:5000 N/A 
Anti-rabbit 
HRP 
- Pierce 31460 Goat 1:5000 N/A 
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2.2 Methods 
2.2.1 Culture of HaCaT cells 
HaCaT cells are a human keratinocyte cell line (Boukamp et al. 1988) non-transfected HaCaT 
cells and those expressing pGIPZRhoE or pGIPZNSC were cultured in Dulbecco’s modified 
Eagles medium (DMEM) (Gibco Cat. No. 41966) supplemented with 50 units/ml penicillin, 50 
ng/ml streptomycin (Gibco) and 5% (v/v) foetal calf serum (FBS) (Sigma). SCC12F cells are a 
primary keratinocyte cell line and were cultured in defined keratinocyte-SFM serum-free 
medium (Gibco Cat. No.  10744-019). Cells were maintained at 37°C in a humidified 5% CO2 
atmosphere. Cells were passaged when they reached approximately 80% confluence and low 
passage stocks were stored in liquid nitrogen in 90% (v/v) (FBS) and 10% (v/v) 
dimethylsulphoxide.  
 
2.2.2 Generation of a RhoE-depleted keratinocyte cell line  
To generate a stable RhoE-depleted (shRhoE) and control (shNSC) keratinocyte cell line HaCaT 
cells were transfected with the shRNA constructs pGIPZ-RhoE and pGIPZ-NSC (Section 2.1.3) 
by nucleofection, based on electroporation, using the Amaxa Nucleofector kit V (Amaxa 
Biosystems Inc.).  For each transfection 3x106 cells/ml and 3 ug of DNA were used and 
transfections were performed according to the manufacturer’s instructions. shRhoE and shNSC 
stable cell lines were maintained in a selection of 0.5 µg/ml puromycin (Sigma Cat. No. P7522) 
diluted in complete growth medium.  
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2.2.3 Reconstitution of RhoE 
To rescue the levels of RhoE in the RhoE-depleted keratinocyte cell line (Section 2.2.2) RhoE 
was reconstituted using wild type mouse RhoE. shRhoE HaCaT cells were transiently 
transfected with pCVM5FlagRhoE (wild type mouse) or pCMV5EVFlag while shNSC HaCaT 
cells were transfected with pCMV5EVFlag by lipid transfection using Lipofectamine 2000 
(Invitrogen Cat. No. 11668-019). Forward transfections were performed in p6 well plates when 
cells were 60% confluent with each transfection using a total of 500 µl of Opti-mem (Invitrogen 
Cat. No. 11058-021) as diluting medium, 6 µl of Lipofectamine 2000, 3 µg of DNA and a total 
plating volume of 2.5 ml made up by normal growth medium minus penicillin and streptomycin. 
Transfections were performed according to the manufacturer’s instructions.  
 
2.2.4 Reverse transfection of siRNA in HaCaT cells  
A number of siRNA oligos were used in this study to deplete keratinocytes of proteins of 
interest (Section 2.1.4). HaCaT cells were transiently transfected with either a specific oligo or 
combination of oligos by lipid transfection using Lipofectamine RNAiMAX (Invitrogen Cat. 
No. 13778). Reverse transfections were performed in p6 well plates with each transfection using 
500 µl of Opti-mem (Invitrogen Cat. No. 11058-021) as diluting medium, 5 µl of Lipofectamine 
RNAiMAX and a total plating volume of 2.5 ml made up by normal growth medium minus 
penicillin and streptomycin. Concentrations of oligo used in each transfection were as follows 
siRhoE A and B oligos were 9 pmol while siPG and siDsp oligos were 18 pmol, the siCtrl oligo 
  60 
concentration corresponded to the highest concentration in each experiment. Transfections were 
performed according to the manufacturers instructions. For each experiment three reverse 
transfections were performed resulting in a 144-168 hrs knockdown. Treatments were 
performed during 24 hrs prior to lysis/fixation unless stated (Figure 10).  
 
2.2.5 Y-27632 Treatments  
Y-27632 is a pharmacological inhibitor of ROCKI/II and PRK-2 when used at 5 µM (Darenfed 
et al. 2007). All experiments in this study used Y-27632 at 5 µM. Y-27632 was diluted in 
normal growth medium and incubated with cells for varying time points (specified in text). The 
half-life of Y-27632 is 12-16 hrs so when a time point extending this time occurred fresh 
medium containing Y-27632 would be applied every 12 hrs. 
 
2.2.6 Induction of apoptosis 
In this study cisplatin was used to induce the intrinsic apoptosis pathway while TRAIL was used 
to induce the extrinsic apoptosis pathway (Walczak et al. 2000). Both stably and transiently 
RhoE-depleted cells were seeded at least 24hrs before being treated with either cisplatin or 
TRAIL (concentrations specified in text).  Cells were treated with cisplatin or TRAIL, diluted in 
normal growth medium, for 24 hrs in normal growth conditions before being fixed (Section 
2.2.17) and lysed (Section 2.2.9). Cisplatin is made up in N, N-dimethylformamide (DMF) and  
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Figure 10 Flow chart and time course of siRNA oligo transfection protocol. 
For each experiment in which siRNA was used to depleted RhoE levels HaCaT cells were 
transfected three times resulting in a 144-168 hours knock-down. Reverse transfections were 
performed enabling cell passage during the experiment. Treatments were performed 24 hours 
prior to lysis and/or fixation unless otherwise noted. 
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control experiments were performed using equal volumes of DMF added to the normal growth 
media. 
 
2.2.7 Rescue treatments 
shRhoE and shNSC cells (non-transfected (NT)) were seeded, onto cover slips, along side 
shRhoE with reconstituted RhoE (RhoE wt), shRhoE and shNSC cells transfected with empty 
vector (EV) (Section 2.2.3) in p6 well plates. 48 hrs after initial seeding and 24 hrs after 
transfection the cells were treated with cisplatin 60µM or TRAIL 25 ng/ml, diluted in normal 
growth medium, for 24 hrs before cover slips were fixed and cells were lysed. 
 
2.2.8 Calcium depletion 
Prior to calcium depletion shRhoE and shNSC cells were seeded on cover slips 48hrs and 
siRhoE and siNSC cells were transfected for 96-144 hrs. Calcium depletion was carried out as 
described previously (Leigh et al. 1994). Normal growth medium was removed and cells were 
washed twice in versene (0.02% (v/v) EDTA pH8.2 in PBS) before low calcium medium 
(DMEM-high glucose low calcium (Gibco Cat. No. 21068-028), 0.1 mM CaCl2, 5% calcium 
depleted FSB) was added back to cells and incubated for 24 hrs. Calcium depletion commenced 
for 24 hrs before phase microscopy, fixation and lysis or cisplatin addition (concentration 
specified in text) for 24 hrs or re-addition of calcium for 24 hrs before phase microscopy, 
fixation and lysis.  
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2.2.9 Cell lysis 
Adherent HaCaT cells were lysed by scrape lysis. Media was removed from adherent cells 
followed by 2 washes in PBS (phosphate-buffered saline). Cells were incubated with a small 
amount of 3xLaemelli buffer (125 mM tris-HCL pH6.8, 3% (w/v) SDS (sodium dodecyl 
sulfate), 1.735% (w/v) DTT (dithiothreitol), 15% glycerol, 0.1% (v/v) bromophenol blue) for 
4min before being scrape lysed and boiled at 100°C for 5 min followed by 15 sec sonication. 
Lysates were centrifuged at 14000 rpm for 1min and stored at -20°C. In experiments were 
cisplatin or TRAIL treatment was used the media taken off the adherent cells was retained and 
centrifuged at 14000 rpm for 1 min to pellet cells that had detached from the adherent layer. 
These pellets were added back to the cell lysate prior to boiling. 
 
2.2.10 SDS-PAGE 
SDS-PAGE was carried out as described previously (Laemmli 1970). 10-30 µl of cell lysate 
(Section 2.2.9) equalling ~15-25 µg of protein were loaded onto 7.5, 10 or 12.5% SDS-PAGE 
gel (4% stack) depending on the molecular weight of the protein being analysed.  Gels were run 
in tris-glycine running buffer (0.2 M glycine, 0.02 M tris, 0.1 M SDS) at 250V/25mA until the 
dye front reached the bottom. Molecular weight markers from New England Biolabs (Cat. No. 
P7708G) were run on each gel. Proteins were transferred onto a PVDF-FL membrane (Section 
2.2.11). 
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2.2.11 Immunoblotting 
Western blotting was carried out as described previously (Towbin et al. 1979). Following SDS-
PAGE (Section 2.2.10) proteins were transferred electrophoretically onto PVDF-FL membrane 
(Millpore Cat. No. IPFL00010) in tris-glycine transfer buffer (0.2 M glycine, 0.02 M tris, 20% 
(v/v) methanol) for 75 min at 100V/400mA at 4°C. None specific binding was blocked by 
incubating the membrane with 5% (w/v) milk in tris-buffered saline containing tween 20 
(TBST) (20 mM tris pH7.5, 150 mM NaCl, 0.05% (v/v) tween 20) for 1hr at room temperature 
or dried in methanol if using Odyssey developing method. The membrane was then incubated 
with the primary antibody, diluted in 5% (w/v) milk in TBST, overnight at 4°C and washed 4 
times for 10 min in TBST. Following this the membrane was then incubated with either 
horseradish-peroxidase (HRP)-conjugated secondary diluted in TBST or Odyssey secondary 
antibody diluted in 5% (w/v) milk in TBST for 1hr at room temperature and washed again 
(Odyssey secondary and second set of washes to be kept in the dark). Bound antibody was 
detected using a chemiluminescent kit (Pierce) and the signal was visualised by exposure to 
medical X-ray film (Scientific Lab Suppliers Ltd), which was processed using an X-ograph. 
Odyssey antibody detection was visualised by scanning the membrane onto an Odyssey infrared 
imaging system (LI-COR Biosciences). 
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2.2.12 Purification of plasmid DNA 
Constructs used in this study (Section 2.1.5) were purified using a maxiprep kit (Quiagen Cat. 
No. 12262). 5 ml of LB (Lurai Bertani broth) containing the appropriate selection was 
inoculated with E. coil transformed with the plasmid of interest and grown for 8 hrs at 37°C. 
This culture was then diluted into 500 ml of LB, again containing appropriate selection, and 
grown overnight at 37°C. Bacteria were harvested by centrifugation at 2350g for 15 min at 4°C 
and maxipreps were performed according to the manufacturers instructions. Purified DNA was 
stored at -20°C. 
 
2.2.13 Quantification of DNA concentration 
The concentration of DNA purified by maxipreps (Section 2.2.12) was determined by measuring 
the absorbance of the DNA solution diluted in dH2O at 260 nm. One optical density unit 
represents 50 µg/ml DNA.  
 
2.2.14 Preparation of competent cells 
To prepare E. coli for transformation with plasmid DNA, competent cells were prepared using 
calcium chloride method (Cohen et al. 1972). 5 ml of LB was inoculated with E. coli and grown 
overnight at 37°C. 500 µl of this culture was used to inoculate 50 ml of LB and this was grown 
on until an absorbance of 0.5 at 650 nm was measured. Cell were harvested by centrifugation at 
2350g for 5min and then resuspended in 10 ml of cold 100 mM calcium chloride. Cells were left 
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on ice for 20 min then harvested as before. Cells were resuspended in 5 ml of freeze thaw buffer 
(100 mM calcium chloride, 15% (v/v) glycerol) then aliquoted and stored at -70°C. 
 
2.2.15 Transformation of competent E. coli  
Competent cells were prepared as describe in (Section 2.2.14) and 50 ng of plasmid DNA was 
added to 100 µl of these cells. Cells were left on ice for 40 min then heat shocked at 42°C for 2 
min before being returned to ice for 5 min. 1 ml of LB without selection was added and cells 
were grown at 37°C for 90 min. Bacteria were pelleted by centrifugation at 14000 rpm for 2 min 
and resuspended in 100 µl of LB. Cells were plated onto agar plates containing the appropriate 
selection and grown overnight at 37°C.  
 
2.2.16 Preparation of glass cover slips for cell culture 
13 mm glass cover slips where treated for 5 min in concentrated nitric acid at room temperature. 
The nitric acid was then diluted into water and the cover slips were washed in water for 30 min. 
Following washing cover slips were washed in methanol that was left to evaporate at room 
temperature overnight. Cover slips were autoclaved before use. 
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2.2.17 Immunofluorescence staining  
Indirect immunofluorescence staining was performed as described previously (Akhtar et al. 
2000). Cells grown on pre-prepared glass cover slips (Section 2.2.16) were washed three times 
in PBS and fixed in PBS containing 4% (w/v) paraformaldehyde for 10min at room temperature. 
Following fixation and washing in PBS cells were permeabilised with 0.2% (v/v) Triton X100 
in PBS for 5 min. Cells were washed three times in PBS and the cover slips were incubated with 
primary antibody, diluted in PBS, for 1 hr at room temperature. Cover slips were wash three 
times in PBS and incubated with the appropriate FITC or Texas Red-conjugated secondary 
antibodies, diluted in PBS, for 1 hr at room temperature. Cover slips were wash extensively and 
mounted using Mowiol and immunostained cells were visualised using a Leica DMRB 
microscope equipped with a Hamamatsu ORCA camera. The images were captured and 
processed using OpenLab software (Improvision, UK). 
 
2.2.18 Immunofluorescence staining for Flag 
For Flag immunofluorescence staining blocks were used in the immunofluorescence staining 
protocol (Section 2.2.17) to reduce non-specific antibody binding. After fixation cells were 
incubated with 50 mM NH4Cl diluted in PBS for 10 min at room temperature before being 
permeabilised. Following permeabilsation cells were washed three times in PBS and cover slips 
were incubated in 20% (v/v) Heat-inactivated normal goat serum (HINGS) (Jackson Labs Cat. 
No. 005-000-121) in PBS for 30 min. Anti-Flag primary antibody was diluted in 20% (v/v) 
HINGS for 1 hr, the rest of the protocol is as described above. 
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2.2.19 MitoTracker incorporation and Bax immunofluorescence staining  
MitoTracker Red CMTRos was used to stain mitochondria. MitoTracker passively diffuses 
through the plasma membrane and accumulates in the mitochondria (Molecular Probes Cat. No. 
M-7512). MitoTracker was added to normal growth medium at 250 nM for 45 min prior to 
fixation. Fixation and permeabilised were carried out as described above in (Section 2.2.17). To 
reduce non-specific antibody binding cover slips were incubated in 4% (w/v) bovine serum 
albumin (BSA) in PBS for 10 min, the rest of the protocol is as described in (Section 2.2.17). 
 
2.2.20 Bax translocation  
HaCaT cells transfected with the shRNA constructs were seeded on cover slips 2 days prior to 
treatment of 25 ng of TRAIL for 6 hrs. Cover slips were incubated with MitoTracker (Section 
2.2.19) and then fixed and stained with anti-Bax and Hoechst 33342. Both the total number of 
nuclei and cells with punctate Bax staining were counted, with approximately 200 cells counted 
per condition. The condition of the cell and nuclei was also taken into account and if the cell had 
become rounded or the nuclei fragmented these cells were not included in the counts 
contributing to punctate Bax staining. 
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2.2.21 BrdU labelling of cells 
Entry into S-phase was analysed by incorporation of BrdU (Bromodeoxyuridine) using a BrdU 
labelling and detection kit from Boehringer Mannheim (Cat. No.  1296732). Cells were grown 
on glass cover slips and were incubated with BrdU, diluted in normal growth medium, for 1 hr 
in normal cell culture conditions. Cells were fixed in 70% ethanol in 50 mM glycine pH2 for 
20min at -20°C and BrdU incorporation was accessed by indirect immunofluorescence using 
monoclonal antibody against BrdU. Hoechst 33342 was used to label all nuclei. Cells were 
visualised on a Leica DMRB microscope equipped with a Hamamatsu ORCA camera, images 
were taken of both BrdU positive cells and Hoechst then combined for each field of view, with 
four fields of view for each condition.  The number of BrdU positive cells was expressed as a 
percentage of the total number of cells and statistical analysis was carried out using Microsoft 
Excel.  
 
2.2.22 Preparation of Mowiol 
Mowiol, for use in mounting cover slips for immunofluorescence, was prepared by rotating 2.4g 
Mowiol-4-88 (Calbiochem) in dH2O with 0.42 mM glycerol for 2hrs at room temperature then 
adding Tris-HCL pH8.5 to give a final concentration of 0.13 M. This was allowed to dissolve at 
50°C and then centrifuged at 5000g for 5 min at 4°C. A small O-phenyldiamine crystal was 
allowed to dissolve at 4°C in the dark and the Mowiol was aliquoted and stored at -70°C. 
 
  70 
2.2.23 Microinjection 
HaCaT cells were seeded on to cover slips 24 hrs prior to microinjection with 50 µg/ml pCAG-
myc-p160 (WT) (pCAGmycROCK I (wt)) wild type ROCK I or pCAG-myc-KD 
(pCAGmycROCK I (KD)) kinase dead ROCK I a gift from S. Narumirya (Kyoto university 
Japan) (Ishizaki et al. 1997). 6 hrs post injection, cover slips were fixed and stained with anti-
Myc, to visualise transfected cells, and Phalloidin, to visualise F-actin (Section 2.2.17). A Leica 
DMIRB microscope equipped with an Eppendorf micromanipulator 5171 (Eppendorf), using 
Femtotip II needles (Eppendorf).   
 
2.2.24 Confocal microscopy 
Cells were visualised on a Nikon A1R confocal microscope (Nikon) using a 60x oil lens. For 
each 3D image a Z series of 1µm stacks were taken by manually setting the gain and laser 
intensity as well as the bottom and top Z stack and allowing NIS-Elements to take both the Z 
series and channel series. The bottom and top Z series stacks were set at the cover slips surface 
and the last layer to contain evidence of cells. Gains and laser intensities were set and remained 
constant throughout. The images were captured and processed using NIS-Elements (Nikon).  
 
2.2.25 Phase contrast microscopy 
Cells were seeded onto plastic 48hrs prior to live phase microscopy. Cells were visualised on an 
Axiovert 135TV microscope (Zeiss) equipped with a QCam FAST1394 camera (Qimaging) 
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using a 32x phase one air lens. The images were captured and processed using QCapture 
(Qimaging). 
 
2.2.26 Transmission electron microscopy (TEM) 
TEM was used to visualise desmosomes in transiently RhoE-depleted cells. siRhoE and siCtrl 
HaCaT cells were plated onto plastic cover slips 48hrs prior to fixation. For fixation remove 
media and incubate with 2.5% (v/v) Gluteraldehyde in 0.1 M Cacodylate buffer solution pH 7.4, 
with 3% (w/v) sucrose and 0.1% (w/v) CaCl diluted in dH2O, for 1 hr at 4°C. Cover slips were 
embedded and sections were taken orthogonally to the plane of the cover slip and stained using 
negative staining (Work carried out by Theresa Morris,  Centre for Electron Microscopy, 
University of Birmingham). Images were taken on a Jeol 1200EX microscope. 
 
2.2.27 Colony forming efficiency assay  
The efficiency of keratinocytes to form colonies was analysis by experiments previously 
described elsewhere (Jones et al. 1993). Cells were seeded at a density of 1x103 cells/ml into a 
75 cm2 tissue culture flask and cultured for 12 days in normal growth medium. After 12 days 
cells were washed twice in PBS and fixed in PBS containing 4% (w/v) paraformaldehyde for 10 
min at room temperature and stained with 1% (w/v) rhodanile blue (Rheinwald et al. 1975). The 
number of colonies were counted and average colony area was determined using Photoshop. 
Each flask was scanned into Photoshop and saved under the same dimensions and the numbers 
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of colonies were counted. The differences in colony size were accessed by grouping numbers of 
colonies in the same size range into different classes. The approximate sizes of the colonies 
were established using Photoshop brush paint tools with pixel sizes 17, 27, 35, 45, 65 and over 
were classed as >65 (Figure 11). Colony size was expressed as a percentage of the total number 
of colonies and statistical analysis was carried out using Microsoft Excel. 
 
2.2.28 Cell cycle analysis by flow cytometry 
To analyse the cell cycle of transiently RhoE-depleted keratinocytes siRhoE and siCtrl HaCaT 
cells were seeded into cell culture flasks 24 hrs prior to analysis. Cells were removed from the 
flask by washing twice with versene (0.02% (v/v) EDTA pH8.2 in PBS) and treating with 
trypsin for 5 min at 37°C, cells were remove by strong agitation, normal growth medium was 
added and cells were pelleted at 1100 rpm. 1 x 105 cells were resuspended in 1:1 PBS and cell 
cycle buffer (10 μg/ml propidium iodide, 0.1 mM (w/v) sodium chloride, 1% (v/v) Triton X100) 
and incubated for 4 hrs at 4°C prior to analysis by flow cytometry. Staining was analysed using 
a FACS Calibur (Becton Dickinson) and the data evaluated using Cell Quest Pro software 
(Becton Dickinson). 
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Figure 11 Colony forming efficiency assay counting and sizing method. 
Flasks were scanned into Photoshop and saved under the same dimensions, the total number of 
colonies were counted. The differences in colony size were accessed by grouping numbers of 
colonies in the same size range into different classes. The approximate sizes of the colonies 
were established using Photoshop brush paint tools with pixel sizes 17, 27, 35, 45, 65 and over 
were classed as >65.  
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CHAPTER 3 RHOE AND THE CELL CYCLE 
 
3.1 Introduction 
Regulation of proliferation is essential for the normal homeostasis of the epidermis. 
Proliferation in the epidermis is confined to the basal layer and is carried out by stem cell and 
transit amplifying keratinocytes (Watt 1988; Gniadecki 1998; Fuchs 2007). Keratinocyte 
proliferation is mainly regulated in G1 phase of the cell cycle, progression through which is 
regulated by Rho GTPase activity (Olson et al. 1995; Gniadecki 1998). Progression from G1-S 
phase requires Cylin D1 expression but it is not essential as cyclin D1 knockout mice are viable 
(Robles et al. 1998). Rho inhibits the expression of the cyclin dependent kinase inhibitor, p21Cip1 
and promotes the up-regulation of cyclin D1 (Olson et al. 1998; Welsh et al. 2001). RhoE has 
been implicated in the regulation of cell proliferation by a number of studies, however a clear 
role for RhoE in proliferation has yet to be established (Villalonga et al. 2004; Bektic et al. 
2005; Poch et al. 2007; Klein et al. 2008).  
 
In this chapter the role of RhoE in keratinocyte proliferation is investigated by knocking down 
the level of endogenous RhoE in keratinocyte cells, using both stable and transient depletion. An 
increase in ROCK I-induced actin stress fibres was observed in RhoE-depleted keratinocytes 
along with altered colony morphology. Transient depletion of RhoE resulted in decreased levels 
of active ERK and cyclin D1 and a G1 phase cell cycle arrest. This was shown to be 
independent of ROCK I activity. 
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3.2 Results 
3.2.1 RhoE depletion induces stellate actin stress fibres 
To analyse RhoE function a stable RhoE-depleted keratinocyte cell line was generated using 
shRNAmir constructs against human RhoE (pGIPZ-RhoE) and a non-silencing control (pGIPZ-
NSC). HaCaT cells were transfected with the shRNA constructs using the Amaxa nucleofection 
system and were maintained in medium containing puromycin ensuring selection of transfected 
cells. Whole cell lysates were prepared and analysed using immunoblotting to assess the level of 
RhoE protein depletion (Figure 12). On SDS-PAGE RhoE runs as a doublet at ~ 29 kDa (Riento 
et al. 2005). Significant depletion of RhoE was observed and the depletion was stable during 
continued culture (Figure 12). 
 
It is well documented that RhoE over-expression inhibits actin stress fibre formation (Guasch et 
al. 1998; Nobes et al. 1998; Riento et al. 2003) by inhibiting both RhoA and ROCK I (Riento et 
al. 2003; Wennerberg et al. 2003). The effect of RhoE depletion on the actin cytoskeleton was 
analysed in the stably RhoE-depleted cell line. Stable RhoE-depleted (shRhoE) and control 
(shNSC) cells were seeded on to cover slips, fixed and stained with Phalloidin to visualise 
filamentous actin (F-actin). In controls cells actin stress fibres were located to the periphery of 
the cell whereas in RhoE-depleted keratinocytes stellate actin stress fibres, which radiate from 
the cell body, were induced (Figure 13A). The stellate actin stress fibres in RhoE-depleted cells  
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Figure 12 Knock-down of RhoE expression using shRNA. 
To generate RhoE-depleted (shRhoE) and control (shNSC) keratinocyte cell lines, HaCaT cells 
were stably transfected with the shRNA constructs pGIPZ-RhoE and pGIPZ-NSC. Whole cell 
lysates were prepared and analysed by immunoblotting using antibodies against RhoE and 
tubulin (loading control). Data presented are representative immunoblots of three separate 
experiments. A decrease in the expression of RhoE was detected in shRhoE cells when 
compared to shNSC cells.  
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are similar to those produced when ROCK I is over-expressed (Figure 13B). When RhoE-
depleted and control cells were treated for 12 hours with the ROCK inhibitor, Y-27632, actin 
stress fibres were lost (Figure 14). These data indicate an increase in endogenous ROCK I 
activity in RhoE-depleted cells. 
 
RhoE was also transiently depleted in keratinocytes using siRNA oligos as a means to verify 
data generated by the stable RhoE-depleted cell line. Two siRNA oligos targeting different 
sequences of RhoE were used. For most experiments oligo A was used and results were verified 
using oligo B (stated in text). HaCaT cells were transiently transfected with siRNA oligos 
against RhoE and with a non-silencing control oligo using Lipofectamine RNAi max 
(Invitrogen). 144 hours after RhoE-depletion whole cell lysates were prepared from HaCaT cells 
transfected with either siRNA oligo A or oligo B and analysed using immunoblotting to assess 
the level of RhoE protein depletion. In RhoE-depleted HaCaT cells the expression of RhoE was 
significant depleted by oligo A and oligo B (Figure 15). The actin cytoskeleton of transiently 
RhoE-depleted cells treated with Y-27632 and stained with Phalloidin was analysed by 
immunofluorescent microscopy. The same stellate actin stress fibres seen in shRhoE cells were 
observed in siRhoE cells. These actin structures were lost following Y-27632 treatment (Figure 
16).  
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Figure 13 Depletion of RhoE induces the formation of stellate actin stress fibres. 
A HaCaT cells stably depleted of RhoE (shRhoE) and control cells (shNSC), were seeded onto 
cover slips 24 hours prior to fixation. Cover slips were then stained with Phalloidin to visualise 
F-actin. shRhoE cells have stellate actin stress fibres whereas in shNSC cells actin stress fibres 
are located to the periphery of the cell. B HaCaT cells were seeded onto cover slips 24 hours 
prior to microinjection with pCAGmycROCK I (wt) wild type or pCAGmycROCK I (KD) 
kinase dead. 6 hours post injection, cover slips were fixed and stained with anti-Myc to visualise 
transfected cells and Phalloidin. ROCK I (wt) transfected cells have increased stellate actin 
stress fibres compared to non-transfected cells and ROCK I (KD) cells. Data presented are 
representative immunofluorescence images of three separate experiments, taken using a 40x lens 
with the gain and exposure time remaining constant (scale bar 30 µm).   
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Figure 14 Keratinocytes depleted of RhoE lose actin stress fibres following treatment with 
Y-27632. 
HaCaT cells stably depleted of RhoE (shRhoE) and control cells (shNSC), were seeded onto 
cover slips for 24 hours before being treated with 5 µM of Y-27632 for 12 hours prior to 
fixation. Cover slips were then stained with Phalloidin to visualise F-actin and images were 
taken using a 40x lens. Data presented are representative immunofluroescent images of three 
separate experiments, with the gain and exposure time remaining constant (scale bar 30 µm). In 
the absence of Y-27632 shRhoE cells have stellate actin stress fibres whereas in shNSC cells 
actin stress fibres are located to the periphery of the cell. In the presence of Y-27632 both 
shNSC and shRhoE cells lose actin stress fibres.  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Figure 15 Transient knock-down of RhoE expression using siRNA. 
To deplete RhoE expression in keratinocytes, HaCaT cells were transiently transfected three 
times with siRNA oligos against RhoE (siRhoE) (oligo A or B) and non-silencing control 
(siCtrl) for a total of 144 hours prior to lysis. Whole cell lysates were prepared and analysed by 
immunoblotting using antibodies against RhoE and tubulin (loading control). Data presented are 
representative immunoblots of three separate experiments.  
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Figure 16 Keratinocytes transiently depleted of RhoE lose actin stress fibres following 
treatment with Y-27632.  
HaCaT cells transiently transfected with siRNA to depleted RhoE (siRhoE) and control cells 
(siCtrl) were seeded onto cover slips for 24 hours before being treated with 5 µM of Y-27632 
for 12 hours prior to fixation. Cover slips were then stained with Phalloidin to visualise F-actin 
and images were taken using a 40x lens. Data presented are representative immunofluroescent 
images of three separate experiments, with the gain and exposure time remaining constant (scale 
bar 30 µm). In the absence of Y-27632 siRhoE cells have stellate actin stress fibres whereas in 
siCtrl cells actin stress fibres are located to the periphery of the cell. In the presence of Y-27632 
both siCtrl and siRhoE cells lose actin stress fibres.  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3.2.2 Keratinocytes depleted of RhoE form small colonies 
Colony forming efficiency assays were performed to assess the ability of RhoE-depleted cells to 
form colonies. Stably RhoE-depleted (shRhoE) and control (shNSC) HaCaT cells were seeded 
at 1x103 cells/ml into cell culture flask and incubated for 12 days prior to fixation and rhodanile 
blue staining to visualise keratinocyte colonies. A significant decrease in colony size was 
observed in colonies formed by RhoE-depleted cells (Figure 17A). Statistical analysis confirmed 
that RhoE-depleted cells form a significantly larger percentage of small colonies (<17 pixels) 
and fewer large colonies (>45 pixels) compared to controls cells (Figure 17B). The mean total 
number of colonies formed by both RhoE-depleted and control cells showed no significant 
difference (Figure 17C). These data indicate that RhoE-depleted cells have the ability to adhere 
and proliferate to form colonies but expansion of the colony is inhibited. 
 
3.2.3 Transiently RhoE-depleted but not stably RhoE-depleted keratinocytes undergo cell 
cycle arrest 
BrdU incorporation and flow cytometry were used to analyse the cell cycle in RhoE-depleted 
cells. BrdU is a nucleoside analogue and is incorporated into DNA during S-phase, this can be 
used to assess the percentage of cells going through S-phase at a fixed time point. shRhoE and 
control shNSC HaCaT cells were seeded on to cover slips for 24 hours before incubating with 
BrdU for one hour. After fixation cells were stained with an antibody against BrdU and the 
nuclei stain Hoechst 33342. Both BrdU positive and the total number of cells were counted and 
the percentage of cells with BrdU incorporation was analysed. Representative  
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Figure 17 Keratinocytes stably depleted of RhoE exhibited a decrease in colony size. 
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells, were seeded at 1x103 
cell/ml into cell culture flask and incubated for 12 days prior to fixation and rhodanile blue 
staining to visualise colonies. A Scans of flask containing rhodanile blue stained colonies of 
shNSC and shRhoE cells. B Colony size was analysed as described in section 2.2.27 (Figure 
11). The mean colony size of shRhoE colonies is significantly smaller than shNSC colonies. C 
The mean total number of colonies shows no significant difference between shNSC and shRhoE 
cells. Data presented are representative images and the mean, standard error and t-test of three 
separate experiments (* P<0.05, ** P<0.01 and *** P<0.001). B and C data generated from 
three separate experiments. In each experiment three flasks were counted per condition with 
approximately 300 colonies per flask.  
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immunofluorescent images of BrdU incorporation in both shRhoE and shCtrl cells show similar 
levels of incorporation (Figure 18A). This was confirmed by statistical analysis, which revealed 
no significant difference between shRhoE and shNSC cells in the percentage of BrdU 
incorporation (Figure 18B). 
 
BrdU incorporation was also analysed in transiently RhoE-depleted keratinocytes. These data 
revealed a significant decrease in BrdU incorporation in siRhoE cells, with ~35% of siCtrl cells 
incorporation BrdU compared to ~10% in siRhoE cells (Figure 19). These data were confirmed 
using a separate siRNA oligo (oligo B) (Figure 20). As an alternative method for analysing cell 
proliferation, the cell cycle profile of siRhoE and siCtrl cells was analysed by flow cytometery 
using propidium iodide staining. Transient RhoE-depletion resulted in a significant 
accumulation of cells in G1 phase (~80% compared to siCtrl ~60%) and a reduction of cells in 
G2/M phase (~5% compared to siCtrl ~10%) and a significant reduction of cells in S phase 
(~10% compared to siCtrl ~30%) (Figure 21B). These data indicate transient RhoE depletion 
induces G1 phase cell cycle arrest. 
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Figure 18 Stable depletion of RhoE expression in keratinocytes had no effect cell cycle 
progression. 
HaCaT cells stably depleted of RhoE (shRhoE) and control cells (shNSC) were seeded onto 
cover slips for 24 hours before incubating with BrdU for one hour prior to fixation. Cover slips 
were then stained with Hoechst 33342, to visualise the nuclei, and anti-BrdU. Both the total 
number of nuclei and BrdU positive cells were counted, with approximately 400 cells counted 
per condition. A Representative immunofluorescence images of shRhoE and shNSC cells 
stained with Hoechst 33342 and anti-BrdU (scale bar 60 µm). B The percentage of cells with 
BrdU incorporation was analysed and the data presented are the mean, standard error and t-test 
of three separate experiments.  
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Figure 19 Transient depletion of RhoE expression in keratinocytes inhibited cell cycle 
progression. 
HaCaT cells transiently transfected with siRNA oligo A to deplete RhoE (siRhoE) and control 
cells (siCtrl) were seeded onto cover slips for 24 hours before incubating with BrdU for one 
hour prior to fixation.  Cover slips were then stained with Hoechst 33342, to visualise the nuclei, 
and anti-BrdU. Both the total number of nuclei and BrdU positive cells were counted, with 
approximately 400 cells counted per condition. A Representative immunofluroescent images of 
siRhoE and siCtrl cells stained with Hoechst 33342 and anti-BrdU (scale bar 60 µm). B The 
percentage of cells with BrdU incorporation was analysed and the data presented are the mean, 
standard error and t-test of three separate experiments (** P<0.01).  
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Figure 20 Transient depletion of RhoE expression in keratinocytes inhibited cell cycle 
progression. 
HaCaT cells transiently transfected with siRNA oligo B to depleted RhoE (siRhoE oligo B) and 
control cells (siCtrl) were seeded onto cover slips for 24 hours before incubating with BrdU for 
one hour prior to fixation. Cover slips were then stained with Hoechst 33342, to visualise the 
nuclei, and anti-BrdU. Both the total number of nuclei and BrdU positive cells were counted, 
with approximately 400 cells counted per condition. The percentage of cells with BrdU 
incorporation was analysed and the data presented are the mean and standard deviation from one 
experiment.  
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Figure 21 Keratinocytes transiently depleted of RhoE arrest in G1 phase. 
The cell cycle profile of transiently RhoE-depleted (siRhoE) (oligo A) and control (siCtrl) 
keratinocytes was analysed using propidium iodide staining and flow cytometry. A 
Representative images of siCtrl and siRhoE cell cycle profiles. B The mean percentage of cells 
in each phase of the cell cycle. Data presented are the mean, standard error and t-test of three 
separate experiments (* P<0.05). 
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3.2.4 pERK and cyclin D1 expression is decreased in keratinocytes transiently depleted of 
RhoE 
In mid-G1 phase growth factors and adhesion to the basement membrane stimulates the 
mitogen-activated protein kinase signaling pathways resulting in the phosphorylation and 
activation of ERK (Lansbury et al.), which induces cyclin D1 expression (Welsh et al. 2001; 
Diehl 2002; Assoian et al. 2008). Cyclin D1 expression enables cells to undergo G1-S phase 
transition (Klein et al. 2008). Both pERK and cyclin D1 protein levels in transiently RhoE-
depleted keratinocytes were analysed by immunoblotting. A decrease in both pERK and cyclin 
D1 protein levels was observed in siRhoE cells (Figure 22). 
 
3.2.5 Cell cycle arrest induced by transient depletion of RhoE was not rescued by ROCK 
I/II inhibition 
Data generated from the analysis of the actin cytoskeleton in RhoE-depleted cells (Section 
3.2.1) suggested an increase in endogenous ROCK activity in RhoE-depleted cells. I 
investigated whether the inhibition of ROCK activity would rescue the cell cycle arrest observed 
in transiently RhoE-depleted cells. siRhoE and control siCtrl cells were incubated with Y-27632 
for 12 hours before a BrdU assay was performed. No appreciable effect on the percentage of 
BrdU incorporation was observed in the presence of Y-27632 treatment (Figure 23). These data 
indicate that increased ROCK I activity in RhoE-depleted cells is not responsible for cell cycle 
arrest. 
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Figure 22 Phosphorylated ERK and cyclin D1 expression is decreased in keratinocytes 
depleted of RhoE. 
HaCaT cells transiently depleted of RhoE (siRhoE) (oligo A) and control (siCtrl) cells were 
incubated in normal growth conditions prior to lysis. Immunoblotting was used to detect the 
protein levels of ERK, pERK, cyclin D1, RhoE and tubulin (loading control). Data presented are 
representative immunoblots of three separate experiments. A ERK and pERK levels in siRhoE 
cells. B Cyclin D1 expression in siRhoE cells.  
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Figure 23 Cell cycle arrest induced by transient depletion of RhoE was not rescued by 
ROCK I/II inhibition. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were seeded onto 
cover slips for 24 hours before incubating with Y-27632 for 12 hours and BrdU for one hour 
prior to fixation. Cover slips were then stained with Hoechst 33342, to visualise the nuclei, and 
anti-BrdU. Both the total number of nuclei and BrdU positive cells were counted, with 
approximately 400 cells counted per condition. The percentage of cells with BrdU incorporation 
was analysed and the data presented are the mean, standard error and t-tests of three separate 
experiments.  
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3.3 Discussion  
A number of studies have shown that RhoE over-expression inhibits actin stress fibre formation 
(Guasch et al. 1998; Nobes et al. 1998; Riento et al. 2003) through the inhibition of both RhoA 
and ROCK I (Riento et al. 2003; Wennerberg et al. 2003). In experiments where RhoE protein 
levels have been depleted the data are less clear. Transient depletion of RhoE levels in 
melanoma cells induces the formation of actin stress fibres that run in parallel bundles across the 
cell body, due to increased endogenous ROCK I activity (Klein et al. 2008). Ongusaha et al. 
(2006) and Boswell et al. (2007) transiently inhibited DNA damage regulated induction of RhoE 
expression, using siRNA. In both studies no increase in actin stress fibres was observed in RhoE 
“depleted” (induction of RhoE inhibited) cells (Ongusaha et al. 2006; Boswell et al. 2007). 
However, in both studies the basal level of RhoE was unchanged (Ongusaha et al. 2006; 
Boswell et al. 2007). The data generated in this study show that both stable and transient 
depletion of RhoE basal levels induced the formation of stellate actin stress fibres, which bore a 
close resemblance to the stress fibres produced when wild type ROCK I was over-expressed 
(Figure 13). The induction of actin stress fibres induced in both siRhoE and shRhoE 
keratinocytes was prevented when the cells were treated with the ROCK inhibitor Y-27632. 
RhoE is known to inhibit ROCK I (Riento et al. 2003). This, taken together with my data, 
suggests increased endogenous ROCK activity in RhoE-depleted keratinocytes.  
 
Keratinocytes stably depleted of RhoE formed smaller colonies in comparison to control cells. 
Possible causes for decreased colony size include: cell cycle arrest, induced apoptosis or 
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terminal differentiation. Other aspects of colony morphology and the role RhoE plays in 
producing this phenotype are discussed in detail in chapter 4 whereas this chapter focuses on 
cell proliferation. Analysis of colony forming efficiency assays revealed no significant 
difference in the number of colonies produced (Figure 17) and BrdU incorporation (Figure 18) 
was not altered in the stably RhoE-depleted cells ruling out proliferation defects decreasing 
colony size. Changes in cell cycle progression were observed in cells transiently depleted of 
RhoE  (Figure 19). The differences observed in the data from stable and transient RhoE-
depletion are most likely explained by the selection process when creating a stable cell line 
which favours proliferative cells. In contrast, the transiently transfected cell lines are not 
subjected to the same selective pressure. 
 
Previous studies have shown that RhoE over-expression induces G1 phase cell cycle arrest due 
to a decrease in the level of cyclin D1, which is required for the G1-S phase transition 
(Villalonga et al. 2004; Poch et al. 2007). Cyclin D1 expression requires ERK activation, which 
was reported to be decreased in cells over-expressing RhoE and responsible for loss of cyclin 
D1 expression (Poch et al. 2007). However, Villalonga et al. (2004) show that cyclin D1 
expression was decreased in RhoE over-expressing cells but no alteration in ERK activation was 
observed (Villalonga et al. 2004). RhoE over-expression has also been shown to increase the 
levels of ERK activation (Guasch et al. 2007). My analysis of active ERK and cyclin D1 
expression in keratinocytes transiently depleted of RhoE revealed both were decreased (Figure 
22). Studies have reported that RhoE over-expression inhibits cell cycle progression (Villalonga 
et al. 2004:Bektic, 2005 #495; Poch et al. 2007), however I report that RhoE depletion also 
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inhibits cell cycle progression. One possible explanation for the apparent differences observed 
in these studies maybe that RhoE expression is regulated during G1 phase and cell type 
specificity. 
 
A recent study in keratinocytes depleted of RhoE showed increased proliferation and enhanced 
levels of ERK phosphorylation (Liebig et al. 2009). My data contradicts these findings. 
However, both the BrdU assays and analysis of ERK activation in Liebig et al. (2009) were 
performed in cells 24 hours after they were induced to terminally differentiate (Liebig et al. 
2009). My analysis was performed on cells cultured in normal growth conditions and this may 
explain the differences observed. 
 
RhoE is a known antagonist of RhoA/ROCK I signaling (Wennerberg et al. 2003; Riento et al. 
2005). Inhibition of ROCK I/II activity with Y-27632 has been shown to increase cell 
proliferation in keratinocytes (McMullan et al. 2003). My data shows that both stable and 
transient depletion of RhoE expression increased endogenous ROCK I activity (Section 3.2.1). I 
investigated whether the inhibition of cell cycle progression was due to the increased ROCK I 
activity observed in the transiently RhoE-depleted cells. Following ROCK inhibition, using Y-
27632 treatment, no effect on cell proliferation was observed (Figure 23). These data indicate 
that the cell cycle arrest observed in the transiently RhoE-depleted cells is not dependent on 
ROCK activity.  
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In summary, both stable and transient depletion of RhoE in keratinocytes induces the formation 
of ROCK-dependent stellate actin stress fibres. A decrease in colony size was observed in stably 
RhoE-depleted keratinocytes, however cell cycle progression was unaffected in these cells. 
Whereas transient depletion of RhoE in keratinocytes resulted in decreased expression of active 
ERK and cyclin D1, and a G1 phase cell cycle arrest, which was shown to be independent of 
ROCK I activity. 
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CHAPTER 4 RHOE AND REGULATION OF DESMOSOMES 
 
4.1 Introduction 
The architecture of the epidermis is important for the protection of the underlying dermis. The 
epidermis is a stratified epithelium made up predominantly of layers of differentiating 
keratinocytes (Fuchs 1990). Cells in the basal layer adhere to the underlying basement 
membrane, via hemidesomosomes and focal adhesions and have the ability to undergo 
proliferation (Gniadecki 1998). Adhesion to the basement membrane maintains the ability of 
normal basal keratinocytes to proliferate and loss of adhesion has been shown to induce 
differentiation (Green 1977; Muller et al. 2008). Cell-cell adhesion in the epidermis, through 
desmosomes and adherens junctions, is important for stratification, maintaining epidermal 
architecture, mechanical strength and signal transduction (Braga 2002). 
 
Keratinocyte terminal differentiation involves cell cycle arrest followed by a number of 
biochemical and morphological changes, such as changes in protein expression, altered adhesion 
and an increase in cell size (Watt 1983; Fuchs 1990). Alterations in adhesion include loss of 
attachment to the basement membrane and an increase in cell-cell adhesion coupled with 
alterations in the expression of different desmosomal proteins (Garrod et al. 2008). The process 
of terminal differentiation transforms a metabolically active proliferating keratinocyte into a 
dead enucleated stratum corneum cell (squame), which is comprised of a cornified sack 
containing keratin macrofibrils (Fuchs 1990; Fuchs 2007). 
  101 
 
Keratinocytes over-expressing RhoE have been shown to increase in cell size and locate to 
stratified layers in cultures induced to terminally differentiate, implicating RhoE in playing a 
role in terminal differentiation (Liebig et al. 2009). This chapter addresses the altered 
morphology of RhoE-depleted keratinocytes (first reported in Section 3.2.2) by investigating the 
role of RhoE in keratinocyte differentiation. For the investigation both stable and transient 
depletion of endogenous RhoE levels in keratinocyte cells was used. Differentiation was not 
induced by RhoE depletion. However, there was an up-regulation of desomosomal proteins and 
increased numbers of desmosomes, which is responsible for the altered colony morphology 
observed in RhoE-depleted cells.  
 
4.2 Results 
4.2.1 RhoE depletion alters keratinocyte colony morphology 
Previous data (Section 3.2.2) generated from colony forming efficiency assays of stably RhoE-
depleted cells revealed a significant decrease in colony size when compared to control colonies. 
The reduction in colony size was not due to alterations in proliferation or apoptosis, as 
proliferation was unaffected in the stably RhoE-depleted cells (Section 3.2.3) and apoptosis was 
not induced (Section 5.2.3). Colony morphology was analysed using phase contrast microscopy. 
Both stably and transiently RhoE-depleted cell lines (shRhoE and siRhoE HaCaT cells) were 
analysed to verify that changes in colony morphology was not due to off target effects of either 
siRNA or shRNA. shRhoE and siRhoE HaCaT cells and controls (shNSC and siCtrl) were 
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plated into cell culture flasks 48 hours prior to live phase contrast microscopy. Control cells 
formed monolayer colonies in which cells appeared large and spread (Figure 24). In contrast 
shRhoE and siRhoE cells formed colonies with a much more compacted 3D organisation in 
which individual cells appeared small (Figure 24). When comparing colony morphology of 
shNSC against siCtrl or shRhoE against siRhoE HaCaT cells no differences were observed 
(Figure 24). 
 
Colony morphology was also analysed using confocal microscopy by taking Z series images and 
producing a 3D reconstruction of colonies. Stably RhoE-depleted (shRhoE) and control 
(shNSC) HaCaT cells (Figure 25) as well as transiently RhoE-depleted (siRhoE) and control 
(siCtrl) HaCaT cells (Figure 26) were seeded onto glass cover slips 48 hours prior to fixation. 
Cover slips were stained with antibodies against E-cadherin to visualise cell-cell boundaries and 
Hoechst 33342 to visualise nuclei. Both the 3D reconstruction and single Z series imaging of 
control colonies revealed a 2D spread monolayer with nuclei spread evenly throughout the 
colony, with clear spaces between and no overlap from neighbouring nuclei. Individual control 
cells, identified by E-cadherin staining, appeared large and spread. In contrast, both the 3D 
reconstruction and single Z series imaging of RhoE-depleted colonies revealed a 3D compacted 
phenotype with limited stratification. Neighbouring nuclei, in RhoE-depleted colonies, were in 
close proximity to each other and in some cases overlap of nuclei occurred (indicated by 
arrows). Individual cells, identified by E-cadherin staining, appeared small and compacted. The 
nuclei of control cells appeared larger than those in the RhoE-depleted cells. When comparing 
colony morphology of siNSC against siCtrl or shRhoE against siRhoE HaCaT cells no  
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Figure 24 RhoE depletion alters keratinocyte colony morphology. 
Keratinocytes depleted of RhoE were seeded into cell culture flasks 48 hours prior to live phase 
contrast microscopy using a 32x lens. A Phase contrast images of stably RhoE-depleted 
(shRhoE) and control (shNSC) HaCaT cells. B Phase contrast images of transiently RhoE-
depleted (siRhoE) HaCaT cells and control (siCtrl) cells. Data presented are representative 
images of three separate experiments (scale bar 30 µm).  
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Figure 25 Stable depletion of RhoE expression alters keratinocyte colony morphology. 
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were seeded onto 
glass cover slips 48 hours prior to fixation. Cover slips were stained with antibodies against E-
cadherin (green) to visualise cell-cell boundaries and Hoechst 33342 (blue) to visualise nuclei. Z 
series images were taken through the colony using confocal microscopy using a 60x lens. The 
first 4 panels are of the 3D reconstruction of confocal layers. The lower four panels are of a 
single 1 µm Z series stack corresponding to the middle layer of the 3D image. Data are 
representative images of two separate experiments with the gain and exposure times remaining 
constant (scale bar 30 µm). Arrows indicate overlapping nuclei. 
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Figure 26 Transient depletion of RhoE expression alters keratinocyte colony morphology. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were seeded onto 
glass cover slips 48 hours prior to fixation. Cover slips were stained with antibodies against E-
cadherin (green) to visualise cell-cell boundaries and Hoechst 33342 (blue) to visualise nuclei. Z 
series images through the colony were taken using confocal microscopy using a 60x lens. The 
first 4 panels are of the 3D reconstruction of confocal layers. The lower four panels are of a 
single 1 µm Z series stack corresponding to the middle layer of the 3D image. Data are 
representative images of two separate experiments with the gain and exposure times remaining 
constant (scale bar 30 µm). Arrows indicate overlapping nuclei. 
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differences were observed (Figure 25 & 26). These data indicate that RhoE depletion resulted in 
altered colony morphology from a 2D spread monolayer to a 3D compacted limited stratified 
phenotype.   
 
4.2.2 Differentiation is not induced in RhoE-depleted keratinocytes  
Keratinocytes depleted of RhoE appeared to stratify with colonies containing overlapping nuclei 
and RhoE has been implicated in the regulation of keratinocyte differentiation and stratification 
(Liebig et al. 2009). To assess whether RhoE-depleted cells were undergoing terminal 
differentiation whole cell lysates were prepared from transiently RhoE-depleted keratinocytes 
and were analysed using immunoblotting with antibodies against known differentiation markers. 
The markers included involucrin, periplakin, keratin 1 and desmocollin 2, which are up-
regulated during differentiation and keratin 5 and 14, which are down-regulated during 
differentiation (Rice et al. 1979; Fuchs et al. 1980; Watt 1983; Legan et al. 1994). No change in 
expression was detected for involucrin, periplakin or keratin 14 in siRhoE cells when compared 
to siCtrl cells. Interestingly a decrease in keratin 1 expression and an increase in keratin 5 and 
desmocollin 2 expression were detected in siRhoE cells when compared to siCtrl cells (Figure 
27). These data suggest that despite evidence for stratification RhoE-depleted cells are not 
undergoing differentiation. 
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Figure 27 Differentiation marker profile in keratinocytes depleted of RhoE. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were incubated in 
normal growth conditions prior to lysis. Immunoblotting using antibodies against known 
differentiation markers such as involucrin, periplakin, keratin 1, 5, 14, and desmocollin 2, as 
well as RhoE and tubulin were used to detect the expression of the proteins of interest and as a 
loading control respectively. Data presented are representative immunoblots of three separate 
experiments.  
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4.2.3 RhoE depletion increased expression of desmosomal proteins 
Having observed an increase in desmocollin 2 expression in RhoE-depleted cells (Figure 27) 
immunoblotting was used to analyse the expression of other adhesion proteins. Antibodies 
against E-cadherin, desmocollin 1, 2 and 3, desmoglein 2 and 3, desmoplakin I/II and 
plakoglobin were used to analyse expression of adherens junction proteins and desmosomal 
proteins. No change in E-cadherin expression, a component of adherens junctions, was observed 
(Figure 28A). Increased expression of desmocollin 2 and 3, desmoglein 3 and desmoplakin I/II 
was observed in RhoE-depleted cells whereas no change in expression was detected in 
desmocollin 1, desmoglein 2 or plakoglobin when compared to control cells (Figure 28B-D). 
 
4.2.4 RhoE depletion increased the number of desmosomes 
Transmission electron microscopy (TEM) was used to visualise desmosomes in transiently 
RhoE-depleted cells. siRhoE and siCtrl HaCaT cells were plated onto plastic cover slips 48 
hours prior to fixation. Cover slips were embedded and sections were taken orthogonally to the 
plane of the cover slip and stained using negative staining (work carried out by Theresa Morris, 
Centre for Electron Microscopy, University of Birmingham). Desmosomes were detected in 
both siRhoE and siCtrl cells (indicated by arrows) with no apparent difference in size (Figure 
29A). Desmosomal frequency was analysed by counting the number of desmosomes present 
along each cell-cell boundary. Although these are very preliminary data an apparent increase in 
the number of desmosomes was observed in RhoE-depleted cells (Figure 29B).  
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Figure 28 Expression of desomsomal proteins is increased in keratinocytes depleted of 
RhoE. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were incubated in 
normal growth conditions prior to whole cell lysis. Immunoblotting using antibodies against E-
cadherin, desmocollin 1, 2 and 3, desmoglein 2 and 3, desmoplakin I/II and plakogobin were 
used to analyse the expression of adherens junction and desmosomal proteins. Data presented 
are representative immunoblots of three separate experiments. A E-cadherin expression. B 
Desmocollin 1, 2 and 3 expression. C Desmoglein 2 and 3 expression. D Desmoplakin and 
plakoglobin expression.  
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Figure 29 Transmission electron microscopy in keratinocytes depleted of RhoE.  
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were plated onto 
plastic cover slips 48 hours prior to fixation. Cover slips were embedded and sections were 
taken orthogonally to the plane of the cover slip and stained using negative staining (work 
carried out by Theresa Morris, Centre for Electron Microscopy, University of Birmingham). 
Images were taken on a Jeol 1200EX microscope using 15,000x and 40,000x magnification. A 
Desmosomes were detected in both siRhoE and siCtrl cells (indicated by arrows). Data 
presented are representative images from one experiment. B Desmosomal frequency was 
analysed by counting the number of desmosomes present along each cell-cell boundary and the 
data presented are the mean and standard deviation of 7 cell-cell boundaries in one experiment.  
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To analyse the localisation of desmosomal proteins, cells were stained with antibodies against 
desmocollin 3, desmoplakin I/II and plakoglobin. Cells were also stained with Hoechst 33342 to 
visualise nuclei. In both siCtrl and siRhoE cells desmocollin 3 and desmoplakin I/II staining 
appeared as a punctate pattern along cell-cell boundaries, in siRhoE cells this punctate staining 
is increased (Figure 30 & 31). Punctate desmoplakin I/II staining also occured in the cytoplasm, 
which is increased in siRhoE cells (Figure 31). Plakoglobin staining localised to the cell-cell 
boundaries, like E-cadherin staining, in both siCtrl and siRhoE cells but unlike E-cadherin 
plakoglobin staining was brighter at cell-cell boundaries in siRhoE cells (Figure 32). Taken 
together these data suggest that loss of RhoE expression resulted in an increase in the number of 
desmosomes in keratinocytes. 
 
4.2.5 Colony morphology and desmosomal protein expression is disrupted in low calcium 
conditions 
Both desmosomes and adherens junctions require extra cellular calcium for cell-cell adhesion to 
occur (Chitaev et al. 1997; Jamora et al. 2002). As a preliminary experiment to analyse whether 
colony morphology in RhoE-depleted cells would revert to a normal morphology when cell-cell 
adhesion is disrupted, cells were cultured in reduced calcium conditions. Stably RhoE-depleted 
(shRhoE) and control (shNSC) HaCaT cells were seeded into cell culture flasks and incubated in 
normal growth media for 48 hours (+ calcium). Cells were then incubated in low calcium 
medium for 24 hours (- calcium). Following calcium depletion cells were incubated in normal 
medium for 24 hours (-+ calcium 24hrs) and 48 hours (-+ calcium 48hrs). At each stage colony  
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Figure 30 Desmocollin 3 staining is increased at cell-cell boundaries in keratinocytes 
depleted of RhoE. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were plated onto 
glass cover slips 48 hours prior to fixation. Cover slips were stained with antibodies against 
desmocollin 3 and with Hoechst 33342 to visualise nuclei. Images were taken on an 
epifluorescence microscope using a 40x lens. Data presented are representative images of three 
separate experiments, with the gain and exposure time remaining constant (scale bar 30 µm).  
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Figure 31 Desmoplakin I/II staining is increased at cell-cell boundaries in keratinocytes 
depleted of RhoE. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were plated onto 
glass cover slips 48 hours prior to fixation. Cover slips were stained with antibodies against 
desmoplakin I/II and with Hoechst 33342 to visualise nuclei. Images were taken on an 
epifluorescence microscope using a 40x lens. Data presented are representative images of three 
separate experiments, with the gain and exposure time remaining constant (scale bar 30 µm).  
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Figure 32 Plakoglobin staining is increased at cell-cell boundaries in keratinocytes 
depleted of RhoE.  
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were plated onto 
glass cover slips 48 hours prior to fixation. Cover slips were stained with antibodies against 
plakoglobin, E-cadherin to visualise cell-cell boundaries, and Hoechst 33342 to visualise nuclei. 
Images were taken on an epifluorescence microscope using a 40x lens. Data presented are 
representative images of three separate experiments, with the gain and exposure time remaining 
constant (scale bar 30µm).  
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morphology was documented using live phase contrast microscopy. Following calcium 
depletion shRhoE HaCaT cells appeared more rounded with gaps between neighbouring cells 
and colony morphology had lost the compacted stratified phenotype (- calcium). Following re-
addition of calcium for 24 hours (-+ calcium 24hrs) and 48 hours (-+ calcium 48hrs) shRhoE 
colonies reverted back to the original compacted stratified morphology (+ calcium) (Figure 33). 
The experiment was repeated using transiently RhoE-depleted siRhoE and siCtrl HaCaT cells 
and similar results were observed (Figure 34).  
 
The effect of low calcium conditions on desmosomal protein expression was analysed in control 
and RhoE-depleted cells. Transiently RhoE-depleted (siRhoE) and control (siCtrl) cells were 
incubated in either low calcium or normal growth medium 24 hours prior to lysis. Whole cell 
lysates were analysed by immunoblotting using antibodies against the desmosomal proteins 
desmoglein 3, desmocollin 2 and desmocollin 3. An increase in the expression of desmoglein 3, 
desmocollin 2 and 3 was detected in siRhoE cells compared to siCtrl cells in normal growth 
conditions (+ calcium). In both cells lines calcium depletion resulted in a loss of expression for 
desmoglein 3, desmocollin 2 and desmocollin 3 (Figure 35). These data indicate that in low 
calcium conditions cell-cell adhesion is lost along with the expression of desmosomal proteins, 
which restored the colony morphology of RhoE-depleted cells from a stratified phenotype to a 
monolayer. 
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Figure 33 Colonies formed from keratinocytes stably depleted of RhoE lose the stratified 
morphology when cultured in low calcium medium. 
HaCaT cells stably depleted of RhoE (siRhoE) and control (siCtrl) cells were seeded into cell 
culture flasks and incubated in normal growth medium for 48 hours (+ calcium). Cells were then 
incubated in low calcium medium for 24 hours (- calcium), followed by re-addition of normal 
medium for 24 hours (-+ calcium 24hrs) and 48 hours (-+ calcium 48hrs). At each stage live 
phase microscopy images were taken using a 32x lens. Data presented are representative images 
of three separate experiments (scale bar 30 µm).  
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Figure 34 Colonies formed from keratinocytes transiently depleted of RhoE lose the 
stratified morphology when cultured in low calcium medium.  
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were seeded into 
cell culture flasks and incubated in normal growth medium for 48 hours (+ calcium). Cells were 
then incubated in low calcium medium for 24 hours (- calcium), followed by re-addition of 
normal medium for 24 hours (-+ calcium 24hrs). At each stage live phase contrast microscopy 
images were taken using a 32x lens. Data presented are representative images from three 
separate experiments (scale bar 30 µm).  
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Figure 35 Expression of desmosomal proteins is increased in keratinocytes depleted of 
RhoE in normal growth medium but expression is lost when cells are cultured in low 
calcium medium. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were incubated in 
either low calcium or normal growth medium 24 hours prior to whole cell lysis. Immunoblotting 
using antibodies against desmoglein 3, desmocollin 2, desmocollin 3, RhoE and tubulin were 
used to detect expression of desmosomal proteins, RhoE protein and as a loading control 
respectively. Data presented are representative immunoblots of three separate experiments.  
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4.2.6 Disruption of desmosomes rescues the colony morphology of keratinocytes depleted 
of RhoE  
To analyse whether the up-regulation of desmosomal proteins and increased number of 
desmosomes was responsible for the alteration in colony morphology seen in RhoE-depleted 
cells siRNA oligos were used to disrupt desmosomes. Depletion of major desmosomal proteins, 
desmoplakin I/II or plakoglobin, disrupts desmosomes (Gallicano et al. 1998; Bierkamp et al. 
1999; Vasioukhin et al. 2001; Acehan et al. 2008). I analysed whether this would revert colony 
morphology back to a normal phenotype in HaCaT cells depleted of RhoE. Transient single 
knock-downs of desmoplakin I/II (siDSP), plakoglobin (siPG) and RhoE (siRhoE) as wells as in 
combination decreased expression of target proteins, detected by immunoblotting (Figure 36). 
These cells were plated into cell culture flasks 48 hours prior to phase contrast microscopy and 
lysis. Phase contrast microscopy of siCtrl, siDsp and siPG cells revealed monolayer colonies in 
which individual cells appeared large and spread. In contrast, siRhoE colonies had a 3D 
compacted phenotype in which individual cells appeared small. Both siRhoE:Dsp and 
siRhoE:PG colonies had a control colony phenotype, with monolayer colonies in which 
individual cells appeared larger and more spread when compared to siRhoE cells (Figure 37). 
Taken together these data indicate that RhoE-depletion increases the number of desmosomes 
which leads to altered colony morphology.  
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Figure 36 Transient knock-down of desmoplakin I/II, plakoglobin and RhoE expression in 
keratinocytes, using siRNA oligos. 
Individual and combined depletion of desmoplakin I/II (Dsp), plakoglobin (Diepgen et al.) and 
RhoE (siRhoE) in HaCaT cells were achieved by transiently transfecting cells with siRNA 
oligos to depleted proteins of interest for 144 hours prior to whole cell lysis. Immunoblotting 
using antibodies against desmoplakin I/II, plakoglobin, RhoE and tubulin were used to detect 
the level of the proteins of interest and as a loading control respectively. Data presented are 
representative immunoblots of three separate experiments.  
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Figure 37 Disruption of desmosomes rescues colony morphology of keratinocytes depleted 
of RhoE. 
Transient single knock-downs, of desmoplakin I/II (siDsp), plakoglobin (siPG) and RhoE 
(siRhoE), and combined knock-downs, siRhoE:Dsp and siRhoE:PG HaCaT cells, were seeded 
onto plastic 48 hours prior to live phase microscopy using a 32x lens. Data presented are 
representative images from three separate experiments (scale bar 30 µm).  
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4.3 Discussion 
A recent study reported that, in keratinocytes over-expressing RhoE, cell size was increased and 
stratification was promoted whereas depletion of RhoE using siRNA had no effect on either cell 
size or stratification (Liebig et al. 2009). Using phase contrast and confocal microscopy my data 
revealed that depletion of RhoE altered colony morphology in keratinocytes. RhoE-depleted 
cells formed smaller more compact colonies compared to control cells and cells within the 
RhoE-depleted colonies were less spread and appeared smaller than control cells (Section 4.2.1). 
In addition, in RhoE-depleted colonies there is evidence for increased stratification with 
neighbouring nuclei overlapping each other. A key difference between my study and that of 
Liebig et al. are the culture conditions used and cell type. In Liebig et al. keratinocytes depleted 
of RhoE were cultured in low calcium conditions both prior to, and post, transient transfection 
with siRNA to deplete RhoE expression (Liebig et al. 2009). These RhoE-depleted cells were 
cultured in low calcium medium until a monolayer was formed and then the cells were induced 
to stratify by culturing in medium containing an increased calcium concentration (1.8mM) for 8 
hours (Liebig et al. 2009). In most of my experiments RhoE-depleted cells were cultured at sub-
confluency in normal growth medium containing physiological levels of calcium (1.8mM) 
(Section 4.2.5). However, in experiments where I cultured RhoE-depleted cells in low calcium 
medium no stratification or cell size change was observed (Figure 33 & 34). A second issue is 
the length of time during which cells were cultured in normal medium. In Liebig et al. medium 
containing 1.8mM calcium was only added for 8 hours, whereas in my experiment RhoE-
depleted cells were cultured for 24 hours in this medium (Section 4.2.5). I have shown that the 
altered colony morphology in RhoE-depleted cells is due to an increase in desmosomal protein 
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expression and an increase in desmosome number (Section 4.2.3 & 4.2.4). In low calcium 
conditions cell-cell adhesion through desmosomes and adherens junctions are lost (Chitaev et al. 
1997; Jamora et al. 2002) as is the increase in desomosomal proteins seen in RhoE-depleted 
cells (Section 4.2.5 Figure 35).  
 
The observation that RhoE-depleted cells were forming partically stratified colonies lead me to 
analyse differentiation markers in these cells to assess whether differentiation was being induced 
following RhoE depletion. Commonly used markers for differentiation include an increase in 
involucrin expression and a switch in keratin expression from keratin 5 and 14 to keratin 1 and 
10 (Fuchs et al. 1980; Watt 1983; Fuchs 2007). Other markers that indicate keratinocytes are 
undergoing differentiation include the up-regulation of certain desmosomal proteins, such as 
desmocollin 2, and increased periplakin expression (Rice et al. 1979; Legan et al. 1994; Nemes 
et al. 1999). The expression levels of many of these markers were analysed in RhoE-depleted 
cells (Figure 27). Evidence suggesting RhoE-depleted cells might be undergoing differentiation 
included limited stratification and increased desmocollin 2 expression. However, no other 
change in the expression of differentiation markers was observed, strongly arguing against a 
differentiation phenotype. Furthermore, during differentiation cell size increases (Watt 1983). 
RhoE-depleted cells did not increase in size and appeared smaller than control cells (Section 
4.2.1). Taken together these data indicate that terminal differentiation is not occurring in RhoE-
depleted cells. Consistent with this, Liebig et al. (2009) also looked at differentiation markers 
(involucrin, keratin 1 and transglutaminase) in their RhoE-depleted keratinocytes and observed 
no change in expression. When differentiation was artificially induced they also observed a 
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delay in the up-regulation of these markers in RhoE-depleted cells (Liebig et al. 2009). These 
data suggest that RhoE depletion in keratinocytes does not induce terminal differentiation. 
 
Of all the differentiation markers analysed only desmocollin 2 was up-regulated in RhoE-
depleted keratinocytes. Desomocollin 2 is a desmosomal cadherin and a component of 
desmosomes (Garrod et al. 2008). Analysis of the expression levels and localisation of other 
desmosomal proteins revealed major changes in RhoE-depleted cells (Section 4.2.3 & 4.2.4). Of 
the desmosomal proteins analysed, an increase in the expression of desmocollin 2, desmocollin 
3, desmoglein 3 and desmoplakin I/II was observed in RhoE-depleted cells. Thus RhoE-depleted 
cells show increased expression for most of the components required for desmosomal assembly 
and ectopic expression of these components in fibroblasts can result in the formation of 
desmosomes (Kowalczyk et al. 1997). Transmission electron microscopy was used to 
investigate the structure and number of desmosomes present in RhoE-depleted cells. No obvious 
changes in desmosomal structure were observed. However, preliminary data indicated an 
increase in the number of desmosomes in RhoE-depleted cells (Figure 29). This was also 
suggested by epifluorescent imaging of RhoE-depleted cells where, consistent with the 
immunoblotting data, I observed increased cell-cell staining of desmoplakin I/II, desmocollin 3 
and plakoglobin (Figure 30, 31 & 32). Punctate cytoplasmic desmoplakin I/II staining was 
observed in both cell lines but was increased in RhoE-depleted cells (Figure 31). This type of 
desmoplakin I/II staining is indicative of the formation of non-membrane bound desmoplakin 
I/II-containing particles that subsequently translocate to cell–cell borders and incorporate into 
maturing desmosomes (Godsel et al. 2005). These data indicate that RhoE-depletion in 
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keratinocytes increases the expression of desmosomal proteins and the number of desmosomes.  
 
Plakoglobin localises to several different locations in the cell: These include desmosomes and 
adherens junctions where it is involved in cell-cell adhesion and the nucleus where it can act as 
a transcription factor (Hu et al. 2003; Garcia-Gras et al. 2006; Dusek et al. 2007; Acehan et al. 
2008). Immunoblotting revealed no change in total plakoglobin expression (Figure 28) but 
epifluorescent imaging revealed a marked increase in plakoglobin staining in RhoE-depleted 
cells at the cell-cell boundary (Figure 32). This indicates a relocalisation of plakoglobin to cell-
cell boundaries in RhoE-depleted cells. RhoE-depletion appears to have no effect on adherens 
junctions as the expression and localisation of E-cadherin is unchanged in RhoE-depleted cells 
(Figure 28 & 32). This suggests that RhoE is regulating a desmosome-specific pathway and not 
having a global effect on cell-cell adhesion. 
 
Cell-cell adhesion maintained by desmosomes and adherens junctions is dependent on the 
presence of extracellular calcium (Chitaev et al. 1997; Braga 2002; Garrod et al. 2008). In low 
calcium conditions adherens junctions and desmosomes disassemble due to the cadherins losing 
their ability to form dimers (Garrod et al. 2008). This results in a disruption of cell-cell adhesion 
and prevents stratification (Watt et al. 1984; O'Keefe et al. 1987; Garrod et al. 2008). 
Keratinoncytes depleted of RhoE when cultured in low calcium conditions lose the stratification 
phenotype (Figure 33 & 34). Loss of desmocollin 2, desmocollin 3 and desmoglein 3 expression 
was also observed in RhoE-depleted cells cultured in low calcium medium (Figure 35). Thus, 
the altered colony formation seen in RhoE-depleted keratinocytes is most likely a function of 
  132 
increased desmosome-mediated cell-cell adhesion. Consistent with this, depletion of 
desmoplakin I/II in keratinocytes, using siRNA, disrupted desmosomes and also resulted in 
reduced expression of other desmosomal proteins including desmocollin 2, 3 and desmoglein 1 
and 2 as well as all three plakophilin members (Wan et al. 2007).  
 
A number of studies have demonstrated that depletion of either desmoplakin I/II or plakoglobin 
leads to a loss of desmosomes and decreased cell-cell adhesion (Gallicano et al. 1998; Bierkamp 
et al. 1999; Vasioukhin et al. 2001; Wan et al. 2007; Acehan et al. 2008). I used siRNA to 
deplete expression of desmoplakin I/II or plakoglobin in RhoE-depleted cells and in both cases a 
reversion to control colony phenotype was observed (Figure 36 & 37). Knocking-out 
plakoglobin, or depleting desmoplakin I/II expression, has no apparent affect on adherens 
junctions as E-cadherin staining and expression was unaffected in these cells (Wan et al. 2007; 
Acehan et al. 2008) and I also observed no change in E-cadherin expression or localisation in 
RhoE-depleted cells (Figure 28 & 32). This is an important observation as plakoglobin has been 
reported to localise to adherens junctions (Hu et al. 2003). These data show that depletion of 
either desmoplakin I/II or plakoglobin affects the formation of desmosomes without affecting 
adherens junctions. Taken together these data indicate increased cell compaction and 
stratification observed in RhoE-depleted keratinocytes is a consequence of increased 
desmosome expression and function. 
 
Cell-cell adhesion maintained by desmosomes and adherens junctions is vital for keratinocyte 
differentiation and stratification (Braga 2002). Desmosomes are the principal junctions of the 
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epidermis and are essential for its function (Vasioukhin et al. 2001; Jonkman et al. 2005). Low 
calcium conditions prevent keratinocytes from stratifying even when terminal differentiation has 
been initiated, due to the prevention of cell-cell adhesion (Chitaev et al. 1997; Jamora et al. 
2002). In RhoE-depleted keratinocytes no increase in differentiation markers was observed but 
the numbers of desmosomes was significantly increased (Figure 27 & 28). Thus I hypothesise 
that RhoE-depletion results in increased expression of desmosomal components and the 
formation desmosomes, and that this induces a stratification phenotype without initiating 
differentiation.  
 
RhoE-depleted keratinocytes cultured in normal growth conditions appear smaller, and have 
smaller nuclei than control cells. However, no difference in cell size was observed when RhoE-
depleted keratinocytes were cultured in low calcium conditions (Section 4.2.5). Targeted 
misexpression of desmoglein 2, to the suprabasal layers of the epidermis in mice, increases both 
the size of keratinocytes in the upper suprabasal layers and also the size of the nuclei (Brennan 
et al. 2007). Whilst we see a decrease in cell size, the expression levels of desmoglein 2 are 
unchanged in RhoE-depleted cells. However, other desmosomal components are up-regulated in 
RhoE-depleted cells opening up the possibility that different desmosomal proteins or 
desmosomes could regulate cell growth.  
 
4.3.1 How might RhoE regulate desmosome formation? 
The formation of desmosomes involves desmoplakin I/II being rapidly accumulated at the 
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contacting cell boundary after the initial cell-cell contact is made (Godsel et al. 2005). This is 
followed by the formation of non-membrane bound desmoplakin I/II- and plakophilin 2-
containing particles in the cortical region of the cell. These desmosomal particles translocate to 
cell–cell borders and incorporate into maturing desmosomes (Godsel et al. 2005). The 
translocation of these desmosomal particles requires both intermediate filaments and actin 
microfilament interactions (Godsel et al. 2005). Connection to the intermediate filaments is 
regulated by protein kinase A, through the phosphorylation of desmoplakin I/II (Godsel et al. 
2005). Plakophilin 2 also recruits protein kinase C α to desmoplakin I/II, which attenuates 
desmoplakin I/II interactions with intermediate filaments (Bass-Zubek et al. 2008). The 
formation of desmosomes also requires an intact actin cytoskeleton (Pasdar et al. 1993) and if 
the actin cytoskeleton is disrupted translocation of desmosomal particles to maturing 
desmosomes is prevented (Godsel et al. 2005). These data suggest that both intermediate 
filaments and the actin cytoskeleton are involved in regulating desmosomal assembly. 
 
How RhoE-depletion induces the expression of desmosomal proteins and an increase in 
desmosomes is not known. Unlike desmosomal protein-protein interactions, which are well-
documented, little is known about desmosomal protein expression and assembly (Green et al. 
2007). One possible mechanism whereby RhoE might regulate desmosomes is regulation of the 
actin cytoskeleton through either RhoA-dependent or independent mechanisms. RhoE is known 
to regulate RhoA activity through the p190RhoGAP (Wennerberg et al. 2003) and the RhoA 
GEF Syx (Goh et al. 2010). Constitutively active RhoA was reported to disrupt tight junction 
formation, which was inhibited by RhoE expression (Rubenstein et al. 2005). RhoE over-
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expression also induces the localisation of β-catenin and ZO-1 to adherens junctions and tight 
junctions as well as inducing tight junction sealing (Rubenstein et al. 2005). Inhibition of RhoA 
induces keratinocyte dissociation through the loss of desmosomes (Waschke et al. 2006). 
Activation of RhoA accelerates the initial translocation of desmoplakin I/II to desmosomes but 
sustained RhoA activity compromised desmosomal maturation (Godsel et al. 2010). RhoA 
activity during the redistribution of desmoplakin I/II to desmosomes is not affected by 
p190RhoGAP (Godsel et al. 2010) but this still leaves the possibility that RhoE is regulating 
RhoA through Syx or through some unknown RhoE effector. RhoE is also known to regulate 
the actin cytoskeleton through ROCK I and through ROCK I independent pathways including 
Socius (Katoh et al. 2002; Riento et al. 2003; Komander et al. 2008). Further characterisation of 
the mechanism that regulate desmosomal assembly and disassembly will be important for 
understanding how these systems are disrupted in human disease.  
 
In summary, I have shown that depletion of RhoE expression in keratinocytes results in alatered 
colony morphology with smaller cells and limited stratification. This phenotype is a 
consequence of increased expression of desmosomal proteins and increased number of 
desmosomes following depletion of RhoE.  
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CHAPTER 5 RHOE DEPLETION PROTECTS KERATINOCYTES FROM BOTH THE 
INTRINSIC AND EXTRINSIC APOPTOSIS PATHWAYS 
 
5.1 Introduction  
Apoptosis is a highly regulated process that is critical for normal epidermal homeostasis 
(Ziegler et al. 1994). Apoptosis can be initiated via two major pathways: the intrinsic pathway 
involving subcellular organelles or the extrinsic pathway, which involves the activation of death 
receptors in response to ligand binding (Servais et al. 2008). In this study, cisplatin treatment 
was used to induce the intrinsic pathway (Fulda et al. 2006). Cisplatin mediated DNA damage 
induces p53 up-regulation (Wei et al. 2007), which leads to the activation of Bax and MOMP 
resulting in cytochrome c release and the initiation of the caspase cascade, through caspase 9 
activation, resulting in cell death (Servais et al. 2008). The extrinsic apoptosis pathway was 
induced using TRAIL treatment (Walczak et al. 2000). TRAIL binds to its death receptors 
inducing receptor trimerisation and recruitment of FADD and caspase 8 to the death domain, 
resulting in caspase 8 activation (Walczak et al. 2000). Active caspase 8 cleaves Bid, which in 
turn activates Bax resulting in MOMP and the initiation of the caspase cascade resulting in cell 
death (Yamada et al. 1999). In each case both pathways converge to a final common pathway 
involving the activation of the caspase cascade (Ghobrial et al. 2005). 
 
This chapter focuses on the role of RhoE in keratinocyte apoptosis. RhoE knock-down 
keratinocyte cell lines were used to study the effect of RhoE depletion on apoptosis induced via 
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the intrinsic and extrinsic pathways. RhoE depletion was shown to protect keratinocytes from 
apoptosis induced by both pathways and two possible explanations of how RhoE depletion 
protects from apoptosis have been identified: altered translocation of Bax and a possible role for 
the desmosomal protein plakoglobin.  
 
5.2 Results 
5.2.1 Prolonged Y-27632 treatment protects keratinocytes from apoptosis induced by 
cisplatin  
The pharmacological inhibitor Y-27632 inhibits ROCK I/II activity and has been used to study 
the function of these kinases (Ishizaki et al. 2000). As part of an analysis of ROCK function in 
apoptosis, HaCaT cells were incubated in the presence or absence of 5 µM Y-27632 for up to 96 
hours before cisplatin was added to induce apoptosis via the intrinsic pathway. Cells were also 
grown on cover slips and treated with Y-27632 for up to 96 hours before being fixed and stained 
with Phalloidin, to visualise F-actin. At each time point 24-96 hours Y-27632 treated HaCaTs 
showed a loss of actin stress fibres (Figure 38A) reminiscent of Y-27632 being an inhibitor of 
ROCK I/II (Ishizaki et al. 2000). At 0, 24, 48, 72 and 96 hours whole cell lysates were prepared 
and analysed by immunoblotting with antibodies against full-length caspase 9 and tubulin. A 
loss of full-length caspase 9 expression, under apoptotic stimulation, indicates a loss of caspase 
9 due to cleavage of the full-length protein during apoptosis (Slee et al. 1999; Green et al. 2005). 
Caspase 9 auto-cleavage and activation occurs after MOMP and the formation of the 
apoptosome (Acehan et al. 2002). In the absence of Y-27632 and in early Y-27632 treatment  
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Figure 38 Prolonged Y-27632 treatment protects keratinocytes from cisplatin-induced 
apoptosis. 
HaCaT cells were treated with 5 µM of Y-27632 for up to 96 hours with time points every 24 
hours. Fresh Y-27632 was added every 12 hours and 24 hours prior to whole cell lysis cisplatin 
was added to induce apoptosis. Cover slips in each condition were fixed and stained with 
Phalloidin to visualise F-actin. A Data presented are representative immunofluorescent images 
from three separate experiments, of the actin cytoskeleton in HaCaT cells treated with Y-27632, 
with the gain and exposure time remaining constant (scale bar 30 µm). In the presence of Y-
27632 a loss of actin stress fibres is observed. B Whole cell lysates were prepared and analysed 
by immunoblotting using antibodies against full-length caspase 9 and tubulin (loading control). 
Data presented are representative immunoblots of three separate experiments.  
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time points, treatment of HaCaT cells with 50 µM cisplatin resulted in cleavage of caspase 9 
indicated by a loss of full-length caspase 9 expression and an increase in the level of the cleaved 
form. Prolonged treatment (>48 hours) with Y-27632 resulted in protection from cisplatin-
induced caspase 9 cleavage (Figure 38B).  
 
5.2.2 Prolonged Y-27632 treatment decreased RhoE expression in keratinocytes 
As RhoE is a known ROCK I binding partner (Riento et al. 2003) and has been implicated in 
having a role in apoptosis (Bektic et al. 2005; Ongusaha et al. 2006; Boswell et al. 2007; Poch et 
al. 2007) RhoE expression was analysed in cells treated with Y-27632. HaCaT cells were 
incubated in the presence or absence of 5µM Y-27632 for up to 96 hours. Lysates were prepared 
every 24 hours and RhoE expression was analysed using immunoblotting (Figure 39). After 24 
hours of Y-27632 treatment a decrease in RhoE expression was detected compared to the 
untreated cells. The expression of RhoE was further decreased at 48 hours and maintained at this 
level at later time points. 
 
At the concentration Y-27632 was used at (5µM) during these experiments it is known to inhibit 
ROCK I/II and PRK-2 (Darenfed et al. 2007). ROCK I, but not ROCK II, has been shown to 
bind to and phosphorylate RhoE increasing the protein stability of RhoE (Riento et al. 2003; 
Riento et al. 2005). There is no evidence on whether RhoE and PRK-2 interact so I investigated 
whether ROCK I depletion would decrease RhoE expression using ROCK II-depleted cells as a 
control. To deplete expression of ROCK I and ROCK II, HaCaT cells were transiently  
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Figure 39 Prolonged Y-27632 treatment decreased RhoE expression in keratinocytes. 
HaCaT cells were incubated with 5 µM of Y-27632 for up to 96 hours. Fresh Y-27632 was 
added every 12 hours and whole cell lysates were prepared every 24 hours. Immunoblotting 
using antibodies against RhoE and tubulin was used to detect the level of endogenous RhoE or 
as a loading control. Data presented are representative immunoblots of three separate 
experiments. 
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transfected with specific siRNA oligos targeting ROCK I (RI) or ROCK II (RII) or in 
combination ROCK I/II (RI/II). Expression of these proteins was knocked down for 96 hours 
prior to whole cell lysis. Immunoblotting was used to detect the expression of endogenous 
ROCK I, ROCK II and RhoE. Specific depletion of ROCK I and ROCK II expression was 
confirmed when compared to control lanes. However, no change in RhoE expression was 
detected (Figure 40).  
 
These data demonstrate that prolonged Y-27632 treatment of HaCaT cells protects from 
cisplatin-induced apoptosis. Prolonged Y-27632 treatment also decreases RhoE expression. 
Interestingly, no loss of RhoE expression was detected when either ROCK I or ROCK II was 
depleted. 
 
5.2.3 RhoE depletion protects keratinocytes from apoptosis induced by cisplatin 
Having observed a decrease in RhoE expression when cells were treated with Y-27632 I 
analysed whether the loss of RhoE played a role in keratinocyte apoptosis. HaCaT cells in which 
RhoE (shRhoE) expression was stably knocked-down by shRNA were treated with cisplatin for 
24 hours prior to lysis. Caspase 9 cleavage was analysed using immunoblotting. In control cells 
a decrease in the level of full-length caspase 9 was detected in cells treated with 25 µM and 50 
µM cisplatin when compared to non-treated cells. However, no change in full-length caspase 9 
was detected in RhoE-depleted cells (Figure 41).  
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Figure 40 ROCK I, ROCK II and ROCK I/II depletion has no affect on endogenous RhoE 
expression. 
In HaCaT cells expression of ROCK I, ROCK II and ROCK I/II (and in combination) were 
depleted for 96 hours prior to whole cell lysis by transiently transfecting cells with siRNA 
oligos. Immunoblotting was used to detect the level of endogenous ROCK I, ROCK II, RhoE 
and tubulin. Data presented are representative immunoblots of three separate experiments.  
 
 
 
 
 
 
 
  144 
 
 
Figure 41 Keratinocytes depleted of RhoE are protected from cisplatin-induced caspase 9 
cleavage. 
HaCaT cells stably depleted of RhoE (shRhoE) and control cells (shNSC) were treated with 
cisplatin for 24 hours prior to lysis. Immunoblotting was used to detect the expression of full-
length caspase 9, RhoE and tubulin. Data presented are representative immunoblots of three 
separate experiments.  
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An alternative method for assessing apoptosis is to analyse the number of condensed nuclei 
(Nakagawa et al. 2000). Nuclear condensation occurs late in apoptosis after MOMP and caspase 
3 activation and is due to the cleavage of DNA by AIF, endonuclease G and caspase 3 targets 
(Reed 1997; Susin et al. 1999; Li et al. 2001). shRhoE and shNSC cells were seeded onto cover 
slips for 24 hours before treatment with cisplatin for 24 hours prior to fixation. Cover slips were 
then stained with Hoechst 33342 to visualise the nuclei and the percentage of condensed nuclei 
was analysed. With increasing concentrations of cisplatin the percentage of cells with condensed 
nuclei is significantly higher in control (shNSC) cells compared to RhoE-depleted (shRhoE) 
cells (Figure 42). The percentage of cells with condensed nuclei rises from ~5% at 0 µM to 25% 
at 25 µM and to ~75% at 50 µM cisplatin in control cells whereas no appreciable increase in the 
percentage of cells with condensed nuclei was observed in RhoE-depleted cells (~5% at 0 µM to 
~10% at 50 µM cisplatin). Indicating that the level of nuclear condensation is occurring at a 
frequency close to the basal rate in shRhoE cells, in the presence of cisplatin. Taken together 
these data suggest that RhoE-depletion protects keratinocytes from apoptosis induced by 
cisplatin. 
 
Dimethylformamide (DMF) was used as a solvent for cisplatin. To analyse whether DMF had 
any effect on shRhoE and shNSC cells, these cells were treated with DMF for 24 hours prior to 
lysis. DMF concentrations were the same as cells were exposed to during the cisplatin-induced 
apoptotic studies. Immunoblotting was used to detect the levels of caspase 9, RhoE and tubulin. 
No change in the level of full-length caspase 9 was detected in shNSC or shRhoE cells with 
increasing concentration of DMF (Figure 43). The percentage of condensed nuclei was also  
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Figure 42 Keratinocytes depleted of RhoE are protected from cisplatin-induced nuclear 
condensation. 
A Examples of condense nuclei in HaCaT cells treated with 50 µM cisplatin for 24 hours fixed 
and stained with Hoechst 33342. B HaCaT cells stably depleted of RhoE (shRhoE) and control 
(shNSC) cells were seeded onto cover slips and treated with cisplatin for 24 hours prior to 
fixation.  Cover slips were then stained with Hoechst 33342 to visualise the nuclei. Both the 
total number of nuclei and condensed nuclei were counted with approximately 500 cells counted 
per condition. The percentage of cells with condensed nuclei was analysed and the data 
presented are the mean, standard error and t-tests of three separate experiments (* P<0.05 and 
*** P<0.001).  
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Figure 43 Caspase 9 cleavage was not induced by DMF treatment.  
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were incubated with 
DMF for 24 hours prior to lysis. Immunoblotting was used to detect the level of full-length 
caspase 9 cleavage, RhoE and tubulin. Data presented are representative immunoblots of three 
separate experiments.  
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analysed in these cells. No increase in the percentage of cells with condensed nuclei was 
detected in either shRhoE or shNSC cells with increasing concentrations of DMF, with the 
percentage of condensed nuclei remaining at ~5% (Figure 44). At the concentrations used in 
these experiments DMF was not inducing apoptosis in HaCaT cells.  
 
5.2.4 Transient knock-down of RhoE expression protects keratinocytes from cisplatin-
induced apoptosis 
Previous data (Section 3.2.3) revealed differences in cell cycle progression data generated using 
stable RhoE-depleted (shRhoE) and transient RhoE-depleted (siRhoE) cell lines. To verify data 
on apoptosis generated using the stably RhoE-depleted cell lines, siRNA was also used to 
deplete RhoE expression in HaCaT cells. HaCaT cells were transiently transfected with siRNA 
oligos targeting RhoE (siRhoE) and a non-silencing control (siCtrl). siRhoE cells were depleted 
of RhoE for 144 hours before being treated with cisplatin for 24 hours prior to lysis. 
Immunoblotting was used to detect the level of full-length caspase 9 and RhoE expression. A 
decrease in the level of full-length caspase 9 was detected in control siCtrl cells treated with 50 
µM cisplatin. However, no change in the level of full-length caspase 9 was detected in siRhoE 
cells in the presence of cisplatin (Figure 45), indicating that siRhoE cells were not undergoing 
caspase 9 cleavage in the presence of cisplatin. The percentage of cells with condensed nuclei 
was also analysed in these cells. With increasing concentrations of cisplatin the percentage of 
cells with condensed nuclei was significantly higher in control (siCtrl) cells compared to RhoE-
depleted (siRhoE) cells (Figure 46). The percentage of cells with condensed nuclei rose from 
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Figure 44 Nuclear condensation was not induced by DMF treatment.  
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were seeded onto 
cover slips and incubated with DMF for 24 hours prior to fixation. Cover slips were then stained 
with Hoechst 33342 to visualise the nuclei. Both the total number of nuclei and condensed 
nuclei were counted, with approximately 500 cells counted per condition. The percentage of 
cells with condensed nuclei was analysed and the data presented are the mean and standard error 
of three separate experiments.  
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Figure 45 Transient RhoE depletion protects keratinocytes from cisplatin-induced caspase 
9 cleavage. 
HaCaT cells transiently transfected with siRNA oligo A to depleted RhoE (siRhoE) and control 
(siCtrl) cells were treated with cisplatin for 24 hours prior to lysis. Immunoblotting was used to 
detect the expression of full-length caspase 9, RhoE and tubulin. Data presented are 
representative immunoblots of three separate experiments.  
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Figure 46 Transient RhoE depletion protects keratinocytes from cisplatin-induced nuclear 
condensation. 
HaCaT cells transiently transfected with siRNA oligo A to depleted RhoE (siRhoE) and control 
(siCtrl) cells were seeded onto cover slips and treated with cisplatin for 24 hours prior to 
fixation. Cover slips were then stained with Hoechst 33342 to visualise the nuclei. Both the total 
number of nuclei and condensed nuclei were counted, with approximately 500 cells counted per 
condition. The percentage of cells with condensed nuclei was analysed and the data presented 
are the mean, standard error and t-tests of three separate experiments (*** P<0.001).  
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 ~5% at 0 µM to ~35% at 25 µM then to ~50% at 50 µM cisplatin whereas no appreciable 
increase in the percentage of cells with condensed nuclei was observed in RhoE-depleted cells 
(~5% at 0 µM to ~10% at 50 µM cisplatin). These data verify data generated from the stably 
RhoE-depleted cell line.  
 
Cisplatin induces apoptosis in control cells, indicated by a loss of full-length caspase 9 as well 
as an increase in the percentage of cells with condensed nuclei. In contrast, keratinocytes 
depleted of RhoE were protected from cisplatin-induced apoptosis as no loss of full-length 
caspase 9 was detected and the percentage of cells with condensed nuclei remained close to 
basal levels during treatment with cisplatin. 
 
5.2.5 Keratinocytes depleted of RhoE are protected from apoptosis induced by TRAIL 
The above data indicate that RhoE depletion protects keratinocytes from cisplatin–induced 
apoptosis. Cisplatin induces the intrinsic-apoptosis pathway, so I was interested to see whether 
RhoE depletion could protect keratinocytes from the extrinsic-apoptosis pathway. To induce this 
pathway cells were treated with the tumour necrosis factor (TNF) related apoptosis-inducing 
ligand (TRAIL) (Walczak et al. 2000). HaCaT cells stably depleted of RhoE (shRhoE) and 
control (shNSC) cells were seeded onto cover slips and treated with 25 ng/ml TRAIL for up to 6 
hours prior to fixation, with time points taken every 2 hours. In shNSC cells the percentage of 
cells with condensed nuclei increased with increased exposure to TRAIL from ~10% at 0 hours 
to ~20%, ~45% and ~55% at 2 hours, 4 hours and 6 hours of TRAIL treatment. However, the 
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percentage of shRhoE cells with condensed nuclei remained at ~10% throughout the 6 hours of 
TRAIL treatment (Figure 47). This indicates that the level of nuclear condensation was 
occurring at a basal rate in shRhoE cells whereas apoptosis was occurring in control cells in the 
presence of TRAIL. 
 
shRhoE and shNSC cells were also treated with higher concentrations of TRAIL for 6 hours and 
apoptosis was analysed using immunoblotting and the percentage of cells with condensed 
nuclei. In shNSC cells a decrease in the level of full-length caspase 9 was detected at both 25 
ng/ml and 50 ng/ml TRAIL when compared to controls. No change in the level of full-length 
caspase 9 was detected in shRhoE cells (Figure 48). With increasing concentrations of TRAIL 
the percentage of cells with condensed nuclei was significantly higher in control (shNSC) cells 
compared to RhoE-depleted (shRhoE) cells (Figure 49). In control cells the percentage of cells 
with condensed nuclei rose from ~10% at 0 ng/ml to ~60% at 25 ng/ml then to ~80% at 50 
ng/ml TRAIL. However, no appreciable increase in the percentage of condensed nuclei was 
observed in RhoE-depleted cells (~10% at 0 ng/ml to ~20% at 50 ng/ml TRAIL).  
 
RhoE-depleted cells were protected from TRAIL-induced apoptosis after 6 hours exposure. The 
effect of 24 hours of TRAIL exposure at 25ng/ml and 50ng/ml was also analysed in shRhoE and 
shNSC cells. Apoptosis was analysed using immunoblotting and the percentage of cells with 
condensed nuclei. In shNSC cells a decrease in the level of full-length caspase 9 was detected in 
the presence of TRAIL whereas no change in the level of full-length caspase 9 was detected in  
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Figure 47 TRAIL-induced apoptosis time course in RhoE-depleted and control 
keratinocytes.  
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were seeded onto 
cover slips and treated with 25 ng/ml TRAIL for up to 6 hours prior to fixation, with time points 
taken every 2 hours. Cover slips were then stained with Hoechst 33342 to visualise the nuclei. 
Both the total number of nuclei and condensed nuclei were counted, with approximately 500 
cells counted per condition. The percentage of cells with condensed nuclei was analysed and the 
data presented are the mean and standard deviation of one experiment.  
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Figure 48 Keratinocytes depleted of RhoE are protected from TRAIL-induced caspase 9 
cleavage. 
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were treated with 
TRAIL for 6 hours prior to lysis. Immunoblotting was used to detect the level of full-length 
caspase 9, RhoE and tubulin. Data presented are representative immunoblots of three separate 
experiments.  
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Figure 49 Keratinocytes depleted of RhoE are protected from TRAIL-induced nuclear 
condensation. 
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were seeded onto 
cover slips and treated with TRAIL for 6 hours prior to fixation. Cover slips were then stained 
with Hoechst 33342 to visualise the nuclei. Both the total number of nuclei and condensed 
nuclei were counted with approximately 500 cells counted per condition. The percentage of cells 
with condensed nuclei was analysed and the data presented are the mean, standard error and t-
tests of three separate experiments (** P<0.01).  
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shRhoE cells (Figure 50). With increasing concentrations of TRAIL the percentage of cells with 
condensed nuclei was significantly higher in control (shNSC) cells compared to RhoE-depleted 
(shRhoE) cells (Figure 51). In shNSC cells the percentage of cells with condensed nuclei 
increased from ~5% at 0 ng/ml to ~50% at 25 ng/ml then to ~75% at 50ng/ml TRAIL. However, 
no appreciable increase in the percentage of cell with condensed nuclei was observed in RhoE-
depleted cells (~5% at 0 ng/ml to ~15% at 50 ng/ml TRAIL). These data indicate that RhoE-
depletion protects keratinocytes from apoptosis induced by TRAIL. 
 
5.2.6 Transient knock-down of RhoE expression protects keratinocytes from TRAIL-
induced apoptosis 
To verify data on TRAIL-induced apoptosis generated using the shRhoE stably depleted cell 
lines, siRNA was used to deplete RhoE expression in HaCaT cells. Transiently RhoE-depleted 
(siRhoE) and control (siCtrl) HaCaT cells were treated with TRAIL for 24 hours prior to lysis. 
Immunoblotting was used to detect the level of full-length caspase 9 and RhoE. In siCtrl cells a 
decrease in the level of full-length caspase 9 was detected in the presence of TRAIL. However, 
no change in the level of full-length caspase 9 was detected in siRhoE cells (Figure 52). The 
percentage of cells with condensed nuclei was also analysed in these cells. With increasing 
concentrations of TRAIL the percentage of condensed nuclei was significantly higher in control 
(siCtrl) cells compared to RhoE-depleted (siRhoE) cells (Figure 53). In siCtrl cells the 
percentage of cells with condensed nuclei increased from ~5% at 0 ng/ml to ~45% at 50 ng/ml 
TRAIL. However, no appreciable increase in the percentage of cells with condensed nuclei was  
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Figure 50 Keratinocytes depleted of RhoE are protected from TRAIL-induced caspase 9 
cleavage. 
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were treated with 
TRAIL for 24 hours prior to lysis. Immunoblotting was used to detect the level of full-length 
caspase 9, RhoE and tubulin. Data presented are representative immunoblots of three separate 
experiments.  
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Figure 51 Keratinocytes depleted of RhoE are protected from TRAIL-induced nuclear 
condensation. 
HaCaT cells stably depleted of RhoE (shRhoE) and control (shNSC) cells were seeded onto 
cover slips and treated with TRAIL for 24 hours prior to fixation. Cover slips were then stained 
with Hoechst 33342 to visualise the nuclei. Both the total number of nuclei and condensed 
nuclei were counted with approximately 500 cells counted per condition. The percentage of cells 
with condensed nuclei was analysed and the data presented are the mean, standard error and t-
tests of three separate experiments (* P<0.05).  
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Figure 52 Keratinocytes transiently depleted of RhoE are protected from TRAIL-induced 
caspase 9 cleavage. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were treated with 
TRAIL for 24 hours prior to lysis. Immunoblotting was used to detect the level of full-length 
caspase 9, RhoE and tubulin. Data presented are representative immunoblots of three separate 
experiments.  
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Figure 53 Keratinocytes transiently depleted of RhoE are protected from TRAIL-induced 
nuclear condensation. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells were seeded onto 
cover slips and treated with TRAIL for 24 hours prior to fixation. Cover slips were then stained 
with Hoechst 33342 to visualise the nuclei. Both the total number of nuclei and condensed 
nuclei were counted with approximately 500 cells counted per condition. The percentage of cells 
with condensed nuclei was analysed and the data presented are the mean, standard error and t-
tests of three separate experiments (* P<0.05).  
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observed in RhoE-depleted cells (~5% at 0 ng/ml to ~15% at 50 ng/ml TRAIL). These data 
verify the data generated from the stably RhoE-depleted cell line. 
 
TRAIL induces apoptosis in control cells, indicated by a loss of full-length caspase 9 as well as 
an increase in the percentage of cells with condensed nuclei. In contrast, keratinocytes depleted 
of RhoE are protected from TRAIL-induced apoptosis as no loss of caspase 9 was detected and 
the percentage of cells with condensed nuclei remained close to basal levels during treatment 
with TRAIL. 
 
5.2.7 Re-expression of RhoE restores sensitivity to both cisplatin- and TRAIL-induced 
apoptosis in keratinocytes 
Another method for verifying the apoptosis data generated using RhoE-depleted cell lines was 
to rescue RhoE expression in these cells. To rescue expression of RhoE in the shRhoE cell line, 
cells were transiently transfected with pCVM5FlagRhoE, containing cDNA encoding wild type 
mouse RhoE to generate shRhoE:RhoE wt cells. As controls both shRhoE and shNSC cells were 
transiently transfected with pCMV5FlagEV (empty vector). shRhoE:RhoE wt, shRhoE:EV and 
shNSC:EV cell lines were treated with cisplatin for 24 hours prior to lysis. Immunoblotting was 
used to detect the level of full-length caspase 9 and RhoE. Reconstitution of RhoE was detected 
and is indicated by the arrow on the third panel (Figure 54). In both shNSC:EV cells and 
shRhoE:RhoE wt cells a decrease in the level of full-length caspase 9 was detected in the 
presence of cisplatin whereas no change in the level of full-length caspase 9 was observed in  
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Figure 54 Re-expression of RhoE restores sensitivity to cisplatin-induced caspase 9 
cleavage. 
Stably RhoE-depleted (shRhoE) and control (shNSC) HaCaT cells were transiently transfected 
with pCMV5 FlagRhoE wild type (RhoE wt) or pCMV5 empty vector for 48 hours. The 
shRhoE:RhoE wt, shRhoE:EV and shNSC:EV cell lines were treated with cisplatin for 24 hours 
prior to lysis. Immunoblotting was used to detect the level of full-length caspase 9, RhoE and 
tubulin. Data presented are representative immunoblots from three separate experiments. 
Expression of exogenous murine RhoE is indicated by the arrow on the third panel.  
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shRhoE:EV cells. The percentage of condensed nuclei was also analysed in these cells. In the 
presence of cisplatin the percentage of cells with condensed nuclei increased significantly in the 
shNSC:EV cells and shRhoE:RhoE wt cells compared to shRhoE:EV cells (Figure 55). The 
percentage of cells with condensed nuclei in shNSC:EV cells and shRhoE:RhoE wt increased 
from ~10% at 0 µM to ~55% at 50 µM cisplatin. However, no appreciable increase in the 
percentage of cells with condensed nuclei was detected in shRhoE:EV cells with cisplatin 
treatment (from ~10% to ~15% with treatment). Cisplatin failed to induce apoptosis in 
shRhoE:EV cells, indicated by no loss of full-length caspase 9 and close to basal rate of 
condensed nuclei. However, apoptosis was induced by cisplatin in both shNSC:EV and 
shRhoE:RhoE cell lines, indicated by a loss of full-length caspase 9 and increased frequency of 
condensed nuclei. These data indicate that reconstitution of RhoE expression restores sensitivity 
to cisplatin-induced apoptosis in keratinocytes. 
 
The effect of RhoE re-expression was also analysed following TRAIL treatment. shRhoE:RhoE 
wt, shRhoE:EV and shNSC:EV cell lines were treated with TRAIL for 24 hours prior to lysis. 
Immunoblotting was used to detect the level of full-length caspase 9 and RhoE. Reconstitution 
of RhoE was detected and is indicated by the arrow on the third panel (Figure 56). In both 
shNSC:EV and shRhoE:RhoE wt cells a decrease in the level of full-length caspase 9 was 
detected in the presence of TRAIL whereas no change in the level of full-length caspase 9 was 
detected in shRhoE:EV cells. The percentage of condensed nuclei was also analysed in these 
cells. In the presence of TRAIL the percentage of cells with condensed nuclei increased 
significantly in the shNSC:EV and shRhoE:RhoE wt cells compared to shRhoE:EV cells  
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Figure 55 Re-expression of RhoE restores sensitivity to cisplatin-induced nuclear 
condensation. 
Stably RhoE-depleted (shRhoE) and control (shNSC) HaCaT cells were transiently transfected 
with pCMV5FlagRhoE wild type (RhoE wt) or pCMV5 empty vector. The shRhoE:RhoE wt, 
shRhoE:EV and shNSC:EV cell lines were seeded onto cover slips and treated with cisplatin for 
24 hours prior to fixation. Cover slips were then stained with Hoechst 33342 to visualise the 
nuclei. Both the total number of nuclei and condensed nuclei were counted with approximately 
400 cells counted per condition. The percentage of cells with condensed nuclei was analysed 
and the data presented are the mean, standard error and t-tests of three separate experiments 
(**P<0.01).  
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Figure 56 Re-expression of RhoE restores sensitivity to TRAIL-induced caspase 9 
cleavage. 
Stably RhoE-depleted (shRhoE) and control (shNSC) HaCaT cells were transiently transfected 
with pCMV5 FlagRhoE wild type (RhoE wt) or pCMV5 empty vector. The shRhoE:RhoE wt, 
shRhoE:EV and shNSC:EV cell lines were treated with TRAIL for 24 hours prior to lysis. 
Immunoblotting was used to detect the level of full-length caspase 9, RhoE and tubulin. Data 
presented are representative immunoblots from three separate experiments. Expression of 
exogenous murine RhoE is indicated by the arrow on the third panel.  
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Figure 57 Re-expression of RhoE restores sensitivity to TRAIL-induced nuclear 
condensation. 
Stably RhoE-depleted (shRhoE) and control (shNSC) HaCaT cells were transiently transfected 
with pCMV5 FlagRhoE wild type (RhoE wt) or pCMV5 empty vector. The shRhoE:RhoE wt, 
shRhoE:EV and shNSC:EV cell lines were seeded onto cover slips and treated with TRAIL for 
24 hours prior to fixation. Cover slips were then stained with Hoechst 33342 to visualise the 
nuclei. Both the total number of nuclei and condensed nuclei were counted with approximately 
400 cells counted per condition. The percentage of cells with condensed nuclei was analysed 
and the data presented are the mean, standard error and t-tests of three separate experiments (* 
P<0.05).  
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(Figure 57). The percentage of condensed nuclei in shNSC:EV and shRhoE:RhoE wt cells 
increased from ~10% at 0 ng/ml to ~35% and ~45% at 25 ng/ml TRAIL. However, no 
appreciable increase in the percentage of cells with condensed nuclei was detected in 
shRhoE:EV cells with TRAIL treatment (from ~10% to ~15% with treatment). TRAIL failed to 
induce apoptosis in shRhoE:EV cells, indicated by no loss of full-length caspase 9 and close to 
basal rate of condensed nuclei. However, apoptosis was induced by TRAIL in both shNSC:EV 
and shRhoE:RhoE wt cell lines, indicated by a loss of full-length caspase 9 and increased 
frequency of condensed nuclei. These data indicate that reconstitution of RhoE expression 
restores sensitivity to TRAIL-induced apoptosis in keratinocytes. 
 
Taken together these data imply that re-expression of RhoE restores keratinocyte sensitivity to 
both cisplatin- and TRAIL-induced apoptosis.  
 
5.2.8 Bax translocation is altered in RhoE depleted cells 
Both the intrinsic and extrinsic pathways, induced by cisplatin and TRAIL, converge to a final 
common pathway involving the activation of Bax, which leads to MOMP and the initiation of 
the caspase cascade (Yamada et al. 1999; Ghobrial et al. 2005; Servais et al. 2008). RhoE has 
been implicated in the regulation of Bax expression, with the over-expression of RhoE 
suppressing Bax expression (Li et al. 2009). Endogenous Bax expression was analysed in both 
stably depleted RhoE (shRhoE) and transiently depleted RhoE (siRhoE) cell lines using 
immunoblotting. No differences in Bax expression was detected between RhoE depleted and 
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control HaCaT cells (Figure 58A & B). I then analysed whether the induction of apoptosis 
altered Bax expression and if there were any differences between RhoE depleted and control 
cells. shRhoE and shNSC HaCaT cells were treated with cisplatin for 24 hours prior to lysis. 
Immunoblotting was used to detect the expression of full-length caspase 9, Bax, RhoE and 
tubulin (Figure 59). A decrease in the level of full-length caspase 9 was detected in the presence 
of cisplatin in shNSC cells whereas no change in the level of full-length caspase 9 was detected 
in shRhoE cells. No changes in Bax expression were detected in either shRhoE or shNSC cells 
in response to cisplatin treatment. Although apoptosis was induced in shNSC cells and 
prevented in shRhoE cells treated with cisplatin, indicated by caspase 9 cleavage, no change in 
Bax expression was detected in either cell line.  
 
During apoptosis activated Bax is translocated from the cytoplasm to the mitochondrial 
membrane and mediates MOMP by inserting into the outer mitochondrial membrane forming 
pore-like structures (Korsmeyer et al. 2000; Basanez et al. 2002). The change from cytoplasmic 
to mitochondrial localised Bax can be seen using immunofluorescent microscopy as diffuse to 
punctate Bax staining localised to the mitochondria (Wolter et al. 1997) (Figure 60A). This 
method was used to analyse Bax translocation in RhoE depleted cells treated with TRAIL. 
shRhoE and shNSC HaCaT cells were seeded onto cover slips and treated with TRAIL for 6 
hours. To visualise the mitochondria the cells were incubated with MitoTracker Red for 45 
minutes prior to fixation. Cover slips were then stained with Bax and Hoechst 33342 to visualise 
Bax localisation and nuclei. To illustrate Bax translocation, epifluorescent images were taken of 
shNSC cells after TRAIL treatment. In most cells Bax staining was diffuse but in cells that were  
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Figure 58 Bax expression is unchanged in RhoE depleted keratinocytes. 
Whole cell lysates were prepared from HaCaT cell lines depleted of RhoE by A shRNA and B 
siRNA. Bax, RhoE and tubulin expression was analysed by immunoblotting. Data presented are 
representative immunoblots of three separate experiments.  
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Figure 59 Bax expression is unchanged in RhoE-depleted and control keratinocytes 
treated with cisplatin. 
Stably RhoE-depleted (shRhoE) and control (shNSC) cells were treated with cisplatin for 24 
hours prior to lysis. Caspase 9 cleavage and the expression level of Bax, RhoE and tubulin were 
analysed using immunoblotting. Data presented are representative immunoblots from two 
separate experiments. 
 
 
 
 
 
 
  172 
 
 
 
  173 
 
Figure 60 The percentage of cells with punctate Bax staining following TRAIL treatment 
is decreased in RhoE-depleted cells.  
Stably RhoE-depleted (shRhoE) and control (shNSC) HaCaT cells were seeded onto cover slips 
and treated with 25 ng/ml TRAIL for 6 hours. To visualise the mitochondria the cells were 
incubated with 250 ng/ml MitoTracker Red for 45 minutes prior to fixation. Cover slips were 
then stained with Bax and Hoechst 33342 to visualise Bax localisation and the nuclei. A 
Epifluorescent images were taken, using a 40x lens, of shNSC cells after 6 hours of TRAIL 
treatment to illustrate punctate Bax staining co-localising with mitochondria. Bax green, 
mitochondria red, merge yellow and nuclei blue. Cells scored as having punctate Bax staining 
are indicated with arrows (scale bar 30 µm). B The total number of nuclei and cells with 
punctate Bax staining were counted, with approximately 200 cells counted per condition. Data 
presented are the mean and standard error of two separate experiments.  
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undergoing Bax translocation, Bax staining was punctate (Green). Mitochodria staining (Red) 
co-localised with punctate Bax staining (Merge) (Figure 60A). To analyse the percentage of 
cells with punctate Bax staining the total number of nuclei and cells with punctate Bax staining 
and were counted. The condition of the cells and nuclei were also taken into account. If a cell 
had become rounded or if the nucleus was fragmented the cell was not included in the count 
contributing to punctate Bax staining. Examples of cells included in counts are indicated with 
arrows in Figure 60A. The percentage of cells with punctate Bax staining in both shNSC and 
shRhoE cells in the absences of TRAIL treatment was ~2% (Figure 60B). With TRAIL 
treatment this was increased to ~22% in shNSC cells and ~6% in shRhoE cells, suggesting the 
translocation of Bax was disrupted in RhoE-depleted keratinocytes.  
 
5.2.9 Relocalised plackoglobin protects keratinocytes depleted of RhoE from apoptosis 
Previous data (Section 4.2.1) revealed that RhoE depletion altered keratinocyte colony 
morphology from a 2D spread monolayer phenotype in control cells, to a 3D compacted 
stratified phenotype. The altered colony morphology was induced by RhoE depletion increasing 
the expression of desmosomal proteins and number of desmosomes (Section 4.2.3 & 4.2.4). In 
low calcium conditions both adherens junctions and desomsomes are disrupted (Chitaev et al. 
1997; Jamora et al. 2002), resulting in the loss of cell-cell adhesion in both control and RhoE-
depleted cells and reverting the RhoE-depleted colony morphology back to a control phenotype 
(Section 4.2.5). The effects of RhoE depletion on keratinocyte apoptosis in low calcium 
conditions were analysed to investigate whether cell-cell adhesion was playing a role in 
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protecting keratinocytes from apoptosis. Transiently RhoE-depleted (siRhoE) and control 
(siCtrl) HaCaT cells were incubated in normal or low calcium medium for 24 hours prior to and 
then during treatment with cisplatin for 24 hours prior to lysis. Immunoblotting was used to 
detect the level of caspase 9 cleavage and RhoE expression (Figure 61). In normal conditions a 
decrease in the level of full-length caspase 9 was detected in siCtrl cells in the presence of 
cisplatin whereas no loss of full-length caspase 9 was detected in siRhoE cells. In low calcium 
conditions a decrease in the level of full-length caspase 9 in the presence of cisplatin was 
detected in both siCtrl and siRhoE cell lines. 
 
Previous data (Section 4.2.6) revealed by depleting desmoplakin I/II or plakoglobin in RhoE-
depleted cells colony morphology reverted back to a more normal phenotype (Figure 37). The 
effects of individual and combined depletion of desmoplakin (Dsp), plakoglobin (Diepgen et al.) 
and RhoE (siRhoE) on keratinocyte apoptosis were analysed. HaCaT cells were transiently 
transfected with siRNA oligos to deplete proteins of interest and were treated with cisplatin for 
24 hours prior to lysis. Caspase 9 cleavage and the expression of desmoplakin, plakoglobin, 
RhoE and tubulin were analysed using immunoblotting. Specific depletion of desmoplakin, 
plakoglobin and RhoE expression was detected when compared to control lanes (Figure 62A). 
In the presence of cisplatin a decrease in the level of full-length caspase 9 was detected in siCtrl, 
siDsp, siPG and siRhoE:PG cells. However, no change in the level of full-length caspase 9 was 
detected in siRhoE or siRhoE:Dsp cells (Figure 62B). A decrease in total caspase 9 was 
observed in cells depleted of desmoplakin I/II (Figure 62B). The percentage of cells with 
condensed nuclei was also analysed in these cells (Figure 63). In the presence of cisplatin the 
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percentage of cells with condensed nuclei is higher in siCtrl, siDP, siPG and siRhoE:PG cells 
compared to siRhoE and siRhoE:DP cells. Taken together these data indicate that sensitivity to 
cisplatin-induced apoptosis is restored in RhoE-depleted keratinocytes when plakoglobin is also 
depleted in these cells. 
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Figure 61 Keratinocytes depleted of RhoE are protected from cisplatin-induced apoptosis 
in normal growth conditions but not in low calcium conditions. 
HaCaT cells transiently depleted of RhoE (siRhoE) and control (siCtrl) cells where incubated in 
normal or low calcium media for 24 hour prior to and then during treatment with cisplatin for 24 
hours prior to lysis. Immunoblotting was used to detect the level of caspase 9 cleavage, RhoE 
and tubulin. Data presented are representative immunoblots of three separate experiments.  
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Figure 62 Depletion of plakoglobin in RhoE-depleted keratinocytes restores sensitivity to 
cisplatin-induced caspase 9 cleavage. 
A HaCaT cells were transiently transfected with siRNA oligos to depleted desmoplakin I/II 
(Dsp), plakoglobin (Diepgen et al.) and RhoE expression individually and in combination. B 
siCtrl, siDsp, siPG, siRhoE, siRhoE:Dsp and siRhoE:PG cells were treated with cisplatin for 24 
hours prior to lysis. Immunoblotting was used to detect the expression of full-length caspase 9, 
RhoE, desmoplakin, plakoglobin and tubulin. Data presented are representative immunoblots of 
three separate experiments.  
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Figure 63 Depletion of plakoglobin in RhoE-depleted keratinocytes restores sensitivity to 
cisplatin-induced nuclear condensation.  
HaCaT cells were transiently transfected with siRNA oligos to deplete desmoplakin I/II (Dsp), 
plakoglobin (Diepgen et al.) and RhoE expression individually and in combination. siCtrl, 
siDsp, siPG, siRhoE, siRhoE:Dsp and siRhoE:PG cells were seeded onto cover slips and treated 
with cisplatin for 24 hours prior to fixation. Cover slips were then stained with Hoechst 33342 
to visualise the nuclei. Both the total number of nuclei and condensed nuclei were counted, with 
approximately 400 cells counted per condition. The percentage of cells with condensed nuclei 
was analysed and the data presented are the mean and standard deviation of one experiment.  
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5.3 Discussion  
5.3.1 ROCK I and apoptosis in RhoE-depleted cells 
Prolonged treatment of keratinocytes with Y-27632 to inhibit ROCK I and ROCK II protected 
keratinocytes from cisplatin-induced apoptosis (Section 5.2.1). Treatment with Y-27632 also 
protects U2OS cells from camptothecin-induced apoptosis (Ongusaha et al. 2006) and the 
administration of Y-27632 greatly reduced endotoxin-induced apoptosis in the liver (Thorlacius 
et al. 2006). During apoptosis, caspase 3-mediated activation of ROCK I induces membrane 
blebbing, stimulates nuclear fragmentation and packaging of nuclear material into blebs at the 
cell surface (Coleman et al. 2001; Sebbagh et al. 2001). Treatment with Y-27632 prevents 
ROCK I-induced membrane blebbing in cells undergoing apoptosis (Coleman et al. 2001; Cocca 
et al. 2002).  
 
RhoE has been implicated in apoptosis (Bektic et al. 2005; Ongusaha et al. 2006; Boswell et al. 
2007; Poch et al. 2007). To investigate how Y-27632 might be protecting keratinocytes I 
analysed the expression of RhoE, which inhibits ROCK I activity (Riento et al. 2003). In 
keratinocytes treated with Y-27632, a decrease in RhoE expression was observed. The temporal 
decrease in RhoE expression also correlated with Y-27632 treatment protecting the cells from 
apoptosis induced by cisplatin (Figure 38B & 39).  
 
ROCK I, but not ROCK II, binds to and phosphorylates RhoE, increasing RhoE protein stability 
(Riento et al. 2003; Riento et al. 2005). To investigate whether the inhibition of ROCK activity 
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was responsible for the loss of RhoE expression in Y-27632 treated cells siRNA oligos were 
used to deplete keratinocytes of ROCK I. Prolonged depletion of ROCK I did not alter the 
expression levels of RhoE in keratinocytes (Figure 40). This was surprising as ROCK I is 
known to phosphorylate RhoE, increasing its protein stability (Riento et al. 2005). Combined 
depletion of ROCK I and ROCK II expression also had no effect on RhoE expression (Figure 
40). Taken together these data indicate that whilst treatment with Y-27632 affected RhoE 
expression this is not a function of ROCK I in keratinocytes. Possible explanations to explain 
how Y-27632 treatment might decrease RhoE expression independently of ROCK I include, 
kinase independent effects or the inhibition of other kinases by Y-27632. The concentration of 
Y-27632 required to inhibit ROCK I and ROCK II also inhibits PRK-2 (Darenfed et al. 2007). 
PRK-2 is an effector of both Rho and Rac GTPases and regulates the actin cytoskeleton and 
cell-cell adhesions (Vincent et al. 1997; Calautti et al. 2002). A recent report correlating Y-
27632 treatment with specific knock-downs of ROCK I, ROCK II and PRK-2 revealed 
significant differences in phenotype (Darenfed et al. 2007). One possibility which has not been 
explored here is that RhoE might also interact with PRK-2 as well as ROCK I. Further 
experiments in which keratinocytes are depleted of PRK-2 and combined depletion of ROCK I, 
ROCK II and PRK-2 would be required to clarify this issue. 
 
Several studies have implicated RhoE in apoptosis (Bektic et al. 2005; Ongusaha et al. 2006; 
Boswell et al. 2007; Poch et al. 2007). Both stably and transiently transfected keratinocytes were 
used to analyse the effect of RhoE-depletion on the intrinsic apoptosis pathway induced by 
cisplatin. Keratinocytes stably and transiently depleted of RhoE were protected from apoptosis 
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induced by the intrinsic pathway, arguing against off-target effects from either system (Section 
5.2 4 & 5.2.5). In addition, reconstitution of RhoE expression in the RhoE-depleted cell line 
rescued sensitivity to cisplatin-induced apoptosis resulting in cell death (Section 5.2.7). Taken 
together these data show that depletion of RhoE protects keratinocytes from apoptosis induced 
by the intrinsic pathway. 
 
A number of studies have reported increased RhoE expression following treatment with various 
apoptosis-inducing stimuli (Murakami et al. 2001; Villalonga et al. 2004; Ongusaha et al. 2006; 
Boswell et al. 2007). Two studies, which used siRNA to inhibit RhoE induction following 
apoptotic stimuli, reported an increase in apoptosis (Ongusaha et al. 2006; Boswell et al. 2007). 
These studies imply RhoE expression protects cells from apoptosis (Ongusaha et al. 2006; 
Boswell et al. 2007). Conversely, other studies have shown RhoE over-expression increases the 
basal rate of apoptosis (Bektic et al. 2005; Poch et al. 2007). These studies use fundamentally 
different approaches to studying the role of RhoE in apoptosis including: different cell types, 
different apoptosis-inducing agents and different expression systems. Unlike other studies I have 
depleted RhoE expression in keratinocytes and in this system I observed protection from 
apoptosis induced via the intrinsic and extrinsic pathways.  
 
Cisplatin induces apoptosis through the intrinsic pathway by up-regulating the tumour 
suppressor gene p53, which induces expression of PIDD protein and PUMA, promoting 
apoptosis (Wei et al. 2007). RhoE is also a transcriptional target of p53 and has been reported to 
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be induced in response to DNA damage (Jeffers et al. 2003; Ongusaha et al. 2006). Treatment 
with cisplatin has also been reported to increase RhoE expression in fibroblasts (Villalonga et al. 
2004). However, no increase in RhoE expression was observed in HaCaT cells following 
treatment with cisplatin (Figure 41). The HaCaT cell line behaves phenotypically like normal 
keratinocytes with regard to patterns of growth and differentiation (Boukamp et al. 1988). 
However, HaCaT cells have three mutations in both alleles of their p53 gene, resulting in p53 
having an extended half-life (Lehman et al. 1993). This results in p53 being highly expressed in 
HaCaT cells when compared to normal human keratinocytes (Bowen et al. 2003). UVB 
irradiation also induces the intrinsic apoptosis pathway through the up-regulation of p53 
(Ziegler et al. 1994). UVB irradiation has been shown to increase the expression of p53 and 
induce nuclear fragmentation in HaCaT cells as well as up-regulating RhoE (Henseleit et al. 
1997; Boswell et al. 2007). Thus, whilst p53 is highly expressed in HaCaT cells, expression can 
be further induced following DNA damage. However, the up-regulation of RhoE observed after 
UVB irradiation in HaCaT cells was shown to be independent of p53 (Boswell et al. 2007). 
These data show that although HaCaT cells have a mutated p53, p53 still up-regulated in these 
cells and that RhoE up-regulation is not solely dependent on p53. The explanation for RhoE up-
regulation in response to cisplatin in fibroblasts but not HaCaT cells could be cell type specific 
and not because RhoE is unable to be up-regulated.  
 
Most studies investigating the role of RhoE in apoptosis have focused on the intrinsic apoptosis 
pathway induced by a variety of different apoptotic stimuli. However, UVB irradiation, which 
induces the intrinsic pathway through DNA damage and p53 up-regulation, can also induce the 
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extrinsic pathway through the activation of the death receptor CD95 (Kulms et al. 2000). UVB-
irradiated HaCaT cells prevented from inducing RhoE expression by siRNA demonstrated an 
increase in apoptosis (Boswell et al. 2007). Depletion of RhoE in HaCaT cells protected cells 
from apoptosis induced via the intrinsic pathway, so I investigated whether RhoE-depletion 
would protect keratinocytes from apoptosis mediated via the extrinsic pathway. To do this I 
used the death ligand TRAIL (Section 1.2.3.1). I observed that keratinocytes depleted of RhoE 
were protected from apoptosis induced by TRAIL. This was confirmed using both stably and 
transiently RhoE-depleted cell lines along with reconstitution of RhoE expression (Sections 
5.2.5-5.2.7). Taken together these data show that RhoE-depletion protects keratinocytes from 
apoptosis induced via both the intrinsic and extrinsic pathways.  
 
Both the intrinsic and the extrinsic pathways converge at the level of Bax activation (Sprick et 
al. 2004; Ott et al. 2007) (Section 1.2.1 Figure 5 & 7). Upon activation, Bax translocates from 
the cytoplasm to the mitochondria and alters the integrity of the mitochondrial membrane, 
resulting in cytochrome c release, which leads to the activation of the caspase cascade (Ott et al. 
2007). RhoE over-expression (in a gastric adenocarinoma cell line) was reported to suppress the 
expression of Bax at a post-transcriptional level, resulting in resistance to multiple anti-tumour 
drugs (Li et al. 2009). No change in Bax expression was observed in RhoE-depleted cells in the 
presence or absence of cisplatin treatment (Figure 58 & 59). Once activated, Bax translocates to 
the mitochondria where it mediates MOMP by inserting into the outer mitochondrial membrane 
forming pore-like structures (Korsmeyer et al. 2000; Basanez et al. 2002) (Figure 5A). Bax 
translocation was analysed in RhoE-depleted cells treated with TRAIL and a decrease in the 
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percentage of cells containing punctate Bax staining was observed in RhoE-depleted cells 
(Figure 60B). These data suggest that whilst Bax expression is unaffected by RhoE-depletion, 
Bax translocation is inhibited, which could be responsible for the protection seen in RhoE-
depleted cells (Figure 64).  
 
During apoptosis, caspase 3 cleaves and activates ROCK I, which induces membrane blebbing 
and aids in the apoptotic process (Coleman et al. 2001; Sebbagh et al. 2001). Consistent with 
this, over-expression of the ROCK I 130kDa fragment produced by caspase 3 cleavage induces 
apoptosis but expression of full-length ROCK I does not (Ongusaha et al. 2006). Loss of ROCK 
I expression, using siRNA, resulted in decreased apoptosis induced by camptothecin (Ongusaha 
et al. 2006). Also, Y-27632 treatment prevents ROCK I-induced membrane blebbing in cells 
undergoing apoptosis (Coleman et al. 2001; Cocca et al. 2002). Treatment with Y-27632 also 
protects other cell types from apoptosis (Ongusaha et al. 2006) and the administration of Y-
27632 reduces endotoxin-induced apoptosis in the liver (Thorlacius et al. 2006). Thus there is 
clear evidence linking ROCK I to the apoptotic pathway. Therefore one argument could be that 
the protection from apoptosis seen in RhoE-depleted cells is a ROCK I-dependent process. This 
would be consistent with a report where cells prevented from inducing RhoE expression show 
an increase in ROCK I activity during campothecin-induced apoptosis (Ongusaha et al. 2006). 
However, I observed that Y-27632 treatment, which inhibits ROCK I kinase activity (as well as 
ROCK II and PRK-2), protected HaCaT cells from cisplatin-induced apoptosis (Figure 38) and 
that this protection correlated with a decrease in RhoE expression (Figure 39). In keratinocytes 
depleted of RhoE, an increase in stellate actin stress fibres was observed indicating increased 
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ROCK activity in these cells (Section 3.2.1). However, apoptosis is still inhibited suggesting a 
ROCK I independent process. This is consistent with Boswell el al. (2007) who also reported 
that the prevention of RhoE induction during UVB irradiation was also independent of ROCK I 
activity (Boswell et al. 2007). These data suggest that it is RhoE depletion that is important for 
protection against apoptosis in keratinocytes and that the protection is independent of ROCK I 
activity. 
 
5.3.2 Desmosomes and apoptosis in RhoE-depleted cells 
RhoE-depleted keratinocytes show clear changes in colony morphology (Section 4.2.1). This is 
a consequence of RhoE-depletion inducing expression of desmosomal proteins and increasing 
the number of desmosomes (Figure 28 & 29). I analysed whether the increase in desmosomal 
proteins or desmosomes played a role in protecting these cells from apoptosis induced by the 
intrinsic pathway. In low calcium conditions, in which both adherens junctions and desomsomes 
are disrupted (Chitaev et al. 1997; Jamora et al. 2002) I observed that RhoE colony morphology 
reverted to a normal phenotype and that the expression of desmosomal proteins was lost 
(Section 4.2.5). Under these conditions induction of the intrinsic apoptosis pathway resulted in 
similar levels of apoptosis in both RhoE-depleted and control cells (Section 5.2.9 Figure 61). 
This indicates that disruption of desmosomal adhesion or loss of desmosomal proteins is 
involved in the protection observed in RhoE-depleted cells. 
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Depletion of desmoplakin I/II or plakoglobin disrupts desmosomes and reverses the stratified 
phenotype in RhoE-depleted cells (Section 4.2.6). I analysed whether depletion of these 
desmosomal proteins affected the response to cisplatin-induced apoptosis. In control 
keratinocytes depleted of either desmoplakin I/II or plakoglobin, apoptosis was observed 
following treatment with cisplatin (Figure 62 & 63). In cells depleted of both RhoE and 
desmoplakin I/II protection from apoptosis was observed (Figure 62 & 63), even though 
desmosomes had been disrupted (Figure 37). However, in cells depleted of both RhoE and 
plakoglobin sensitivity to cisplatin was restored (Figure 62 & 63). The protection from cisplatin-
induced apoptosis generated by RhoE depletion in keratinocytes was lost when cells were 
cultured either in low calcium conditions or when plakoglobin was depleted in these cells. In 
low calcium medium I saw a loss of desmosomal proteins (Figure 35) and although plakoglobin 
expression was not analysed it is possible that it too was decreased or relocalised in these 
conditions. It has also been reported that depletion of desmoplakin I/II disrupts desmosomes but 
does not alter plakoglobin expression (Wan et al. 2007). Taken together, these data suggest that 
the protection from cisplatin-induced apoptosis seen in RhoE-depleted keratinocytes is not 
dependent on desmosomes but on the desmosomal protein plakoglobin. 
 
Plakoglobin is closely related to β-catenin, which functions as a structural protein and as a 
transcriptional activator mediating Wnt signaling (Zhurinsky et al. 2000; Moon et al. 2002). 
Plakoglobin can affect Wnt signaling through binding the transcription factors Tcf/Lcf (Ben-
Ze'ev et al. 1998; Klymkowsky et al. 1999; Zhurinsky et al. 2000). Activation of Wnt signaling 
blocks apoptosis in a variety of cells whilst suppression of Wnt signaling induces apoptosis 
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(Longo et al. 2002). Suppression of desmoplakin I/II expression results in the relocalisation of 
plakoglobin to the nucleus where its accumulation suppresses Wnt signaling (Garcia-Gras et al. 
2006). RhoE has been implicated in the translocation of β-catenin to adherens junctions 
(Rubenstein et al. 2005). Thus it is possible RhoE may also have a role in the translocation of 
plakoglobin. Thus RhoE-depletion may prevent plakoglobin from localising to the nucleus 
following desmosomal disruption (Figure 64). 
 
Plakoglobin has also been reported to regulate members of the Bcl-2 family (Hakimelahi et al. 
2000; Dusek et al. 2007). The Bcl-2 family proteins mediate MOMP and consist of both anti-
apoptotic members that act as repressors of apoptosis by blocking the release of cytochrome c, 
and pro-apoptotic members that act as promoters of apoptosis (Green et al. 2004). Over-
expression of plakoglobin in keratinocytes has been reported to induce the expression of the 
anti-apoptotic protein Bcl-2, protecting the cells from apoptosis (Hakimelahi et al. 2000). In 
contrast, keratinocytes derived from plakoglobin-null mice showed increased expression of the 
anti-apoptotic protein Bcl-xL and reduced susceptibility to apoptosis (Dusek et al. 2007). Taken 
together these data suggest the level of plakoglobin expression is important for the expression of 
different Bcl-2 family members. RhoE expression has also been reported in the regulation of the 
Bcl-2 family member Bax (Li et al. 2009). 
 
In summary, depletion of RhoE expression protects keratinocytes from apoptosis induced via 
the intrinsic and extrinsic apoptosis pathways. The protection generated by RhoE depletion is 
probably independent of ROCK I activity. I suggest two possible explanations for the protection 
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observed following depletion of RhoE expression, firstly I observed significant decrease in Bax 
translocation and secondly depletion of the desmosomal protein plakoglobin restored sensitivity 
to apoptosis (Figure 64).  
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Figure 64 Mechanism of how RhoE depletion protects keratinocytes from apoptosis. 
In normal keratinocytes RhoE may play a role in the translacation of plakoglobin to the 
cytoplasm (PG cyt) and nucleus (PG nuc). Once in the nucleus plakoglobin can suppress Wnt 
signaling leading to apoptosis (1). RhoE may also have a role in translocating Bax to the 
mitochondrial membrane enabling the cell to undergo apoptosis (2). In RhoE depleted 
keratinocytes plakoglobin accumulates at the plasma membrane (PG mem) coupled with a 
decrease in nuclear plakoglobin levels. In this situation Wnt signaling is not suppressed and 
apoptosis is not induced (3). Bax translocation to the mitochondrial membrane in RhoE-depleted 
keratinocytes is inhibited protecting the cells from apoptosis (4). 
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CHAPTER 6 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
6.1 Regulation of the cell cycle by RhoE induced desmosomal proteins 
Loss of RhoE expression in keratinocytes resulted in a G1 phase cell cycle arrest and a decrease 
in the level of active ERK and cyclin D1 expression. I have also shown that RhoE-depletion 
increased the expression of the desmosomal proteins desmoglein 3 and desmoplakin I/II. 
Keratinocytes expressing low levels of desmoglein 3 have increased colony forming efficiency 
as well as increased proliferation compared to keratinocytes expressing high levels of 
desmoglein 3 (Wan et al. 2003). In HaCaT cells depleted of desmoplakin I/II cell proliferation 
was increased with an enhanced G1 to S phase transition (Wan et al. 2007). This was also 
associated with increased ERK and Akt activation (Wan et al. 2007). These data support my 
findings and suggest that RhoE may regulate cell cycle progression in keratinocytes through the 
regulation of desmosomal proteins. Further work is required to confirm this.  
 
6.2 Regulation of desmosomal assembly by RhoE 
Desmosomes are cell-cell adhesion complexes important for maintaining the structural integrity 
of many tissues including the skin and heart (Garrod et al. 2008). Cell-cell adhesion in the skin 
is vital for epidermal differentiation and maintaining architecture of the epidermis (Braga 2002; 
Fuchs 2007). Desmosomes also have roles in tissue morphogenesis, proliferation and 
differentiation (Yin et al. 2004; Muller et al. 2008). Desmosomes are disrupted in several human 
diseases including the autoimmune disease pemphigus vulgaris and the hereditary disease 
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arrhythmogenic right ventricular dysplasia/cardiomyopathy (Garcia-Gras et al. 2006; Waschke 
2008).  
 
My work shows that depletion of RhoE in keratinocytes results in the up-regulation of 
desmosomal proteins and increased numbers of desmosomes. How RhoE regulates these events 
is not known. Unlike desmosomal protein-protein interactions, which are fairly well 
documented, little is known about how desmosomal proteins are regulated (Green et al. 2007). 
Desmosomes are relatively stable structures with not much evidence for recycling (Windoffer et 
al. 2002; Thomason et al. 2010), thus it is likely that the increase in desmosomes in RhoE-
depleted keratinocytes is a consequence of new desmosomes being formed. RhoA activity has 
been implicated in regulating desmoplakin I/II translocation to maturing desmosomes and RhoE 
has been reported to regulate RhoA activity (Wennerberg et al. 2003; Godsel et al. 2010; Goh et 
al. 2010). The actin cytoskeleton is also required for desmosomal assembly (Pasdar et al. 1993; 
Godsel et al. 2005) and RhoE is involved in the regulation of the actin cytoskeleton (Katoh et al. 
2002; Riento et al. 2003; Komander et al. 2008). Further analysis of the role of RhoE in 
desmosomal assembly may help understand how these structures are disrupted in human 
diseases.  
 
6.3 Regulation of Bax by RhoE during apoptosis 
Keratinocytes depleted of RhoE were protected from apoptosis induced by the intrinsic and 
extrinsic pathways. Both the intrinsic and the extrinsic pathways converge at the level of Bax 
activation (Sprick et al. 2004; Ott et al. 2007). Upon activation, Bax translocates to the 
mitochondria where it mediates MOMP initiating the caspase cascade (Korsmeyer et al. 2000; 
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Basanez et al. 2002). RhoE has also been implicated in the regulation of Bax expression (Li et 
al. 2009). Here I report Bax expression in RhoE-depleted cells was not changed. However, the 
translocation of Bax to the mitochondria was disrupted in RhoE-depleted cells. Establishing 
how RhoE regulates Bax translocation would give further insight into how apoptosis is 
regulated and how the intrinsic and extrinsic pathways converge. 
 
6.4 RhoE, plakoglobin and apoptosis 
The protection from cisplatin-induced apoptosis observed in RhoE-depleted cells was lost 
following plakoglobin depletion, implicating plakoglobin in the regulation of apoptosis. 
Plakoglobin can translocate to the nucleus were it can alter transcription. Numerous studies have 
implicated plakoglobin in the regulation of Wnt signaling via Tcf/Lef transcription (Ben-Ze'ev 
et al. 1998; Klymkowsky et al. 1999; Zhurinsky et al. 2000; Garcia-Gras et al. 2006). Wnt 
signaling is known to regulate apoptosis (Longo et al. 2002; Garcia-Gras et al. 2006). Activation 
of Wnt signaling blocks apoptosis in a variety of cells whereas suppression of Wnt signaling 
induces apoptosis (Longo et al. 2002). Depletion of RhoE has no effect on plakoglobin 
expression but relocalisation of plakoglobin was observed in RhoE-depleted cells. Plakoglobin 
has also been implicated in the regulation of Bcl-2 family protein expression (Hakimelahi et al. 
2000; Dusek et al. 2007). Furthermore, RhoE expression has been reported to regulate the 
expression of the Bcl-2 family member Bax (Li et al. 2009). An understanding of how RhoE 
regulates plakoglobin and how plakoglobin regulates apoptosis are clearly key areas for 
research.  
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APPENDIX 1 SEQUENCE OF HUMAN RHOE WITH SHRNA AND SIRNA 
SEQUNCES HIGHLIGHTED 
 
CAGTCGGCTCGGAATTGGACTTGGGAGGCGCGGTGAGGAGTCAGGCTTAAAACTTGTTGGAGGG
GAGTAACCAGCCTGCTCCTCTCGCTCTCCTCCTCGTCTGCGCCGCGTTTCAGAGAGAAAATTCC
TGTTCCAAGAGAAAATAAGGCAACATCAATGAAGGAGAGAAGAGCCAGCCAGAAATTATCCAGC
AAATCTATCATGGATCCTAATCAGAACGTGAAATGCAAGATAGTTGTGGTGGGAGACAGTCAGT
GTGGAAAAACTGCGCTGCTCCATGTCTTCGCCAAGGACTGCTTCCCCGAGAATTACGTTCCTAC
AGTGTTTGAGAATTACACGGCCAGTTTTGAAATCGACACACAAAGAATAGAGTTGAGCCTGTGG
GACACTTCGGGTTCTCCTTACTATGACAATGTCCGCCCCCTCTCTTACCCTGATTCGGATGCTG
TGCTGATTTGCTTTGACATCAGTAGACCAGAGACCCTGGACAGTGTCCTCAAAAAGTGGAAAGG
TGAAATCCAGGAATTTTGTCCAAATACCAAAATGCTCTTGGTCGGCTGCAAGTCTGATCTGCGG
ACAGATGTTAGTACATTAGTAGAGCTCTCCAATCACAGGCAGACGCCAGTGTCCTATGACCAGG
GGGCAAATATGGCCAAACAGATTGGAGCAGCTACTTATATCGAATGCTCAGCTTTACAGTCGGA
AAATAGCGTCAGAGACATTTTTCACGTTGCCACCTTGGCATGTGTAAATAAGACAAATAAAAAC
GTTAAGCGGAACAAATCACAGAGAGCCACAAAGCGGATTTCACACATGCCTAGCAGACCAGAAC
TCTCGGCAGTTGCTACGGACTTACGAAAGGACAAAGCGAAGAGCTGCACTGTGATGTGAATCTT
TCATTATCTTTAATGAAGACAAAGGAATCTAGTGTAAAAAACAACAGCAAACAAAAAGGTGAAG
TCTAAATGAAGTGCACAGCCAAAGTCATGTATACCAGAGGCTTAGGAGGCGTTTGAGAGGATAC
TCATCTTTTTGGAATCCTGACCTTAGGTTCGGCATGTAGACCAAGTGATGAGAAGTGAATACAT
GGAAGAGTTTTTAAGTGTGACTTGAAAAATATGCCAAAAAATGAGAGATACAAATGAGCTAGAG
GAAGATGAGGGGGGATGCGAGTACCTCCAAGAAGAAAAATCACACTCTGAATGGTGCTTGCATT
TTTGGGTTTTTTTTTTTTGTTATAATCTATTCATGGATCTCCACTTTGATTTAATTTTTAAATG
TTTTAATCTCCTTTACAAAAAGTATACGTTAATATACCGTCCTCAAGGGGGAACTGGCACTGTG
ACCTTAGCATTTAGTTTTCTAGAGGATGTGATCTAATTTCTTTCTAGCTCATCATTAAAAAGGA
AATTGTATCAGGACCCATGGGATATATCCAGAGGCAAACTTTATGAGGCTTTGAAATCTTGCCT
TCCTGAAGATAGCTGAGTAGGATGGTTCTAAGGAAAGCCTTTGCAATCTTGCAAGATTTGTAGA
CCAGCACTACAAAGATCGCATAGATCAAATAGGAAAAAAAATGTCGATTTTTATTCAGTCTGAT
GGTTCTGTTCTTCATTGTGATTGTCATTAAAAAGTGGTAAATTGCTCAATGTAATATTTTTGTG
CGCTGTTTAGAAGTTGTGTGATTTTTTGCCATCGTTGATAAAAATGCAAAGTCAAATAAAAGGT
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GTCTTGGTTTGATGTCATAGAATGATCCAAGGAGAGAAAAAAGGTAGTTACTGTTTTCACCAGA
AAAGGTAATGAGTGAAGGAAAGAATAGTAGCAGAAAGCACAGTTTGTGAGTAAAGCTGTCTGGA
ATTAAGTTACCAAAAATACAAAGCAAAAGGACTATTATTTTGGGTTGAAGCTCCAAAACTGACA
GCATCTGATAATCTGTTGGTTTATTTCACTTTTCATTAAATGAACATTGATGAGAGAAGATGCC
ACTTACCCAAGCTTTAGAGAATCCCTAGTGGAAGATTATATGATAAACTTTCAGTCCTGACATA
ACACTAGGGCATTTCTAGAGTGTCATTGCTAAAACCTCACTGAACAGATGCAGCCAAGGTCTGT
GTTCAGCACTTGGTCTCTGTTGTTACGTAAAATAATAAGCATTTAAAATAGTTTACAGATATTT
TTGACCAGTTCCTTTTAGAGATTCTTTCAGAGAAGAAACCAGATCTGACCTGTTTATTGTTGGC
GCTTGTTGAAAACGAGCTTTCTTTCCCATGATAGTGCTTCGTTTTTGAAGTGTTGAAGCTGTGC
TCCCCTTAAATCGTGGCAGGAGAGATTAAGGTAATTACAACACTCAGTTCTATGTCTTACAAGC
ACTTTGTCTTGTCTCTGCAAGAAAATTCGATTCCAGTCATTTCCCATAAAATACAGACATTTTA
CCAACATAATATGCTTTGATTGATGCAGCATTATGCTTTGGGCAGTATTACAAAATAGCTGGCG
AGTGCTTTCTGTATTTAAATATTGTAAAAAGAAAATAAGTTATAACTGTTATAAAGCAGAACTT
TTGTTGCATTTTTTAAACTGTTGAAGTCACTGTGTATGTTTGTTTGGTCAATGTTTCCGCAGTA
TTTATTAAAACATACTTTTTTTTTCTTCAAATAAAAAAGTAACCATGTCTTTGTCTAAA 
 
 
shRNA  [TCTGATAATCTGTTGGTTTAT] 
Oligo A [TAGTAGAGCTCTCCAATCA] 
Oligo B [CAAACAGATTGGAGCAGCT] 
 
shRNAmir pGIPZRhoE construct; green is sense and blue is antisense 
TGCTGTTGACAGTGAGCGCTCTGATAATCTGTTGGTTTATTAGTGAAGCCACAGATGTA 
ATAAACCAACAGATTATCAGATTGCCTACTGCCTCGGA 
 
